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Zusammenfassung 
Dickdarmkrebs ist eine der häufigsten Tumorerkrankungen weltweit. Die größte Schwierigkeit bei 
der Behandlung dieser Art von Tumoren ist die intrinsische und / oder erworbene Resistenz gegen 
Chemotherapeutika oder gezielte Therapien. Dieser mangelnde Therapieerfolg ist oft auf 
Mutationen im KRAS-Gen zurückzuführen, die zur dauerhaften Aktivierung des RAS-
Signalweges und damit zur unkontrollierten Proliferation und zum Überleben der Tumorzellen 
führen. Die Expression des Peroxisomen-Proliferator-aktivierten Rezeptors gamma (PPARγ) 
korreliert mit einer guten Prognose bei Patienten mit kolorektalem Karzinom und kann durch die 
Aktivierung von RAS inhibitorischen Proteinen, wie beispielsweise PTEN, DOK1 oder Caveolin-
1 eine Hemmung der RAS-Aktivität hervorrufen.  
 
In dieser Arbeit wurde die Beziehung zwischen PPARγ und seinem neuen Bindungspartner, dem 
Myotubularin-verwandten Protein 7 (MTMR7), hinsichtlich seiner hemmenden Wirkung auf den 
RAS-Signalweg untersucht. Die Interaktion der beiden Proteine im Zytosol von kolorektalen 
Karzinomzelllinien konnte durch Co-Immunopräzipitation, „Proximity Ligation Assay“ sowie 
Immunfluoreszenz-Co-Färbung verifiziert werden. Darüber hinaus konnte als Folge der 
Transfektion des MTMR7 Plasmids eine erhöhte Expression von PPARγ-Zielgenen, wie TFF3, 
sowie eine erhöhte transkriptionelle Aktivität von PPARγ festgestellt werden. Im Gegensatz dazu 
zeigte die subzelluläre Fraktionierung keinen Einfluss von MTMR7 auf die PPARγ-Lokalisation.  
 
Dieser positive Einfluss von MTMR7 auf die PPARγ-Aktivität wurde anschließend näher 
differenziert, indem der Einfluss der MTMR7-Überexpression auf den RAS-Signalweg untersucht 
wurde. Bemerkenswerterweise reduzierte MTMR7 sowohl das aktive RAS als auch den 
Gesamtproteingehalt von RAS. Dieser Effekt konnte durch proteasomale / lysosomale Inhibitoren 
(MG132 / Chloroquin) nicht verhindert werden. Die Behandlung der Zellen mit KCl verstärkte 
sogar die Abnahme des RAS Proteingehalts, während Amilorid, ein epithelialer 
Natriumkanalblocker, diese Abnahme des RAS Proteins verhinderte.  
 
Die Untersuchung der Wirkung von MTMR7 auf die Therapie-Resistenz zeigte, dass eine 
Kombinationstherapie mit Everolimus und Sorafenib die Lipidphosphatase nicht ersetzen konnte. 
Die Behandlung der Zellen mit einem MTMR7-Peptid verringerte jedoch die Zellproliferation 
signifikant. Eine weitere Untersuchung des MTMR7-Peptids zeigte, dass es in der Lage ist, die 
Aktivierung des „Serum-Response-Elements“ zu reduzieren, und dass es eine Tendenz zur RAS-
Inhibierung besitzt.  
 
Zusammenfassend lässt sich feststellen, dass der Tumorsuppressor MTMR7 die Abnahme des 
RAS Proteingehalts fördert, was zu einer geringeren ERK1/2-Aktivität führt und als Folge die 
transkriptionelle Aktivität des nukleären Rezeptors, PPARγ, erhöht. Dies wiederum führt zu einer 
Aktivierung von Tumorsuppressorgenen wie CAV-1, DOK1 oder PTEN.  
Daher könnte die MTMR7-PPARγ-Interaktion ein neues Ziel für die Behandlung von kolorektalen 
Karzinomen darstellen, bei denen mutiertes KRAS zu einem Therapieversagen der EGFR-
Therapie führt. 
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Summary 
Colorectal cancer (CRC) is one of the most common types of cancer worldwide. The most 
important difficulty of treating this type of cancer, is the intrinsic and/or acquired resistance to 
chemotherapeutic drugs or targeted therapies. This unresponsiveness is often due to mutations 
in the KRAS gene, leading to constitutive activation of the RAS signaling pathway and in turn to 
the proliferation and survival of the tumor cells. The expression of the peroxisome proliferator 
activated-receptor (PPARγ) is correlated with a good prognosis in CRC patients and it is one of 
the candidates to inhibit RAS through the upregulation of Ras-inhibitory proteins like PTEN, DOK1 
or Caveolin-1. 
 
In this thesis, the relationship between PPARγ and its new binding partner, myotubularin-related 
protein 7 (MTMR7), was evaluated concerning its inhibitory effect on RAS signaling. The 
interaction of the two proteins in the cytosol of colorectal cancer cell lines could be verified using 
coimmunoprecipitation, proximity ligation assay as well as immunofluorescence co-staining. 
Furthermore, the expression of PPARγ target genes like TFF3 were upregulated and PPARγ-
responsive-element (PPRE) activity significantly enhanced upon MTMR7 transfection. In contrast, 
subcellular fractionation revealed no influence of MTMR7 on PPARγ localization. This positive 
influence of MTMR7 on PPARγ activity was then further elucidated by assessing the impact of 
MTMR7 overexpression on RAS signaling. Notably, MTMR7 reduced active RAS as well as total 
protein levels of RAS. This effect could not be prevented by using proteasomal/lysosomal 
inhibitors (MG132/Chloroquine). Treating the cells with KCl facilitated RAS reduction, whereas 
amiloride, an epithelial sodium channel blocker prevented its reduction. 
 
Studying the effect of MTMR7 on therapy resistance indicated that a combination therapy using 
everolimus and sorafenib could not substitute for MTMR7 in vitro. Treating the cells with a 
MTMR7-peptide, though, reduced cell proliferation significantly. Further investigation of the 
MTMR7-peptide showed that it is capable to reduce serum response element activation and 
displayed a tendency of RAS-inhibition.  
 
Conclusively, the tumor suppressor MTMR7 promotes RAS down-regulation, which leads to a 
reduced ERK 1/2 activation and a transcriptional activation of the nuclear receptor PPARγ. This 
in turn results in the activation of tumor suppressor genes like CAV1, DOK1 or PTEN. Thus, the 
MTMR7-PPARγ crosstalk might be a new target for the treatment of colorectal cancer, where 
mutant KRAS leads to treatment failure of EGFR therapy. 
Introduction 
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1. Introduction 
1.1. Colorectal cancer 
1.1.1. Epidemiology 
Colorectal cancer (CRC) is one of the most common types of cancer worldwide. Due to nearly 
one million new diagnosed cases, colorectal cancer ranks third as the most common cancer, 
second in terms of incidence and mortality, and fourth in cause of death with 500.000 per year 
(IARC Press 2014). It is a gender independent type of cancer and affects both men and women 
similarly (Boyle and Langman 2000, Marmol, Sanchez-de-Diego et al. 2017).  
Although, colorectal cancer is not equally common throughout the world. Cases of colorectal 
cancer range from 9.4 % in men and 10.1 % in women worldwide. However, incidences in men 
and women are much higher in western countries (men 12.6 %; women 14.1 %) compared to 
colorectal cancer patients in non-western countries (men 7.7 %; women 7.9 %) (Boyle and 
Langman 2000). 
Therefore, colorectal cancer has a geographical variation with 63 % of cases in developed 
western countries (Haggar and Boushey 2009). For example, the incidence rate ranges from more 
than 40 out of 100.000 people in Australia, New Zealand, the United States, and Western Europe 
compared to less than 5 out of 100.000 people in Africa and some parts of Asia (Haggar and 
Boushey 2009).  
However, the incidence rates of colorectal cancer change with time. Recently, North America 
confronted a reverse trend as the incidence rate decreased. The rates declined from the mid-
1980s to the mid-1990s, followed by a short period of stabilization and another declining period 
from 1998 to 2005 (Jemal, Thun et al. 2008). This decline could be due to new screening methods 
that improved the detection of polyps (Jemal, Clegg et al. 2004). This trend is not seen in Western 
Europe, although the incidence might be stabilizing (Jemal, Thun et al. 2008, IARC Press 2014). 
There is a rapid increase in incidence rates in former low-income countries that have become 
high-income economies like Singapore, Japan, and other Eastern European countries (Boyle and 
Langman 2000, Janout and Kollarova 2001). 
1.1.2. Environmental factors 
There are many lifestyle related habits known to be associated with an increased risk for 
developing polyps or colorectal cancer. The most important risk factor of developing CRC is age. 
Most of the tumors occur beyond the age of fifty whereas below that age the development of a 
carcinoma is rare (Levin, Lieberman et al. 2008).  
In addition to age there might be a personal history for diseases like inflammatory bowel disease 
(Eaden, Abrams et al. 2001, Canavan, Abrams et al. 2006). These diseases lead to a chronic 
inflammation which often produces dysplasia, an abnormal cell growth. These dysplastic cells are 
not per se malignant, but the risk of developing into a tumor is very high. 
Another risk factor that can be included in this group is a genetic predisposition for developing 
CRC because of a positive familial history of CRC in relatives which can be due to inherited 
mutations or the environment (Johns and Houlston 2001).  
Lifestyle factors are also important to take into consideration. For example, a sedentary lifestyle 
can increase the risk of CRC development. The relationship has to be further assessed but it has 
been proven, that a moderate physical activity increases metabolic rates as well as gut motility 
and in a long term view metabolic efficiency (Robertson 2012). 
In addition, a sedentary lifestyle could be the cause for obesity, another important risk factor which 
can be related to food intake on the one hand and high levels of visceral adipose tissue (VAT) on 
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the other hand. The latter is secreting proinflammatory cytokines which can cause inflammation 
in the colon and rectum as well as insulin resistance (Martinez-Useros and Garcia-Foncillas 
2016).  
In this context, nutritional habits or diet represent another risk factor. People whose diet is not 
balanced, meaning the intake of high animal fat (e.g. red meat), high calories and poor vegetables 
and fibers have a 70 % higher chance to develop colorectal cancer than patients with healthy 
nutritional habits. In contrast, a low fat, high vegetable and high fiber diet has a protective effect 
(Willett 2005, IARC Press 2014).  
Furthermore, long-term smoking and alcohol intake have also been suggested to increase CRC 
risk (Poschl and Seitz 2004). In case of smoking the high content in carcinogens like nicotine can 
easily reach the intestine and promote the formation of polyps so that the chances to suffer from 
colorectal cancer may increase by up to 11 %. However the relationship between alcohol 
consumption and CRC has to be further elucidated (Botteri, Iodice et al. 2008, Cross, Boca et al. 
2014).  
1.1.3. Molecular pathways of colorectal cancer 
There are three molecular pathways of colorectal cancer: (1) chromosomal instability (CIN), (2) 
microsatellite instability (MSI), and (3) CpG island methylator phenotype (CIMP).  
(1) The classical pathway is the CIN pathway which causes about 80-85 % of all colorectal cancer 
cases (Geigl, Obenauf et al. 2008, Grady and Carethers 2008). This pathway is characterized 
by imbalances in the number of chromosomes, resulting in aneuploidic tumors and loss of 
heterozygosity (LOH), which is due to alterations in chromosome segregation, telomere 
dysfunction, and defective DNA repair mechanisms. These alterations affect genes like 
adenomatous polyposis coli (APC), kirsten ras (KRAS), phosphatidylinositide 3-kinase (PI3K) 
and TP53 (tumor protein 53), which maintain correct cell functions. Mutations in the APC gene 
lead to the import of β-catenin to the nucleus and to the transcription of tumorigenic and 
invasive genes. In addition, KRAS and PI3K mutations lead to a constantly active MAP kinase, 
resulting in cell proliferation and survival, whereas mutations in the tumor suppressor TP53, 
encoding for the cell-cycle checkpoint p53, cause uncontrolled entry in the cell cycle (Pino 
and Chung 2010).  
(2) The second pathway is the microsatellite instability pathway (MSI). Microsatellites are 
polymorphic DNA loci containing repeated nucleotide sequences which have a higher 
mutation rate than other areas of the DNA (Brinkmann, Klintschar et al. 1998). Alterations 
occur in 15-20 % of sporadic colorectal cancers and cluster in genes responsible for the repair 
of DNA mismatches like MLH1 and MSH2. The repair of these short DNA chains is reduced 
in tumors, resulting in an accumulation of alterations in those regions and thus in a defective 
DNA mismatch repair (MMR) (IARC Press 2014). 
(3) The third pathway is the CpG island methylator phenotype (CIMP) that is based on epigenetic 
instability. This pathway is characterized by hypermethylation of promoter CpG island sites 
which result in the transcriptional inactivation of a series of tumor suppressor genes like APC 
or the DNA mismatch repair gene MLH1 (Ahuja, Mohan et al. 1997, Weisenberger, Siegmund 
et al. 2006). The CIMP status is defined by five markers including CACNA1G, IGF2, 
NEUROG1, RUNX3 and SOCS1. A tumor is CIMP positive if at least three markers are 
methylated (Al-Sohaily, Biankin et al. 2012). 
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1.1.4.  Classification of colorectal cancer 
The classical adenoma-carcinoma sequence 
 
Like many other types of cancer, mutations in specific genes are causal for the development of 
colorectal cancer. These alterations can occur in tumor suppressor genes, oncogenes, as well as 
in genes responsible for DNA repair. Due to the origin of these mutations, colorectal cancers are 
classified as sporadic and inherited.  
Sporadic, non-hereditary CRC are mostly derived from point mutations and occur in 70 % of all 
CRCs. Most of the sporadic cancers follow a specific order of mutations, which are correlated 
with a specific morphological state, starting with adenoma development and culminating with 
carcinoma formation (Fearon and Vogelstein 1990, Marmol, Sanchez-de-Diego et al. 2017). 
A scheme of the development of colorectal cancer starting from normal epithelium to adenoma 
and finally carcinoma by accumulation of genetic abnormalities is shown in Figure 1. 
 
 
Figure 1: The Vogelstein adenoma to carcinoma sequence (modified by Davies). Scheme of the development of colorectal 
cancer starting from normal epithelium to adenoma and finally carcinoma by accumulation of genetic abnormalities ((Davies, 
Miller et al. 2005)/ copied from http://syscol-project.eu/about-syscol/).  
 
The first mutation arises in a tumor suppressor gene termed APC, followed by mutations in KRAS, 
TP53 and DCC (Deleted in Colorectal Cancer). The APC gene is located on chromosome 5q21-
22 and encodes the APC protein. The latter is a negative regulator which controls β-catenin, a 
signaling molecule of the WNT-pathway (IARC Press 2014). Defects in the WNT-pathway lead to 
active c-Myc, which disturbs the balance between proliferation, apoptosis, and in the end result 
in a hyperproliferative epithelium (Fearon and Vogelstein 1990, Arends 2000).  
The genotype/phenotype of a tumor differs, depending on where the alteration in the APC gene 
occurs. If the mutations are located in the first or the last third of the coding sequence (CDS), 
tumors are related to attenuated polyposis, alterations after codon 1444 to desmoid tumors while 
mutations in the central region show a severe phenotype (IARC Press 2014).  
Additional alterations in KRAS, TP53 and DCC trigger the formation of non-malignant adenomas, 
known as polyps. KRAS is a proto-oncogene which, due to mutations, gets activated and 
stimulates cell survival whereas mutations in the tumor suppressor gene TP53 lead to its 
inactivation which results in a defective DNA repair and finally in the induction of growth arrest 
and apoptosis. These modifications lead to the imbalance between proliferation and apoptosis of 
epithelial cells, resulting in growth of polyps that in the end turn into carcinomas (Fearon and 
Vogelstein 1990, Arends 2000). 
 
Another class of CRCs is the inherited form which accounts for 5 % of all CRCs. This form is 
caused by mutations which affect one allele of the mutated gene so that an additional point 
mutation in the second allele of the same gene leads to an accumulation of tumor cells and finally 
to a carcinoma.  
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Inherited cancers can also be classified into two groups: a polyposis and a non-polyposis group. 
The polyposis group includes familial adenomatous polyposis (FAP), characterized by the 
development of many potentially malignant polyps in the colon (Lynch and de la Chapelle 2003, 
Marmol, Sanchez-de-Diego et al. 2017). The second group is the hereditary non-polyposis 
colorectal cancer (HNPCC), also called Lynch syndrome, which is mainly caused by mutations in 
DNA repair mechanisms. These tumors often appear in the proximal colon and are due to 
microsatellite instability (MSI) (Green, Bradburn et al. 1998). 
 
 
Consensus molecular subtypes (CMS) 
 
There are often discrepancies in the classification of carcinomas which are due to differences in 
data processing and algorithms. To overcome these, Guinney et al. combined six independent 
classification systems into four molecular subtypes (CMS) with different characteristics (Figure 
2). 
 
 
Figure 2: Proposed taxonomy of colorectal cancer. CIMP: CpG island methylator phenotype; MSI: microsatellite instability; SCNA: 
somatic copy number alterations. Copied from (Guinney, Dienstmann et al. 2015). 
 
Subtype CMS1 (MSI immune) accounts for about 14 % of colorectal cancers. These are 
microsatellite unstable, hypermutated, and have a strong immune activity. CMS2 (canonical) 
includes 37 % of colorectal carcinomas; which are epithelial and have a marked activation in the 
WNT and MYC signaling pathways. The metabolical subtype CMS3 includes carcinomas with an 
evident metabolic dysregulation and accounts for 13 % of colorectal cancers.  
CMS4 (mesenchymal) comprises 24 % of cases and is characterized by a known activation of 
the transforming growth factor β (TGF-β), an invasion of the stroma and an increased 
angiogenesis. The remaining 13 %, which are not attributable to either CMS, are believed to be 
due to intratumoral heterogeneity or a transition phenotype (Guinney, Dienstmann et al. 2015). 
This classification of molecular subtypes is currently an appreciated reliable and most stable 
system for categorizing colorectal carcinomas. 
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1.1.5. Treatment 
Classical: surgery, chemotherapy 
 
The treatment of colorectal cancer mainly depends on the stage of the disease as well as the 
patient's’ state of health. The first choice of treatment in stage 0 or UICC stage I (localized 
disease) is surgery without any complementary therapy. However, most of CRCs (50-70 %) are 
diagnosed at more advanced stages, like stage II (cancer has spread beyond the colon into the 
submucosal tissue layers) or stage III (cancer has spread across the intestinal wall and into the 
surrounding lymph nodes). In these stages, adjuvant postoperative chemotherapy is used to 
destroy potentially existing micrometastases, thus increasing the recovery rate by reducing the 
disease recurrence.  
Patients with metastatic disease (stage IV) can be classified into three different groups: 
unresectable metastatic disease, resectable disease, and initially unresectable disease. For the 
first group, palliative treatment based on chemotherapy is used to control tumor growth and 
improve the quality of life of these patients. Therapy of patients with resectable disease (i.e. low-
tumor-burden) includes early resection of metastases combined with chemotherapy. However, 
the best sequence of surgery and chemotherapy has to be established. The last group, patients 
with initially unresectable disease first undergo chemotherapy to reduce tumor burden followed 
by surgery of metastases (Marin, Sanchez de Medina et al. 2012, Pox, Aretz et al. 2013).  
For the adjuvant treatment of CRC, several chemotherapeutic drugs as well as targeted therapies 
are commonly used (Marin, Sanchez de Medina et al. 2012). In clinical praxis, standard 
treatments include 5-fluorouracil (5-FU), irinotecan, and oxaliplatin. 5-FU is a thymidylate 
synthase (TYS) inhibitor and has been used in the treatment of colorectal cancer since the 1990s 
(Marin, Romero et al. 2009). Interestingly, the combination of 5-FU with folinic acid (leucovorin, 
LV) improved the response on overall survival (OS) due to the fact that LV is stabilizing the 5-FU 
and TYS complex and thereby enhancing the anti-tumor effect of 5-FU (Gill, Loprinzi et al. 2004, 
Pox, Aretz et al. 2013, Andre, de Gramont et al. 2015). 
Irinotecan, another TYS-inhibitor, is a camptothecin derivative which is used in second-line 
treatment for patients who do not respond to 5-FU-therapy (Rothenberg, Eckardt et al. 1996, 
Saltz, Cox et al. 2000). However, these drugs are mostly used in combination therapy, including 
irinotecan combined with leucovorin followed by 5-FU bolus and an infusion of 5-FU, called 
FOLFIRI (Marin, Sanchez de Medina et al. 2012). 
Another chemotherapeutic drug, oxaliplatin, is often used in combination with other drugs. 
Oxaliplatin is a platin derivative which crosslinks metabolites with DNA resulting in the inhibition 
of DNA-synthesis (Graham, Mushin et al. 2004, Pox, Aretz et al. 2013). The most commonly used 
combination is oxaliplatin with LV and 5-FU, named FOLFOX. 
Other approaches to treat CRC are targeted therapies with monoclonal antibodies (mABs) like 
bevacizumab (targeting the vascular endothelial growth factor; VEGF) or cetuximab (targeting the 
epidermal growth factor receptor; EGFR).  
The EGFR is a glycoprotein, located on chromosome 7 with a size of 170 kD. It belongs to the 
transmembrane tyrosine kinase family and is typically activated by ligands such as TGF-α or EGF. 
Its activation leads to a homo- or heterodimerization and autophosphorylation of c-terminal 
residues resulting in activation of signaling pathways like the RAS/RAF/ERK-pathway or the PI3K-
AKT-pathway and finally in survival and proliferation (Davies, Grosse et al. 1980, El Zouhairi, 
Charabaty et al. 2011, Hagan, Orr et al. 2013).  
Since the EGFR is overexpressed in many epithelial tumors, two EGFR antagonists, cetuximab 
(Erbitux™), and panitumumab (Vectibix™) have been approved by the Food and Drug 
administration (FDA) in 2004 and 2006. Cetuximab is a chimeric immunoglobulin of the IgG1 
isotype and targets the ligand binding domain of the EGF-receptor in different ways (Hagan, Orr 
et al. 2013).  
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In detail, cetuximab leads to a receptor downregulation and its reduced cell surface expression 
thus promotes receptor internalization and degradation. Additionally, effects on DNA transcription 
and repair are inhibited through blocking the nuclear import of the EGFR. Last but not least, the 
receptor dimerization is inhibited sterically (El Zouhairi, Charabaty et al. 2011). Furthermore, 
combinations of FOLFOX together with monoclonal antibodies are in use and reported to improve 
efficiency of colorectal cancer treatment (Prenen, Tejpar et al. 2010).  
A new, upcoming therapy targets the immune system, e.g. the cell surface receptor programmed 
death (PD1/PDL1) pathway, also termed “immune checkpoints”. These receptors are often 
upregulated in tumors such as bladder cancer, non-small-cell lung cancer and melanomas which 
can be circumvented by using antibodies like pembrolizumab to block the system. This therapy 
has already been shown to be effective in 40 % of patients with MSI-H carcinomas in the UICC 
stage IV whereas it did not show any effect in MSS colorectal cancers (Le, Uram et al. 2015).  
 
 
Prevention  
 
Many approaches to avoid the development of colorectal cancer have been discussed. The most 
important approach is endoscopic screening which is lowering the risk of CRC by diagnosing CRC 
cases 2-3 years before showing symptoms (Cunningham, Atkin et al. 2010). However most of the 
chemopreventive drugs are controversial discussed.  
For instance, calcium intake has been reported to reduce the risk of developing CRC by 10-15 % 
(Cho, Smith-Warner et al. 2004). This may be due to direct effects on epithelial cells or indirectly 
by binding bile acids and fatty acids in the colonic lumen. Some studies have shown that calcium 
intake reduces the risk of secondary adenomas by 15 % (Baron, Beach et al. 1999, Bonithon-
Kopp, Kronborg et al. 2000) whereas others did not determine any significant protective effect 
(Wactawski-Wende, Kotchen et al. 2006). 
Same is true for fiber-rich diets, which may decrease carcinogens in the colonic lumen and 
thereby reduce the risk of colorectal cancer development. However, this effect could not be 
confirmed in a meta-analysis by Park et al., 2005. Nevertheless, the American Institute for cancer 
research is recommending fiber-rich diets to “probably” prevent CRC. 
Furthermore, vitamin D is linked to reduce the risk of colorectal cancer by 29 % (Garland, Garland 
et al. 1999, McCullough, Robertson et al. 2003). Other substances like cyclooxygenase (COX) 
inhibitors are also discussed to prevent colorectal cancer by about 40 %. These substances inhibit 
COX2 activity, which is often upregulated in CRC, and thereby the synthesis of prostaglandins 
which is associated with cancer development (Jaffe 1974, Bennett and Del Tacca 1975). In 
addition, the chronic use of non-steroidal anti-inflammatory drugs such as aspirin, have reduced 
the risk of developing colorectal cancer. Furthermore physical activity is suggested to be 
protective (Clapper, Chang et al. 2001). 
 
 
Resistance 
 
The most important difficulty of treating cancer, and colorectal cancer in particular, is the intrinsic 
and/or acquired resistance to chemotherapeutic drugs or targeted therapies. These resistances 
limit the effectiveness of current therapies and are believed to cause treatment failure in over 
90 % of patients with metastatic disease (Cunningham, Humblet et al. 2004).  
One example for an intrinsic resistance is the unresponsiveness of patients to EGFR-based 
therapy with cetuximab.  
This is due to mutations in the KRAS gene, located on chromosome 12 and 13, encoding for the 
small GTPase downstream of EGFR (De Stefano and Carlomagno 2014). This is also supported 
by Lievre et al., who showed that KRAS mutations occur in 13 out of 30 tumors and that 68 % of 
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the nonresponders to cetuximab had that alteration whereas it wasn’t detected in the responding 
group (Lievre, Bachet et al. 2006).  
RAS proteins are small GTPases that are the most frequently mutated proteins in cancers and 
other diseases. Moreover, small GTPases are involved in the regulation of important cellular 
functions such as proliferation, differentiation, and apoptosis (Malumbres and Barbacid 2003).  
In mammalian cells, three isoforms of RAS proteins are expressed: Kirsten RAS (KRAS4B, 
KRAS), Harvey RAS (HRAS) and neuroblastoma RAS (NRAS). These proteins can be present in 
an active (GTP-bound) or inactive (GDP-bound) state (Barbacid 1987).  
All isoforms contain an almost identical G domain (residues 1-165) that binds guanosine 
nucleotides, whereas the C-terminal end (last 24-25 aa) is a variable region that differs in the 
isoforms and is necessary for the membrane anchoring. Thus, the specific subcellular locations 
of the isoforms are due to changes in their C-terminal domain.  
The synthesis of RAS proteins occurs in the cytosol where they are found as hydrophilic proteins 
displaying different C-terminal sequences for several post-translational modifications e.g. 
farnesylation (CAAX), proteolysis (AAX), or cysteine methylation in the endoplasmic reticulum 
(Calvo, Agudo-Ibanez et al. 2010, Gelabert-Baldrich, Soriano-Castell et al. 2014).  
Furthermore, active KRAS converts GTP to GDP, thus inactivating itself. The guanosine 
nucleotide exchange factor (GEF) catalyzes the release of the GDP molecule, facilitating the 
reactivation of KRAS through binding a new GTP molecule. Reactivated KRAS then binds to the 
serine/threonine kinase rapidly accelerated fibrosarcoma (RAF) (Bergstraesser, Hoeger et al.), 
which phosphorylates and thus activates the mitogen-activated kinase (MEK). Activated MEK 
then phosphorylates extracellular signal-regulated kinase (ERK), which subsequently activates 
transcription factors to increase transcription of genes that promote cell proliferation (Normanno, 
Tejpar et al. 2009, Lee and Kopetz 2015). Thus, mutations in the KRAS gene lead to stimulation 
in survival and proliferation.  
Consequently, targets downstream of KRAS, like RAF or mTOR, may hold the promise to 
overcome therapy resistance. 
There are many other molecular mechanisms of therapy resistance which are due to EGFR/ HER-
2 oncogene amplification (Gnjatic, Wheeler et al. 2009, Bertotti, Papp et al. 2015), the reactivation 
of proangiogenic factors like the vascular endothelial growth factor (VEGF) (Kerbel, Yu et al. 
2001) or mutations in the phosphatidylinositol 3-kinase (PIK3CA) (Samuels and Velculescu 
2004). 
1.2. Myotubularins 
Myotubularins are a large family of 16 conserved proteins which dephosphorylate 
phosphatidylinositol(3)phosphate (PI(3)P), and PI(3,5)P2 and thereby form PI and PI(5)P. They 
are involved in the control of cellular processes such as endocytic trafficking, autophagy, and cell 
proliferation.  
The first described myotubularin was MTM1, followed by 15 other family members which are 
called myotubularin-related phosphatases (MTMR1-15). Seven of these phosphatases are 
inactive due to mutations within the catalytic motif. Nevertheless, some of these proteins are still 
involved in cellular functions and can cause diseases (Begley, Taylor et al. 2006).  
Many myotubularins like MTMR1-6 and 12 are ubiquitously expressed in many tissues and cell 
types (Laporte, Blondeau et al. 1998, Nandurkar, Caldwell et al. 2001, Zhao, Qi et al. 2001), 
whereas some of them are tissue specific like MTMR5 in the testes or MTMR7, which is mainly 
expressed in the brain (Laporte, Blondeau et al. 1998, Firestein, Nagy et al. 2002). 
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1.2.1. Structure and substrate specificity 
These lipid phosphatases consist of a PH-GRAM- (Pleckstrin-Homology-Glycosyltransferase), a 
RID (Rac-induced recruitment) domain, a dual specific tyrosine phosphatase C(X)5R-containing 
domain (PTP domain), a conserved SID- (Set Interaction Domain), and a coiled-coil-domain 
(Begley, Taylor et al. 2003, Laporte, Bedez et al. 2003, Begley, Taylor et al. 2006) (Figure 3).  
 
 
Figure 3: The schematic structure of the myotubularin protein family. PH-GRAM: Pleckstrin Homology Glucosyltransferase Rab-
like GTPase Activator; RID: rac-induced recruitment domain; PTP: protein tyrosine phosphatase domain; SID: set interaction domain; 
"Coiled-coil" -Heterodimerization. Modified from (Hnia, Vaccari et al.) 
 
The PH-GRAM domain mediates the interaction between enzyme and substrate through the 
binding of PI(5)P (Balla, Wymann et al. 2012), PI(3,5)P2, PI(4)P and PI(3,4,5)P3 (Berger, 
Schaffitzel et al. 2003), whereas the RID is a membrane targeting motif (Laporte, Blondeau et al. 
2002). The PTP domain contains the substrate binding pocket with the C(X)5R active site motif 
(Yuvaniyama, Denu et al. 1996). 
Because of their specificity for membrane embedded PI substrates, MTMs are unique among 
PTPs (Begley and Dixon 2005). This specificity underlies three structural characteristics: Firstly, 
the positive charge of the protein surface allows non-specific electrostatic interaction with 
negatively charged, PI-containing membranes, secondly, the dimensions of the substrate binding 
pocket are matched to those of the PIs, and thirdly, a selectivity towards lipophilic substrates is 
possible through a hydrophobic, the substrate binding pocket shielding helix (Begley and Dixon 
2005). 
 
In addition to the catalytic site, there are other MTM-typical domains that are important for the 
regulation of protein function: The above-mentioned RID, SID and coiled-coil domains mediate 
the central regulatory mechanism regarding enzymatic activity and subcellular localization. In 
particular, the coiled-coil heterodimerization domain mediates interaction with other 
myotubularins (Mochizuki and Majerus 2003, Balla, Wymann et al. 2012, Hnia, Vaccari et al. 
2012), while the others either enhance them (SID) (Mochizuki and Majerus 2003) or are 
responsible for protein interactions with other protein classes, such as class III PI3K (Cao, Backer 
et al. 2008). 
 
The myotubularins mainly use the 3-phosphorylated phosphoinositides as substrates by 
hydrolyzing PI(3)P and PI(3,5)P2 at their 3-position (Taylor, Maehama et al. 2000, Zhao, Qi et al. 
2001, Berger, Bonneick et al. 2002, Naughtin, Sheffield et al. 2010, Tooze and Yoshimori 2010, 
Velichkova, Juan et al. 2010) (Figure 4). 
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Figure 4: Substrate specificity of myotubularins. Seven different myotubularins are involved in PI metabolism. Metabolic reactions 
catalyzed by myotubularins are indicated in green. Adapted from (Hnia, Vaccari et al. 2012). 
 
To understand the mechanism of action, the events of endosomal PI(3)P and PI(3,5)P2 synthesis 
need to be explained. PI(3)P is produced on early and late endosomes by a type III PI3-kinase 
complex, consisting of a catalytic (hVsp34) and a regulatory (hVsp15) subunit (Gillooly, Morrow 
et al. 2000, Simonsen, Wurmser et al. 2001, Stein, Feng et al. 2003). Synthesis of PI(3)P starts 
with the activation of Rab5 and Rab7 GTPases on early and late endosomes (Christoforidis, 
Miaczynska et al. 1999, Feng, Press et al. 2001, Murray, Panaretou et al. 2002, Stein, Feng et al. 
2003, Stein, Cao et al. 2005), followed by their binding and recruitment of the hVsp34/hVsp15 
PI3-kinase complex and thereby activation of PI(3)P synthesis. On multivesicular endosomes 
PI(3)P is subsequently converted to PI(3,5)P2 by the phosphoinositide kinase PIKfyve, leading to 
protein sorting into intraluminal vesicles (Rudge, Anderson et al. 2004, Nicot, Fares et al. 2006, 
Shisheva 2008). The synthesized products lead to the recruitment of myotubularins to 
membranes, where they degrade PI(3)P to PI.  
The mechanism of activation/ inactivation of myotubularins was first described by Cao et al., 
showing that MTMR2 is interacting with the hVsp34/hVsp15 lipid kinase complex. They propose 
that membrane bound phosphatases begin to degrade PI(3)P until they become complexed again 
with hVsp34/hVsp15. This in turn leads to the steric occlusion of the phosphatase domain and 
the simultaneous displacement of the Rab GTPase, and thus causes the inactivation of the 
myotubularin (Cao, Backer et al. 2008).  
 
Hence, myotubularins coordinate endosomal PI(3)P synthesis and degradation and thereby 
regulate endosomal transport.  
1.2.2. Association with human disease 
There are several human diseases which are due to mutations in either active or inactive 
myotubularins. The most prominent disorders are x-linked centronuclear myopathy (XLMTM) and 
Charcort-Marie-Tooth (CMT) (Laporte, Bedez et al. 2003, Robinson and Dixon 2006, Nicot and 
Laporte 2008).  
The congenital disease XLMTM arises from mutations in MTM1; either loss of MTM function or 
the absence of MTM protein (Thomas, Williams et al. 1990, Liechti-Gallati, Muller et al. 1991). 
Disease occurrence varies from individual to individual and is due to the type of mutations. 
Generally, truncation or splice-site mutations are linked to severe forms, whereas missense 
mutations that occur outside of MTM functional domains, result in moderate or mild phenotypes 
(Nicot and Laporte 2008, Mruk and Cheng 2011). At the cellular level, the disease is most likely 
due to the improper regulation of PI(3)P and/ or PI(3,5)P2, resulting in the disruption of vesicle 
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trafficking in the skeletal muscle of affected individuals (Mruk and Cheng 2011). XLMTM affects 
mainly males and is characterized by severe muscle weakness and often results in death from 
respiratory failure at an average age of 4 to 5 months (Laporte, Hu et al. 1996).  
CMT is an inherited disorder, affecting motor and sensory neurons leading to progressive muscle 
weakness and atrophy in feet, legs, hands and arms. This disease is associated with mutations 
in the lipid phostphatases MTMR2 and MTMR13, as well as with several other genes (Mruk and 
Cheng 2011). A mutation in the lipid phosphatase MTMR2 leads to Charcot-Marie-Tooth disease 
type 4B1 whereas a mutation in its inactive binding partner MTMR13 results in a similar clinical 
syndrome (Charcot-Marie-Tooth disease type 4B2) (Bolino, Muglia et al. 2000, Berger, Bonneick 
et al. 2002, Azzedine, Bolino et al. 2003, Senderek, Bergmann et al. 2003).  
Notably, all genes involved in the development of CMT are encoding for proteins with functions 
in endocytosis and membrane trafficking which suggests that the pathogenesis of CMT is 
contributed by defects in these cellular processes (Mruk and Cheng 2011).  
Furthermore, MTMR9 gene is associated with obesity. This gene is expressed in the lateral 
hypothalamic area (LHA), paraventricular nucleus (PVN) and the arcuate nucleus (ARC) of the 
hypothalamus, and the center of food intake regulation (Yanagiya, Tanabe et al. 2007). In 
addition, it is located on segment 8p23-p22, which has been linked to obese phenotypes 
(Johnson, Luke et al. 2005). 
MTMR7 gene is linked with the variant Creutzfeldt-Jakob disease, a type of brain disease within 
the transmissible spongiform encephalopathy (Lloyd, Mead et al. 2011, Sanchez-Juan, Bishop et 
al. 2012). 
Finally, MTMR3 is associated with an increased risk of gastric and colon carcinomas (Song, Kang 
et al. 2010). 
1.2.3. Inactive myotubularins, protein complex formation and cellular functions 
The myotubularins can be divided in active and inactive proteins and are localized to different cell 
compartments (Figure 5).  
 
 
Figure 5: Localization and activity of myotubularins. 7 out of 16 myotubularins possess catalytic activity, dephosphorylating PI(3)P 
and PI(3,5)P2 to PtdIns and PI(5)P. They can either homodimerize or heterodimerize into active–active (indicated by red brackets) or 
active–dead complexes (indicated by red arrows), which confers more precise regulation of myotubularin PI phosphatase activity. 
Adapted from (Hnia, Vaccari et al. 2012, Weidner 2016) 
 
Introduction 
 
13 
Inactive myotubularins are essential for the regulation and subcellular localization of active 
myotubularins (Berger, Schaffitzel et al. 2003, Kim, Vacratsis et al. 2003, Nandurkar, Layton et 
al. 2003, Berger, Berger et al. 2006). Inactive MTMR13, for example, forms a complex with active 
MTMR2 and thereby increases its activity towards PI(3)P and PI(3,5)P2 by 10- and 25-fold. 
Furthermore, the subcellular distribution of the two proteins is overlapping under resting 
conditions while it diverges under hypo-osmotic stress situations. This fact suggests that inactive 
phosphatases do not only regulate the enzyme activity of the active ones but also their localization 
to subcellular compartments (Berger, Berger et al. 2006).  
Other examples of interactions between myotubularins are the complex formation of MTM1 with 
MTMR12 as well as MTMR2 (Nandurkar, Layton et al. 2003, Cao, Laporte et al. 2007, Cao, 
Backer et al. 2008).  
Inactive MTMR9 forms a complex with MTMR6, MTMR8 and MTMR7 while the last interaction 
requires the coiled-coil domain and leads to an increased MTMR7 phosphatase activity 
(Mochizuki and Majerus 2003, Lorenzo, Urbe et al. 2006). 
Since myotubularins are using phosphoinositides as substrates, they play a role in the 
phosphoinositide signaling process. Because PI(3)P is localized to the plasma membrane and to 
early and late endosomes, myotubularins are regulators of endocytic trafficking like endocytosis, 
degradative pathways, recycling pathways, and autophagy (Gillooly, Morrow et al. 2000, Fares 
and Greenwald 2001, Gillooly, Raiborg et al. 2003, Xue, Fares et al. 2003, Tooze and Yoshimori 
2010). One example for a recycling route is the sorting of the EGFR (Keohavong, DeMichele et 
al.) for degradation.  
MTM1 and MTMR2 inhibit EGFR degradation (Tsujita, Itoh et al. 2004, Berger, Tersar et al. 2011). 
In addition, PI(3)P are involved in autosomal initiation, a process in which portions of cellular 
contents are internalized into double membrane autophagosomes for degradation (Vergne, 
Roberts et al. 2009, Dowling, Low et al. 2010, Taguchi-Atarashi, Hamasaki et al. 2010).  
Myotubularins have been initially identified as "survival" phosphatases and are said to positively 
regulate cell proliferation and/or inhibit apoptosis. For example, silencing of MTMR2 in cultured 
Schwann cells leads to decreased proliferation and enhanced caspase-dependent cell death 
(Chojnowski, Ravise et al. 2007). 
1.2.4. MTMR7 and PPARγ 
The lipid phosphatase MTMR7 was first characterized by Majerus et al. to be specifically 
expressed in brain, neuronal cells, liver, kidney and the testis. MTMR7 has been localized to 
granules close to the nucleus and the cytosol assuming that it might be enriched in the Golgi 
apparatus or endosomes. It is found in a soluble form in the cytosol, where it uses free inositol-
1,3-bisphosphate (Ins(1,3)P2) as substrate (Mochizuki and Majerus 2003). 
In 2016 our research group first described, the role of MTMR7 in colorectal cancer, where it 
inhibits the insulin-mediated activation of the AKT and ERK 1/2 signaling pathways, leading to a 
reduced proliferation in human colorectal cancer cells. MTMR7 protein was further downregulated 
in human colorectal cancer cells and many patients (Weidner, Söhn et al. 2016). 
 
We identified the peroxisome proliferator-activated receptor gamma (PPARγ) as a cytosolic 
binding partner of MTMR7 in a MALDI-MS screen (Söhn, Weidner et al., unpublished). PPARγ 
belongs to the nuclear receptor superfamily of transcription factors. PPARγ is involved in the 
regulation of several processes including, glucose and lipid metabolism (Polvani, Tarocchi et al. 
2016), inflammation, differentiation, including tissue regeneration such as wound healing and 
cancer (Burgermeister and Seger 2007, Srivastava, Kollipara et al. 2014, Zurlo, Ziccardi et al. 
2016). 
PPARγ is extensively expressed in brown and white adipose tissue, cells and organs of the 
immune system and the large intestine (Taheri, Salamian et al. 2015). It can be activated by its 
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natural ligands such as prostaglandin J2 derivatives or polyunsaturated fatty acids or by synthetic 
ones like rosiglitazone and pioglitazone, belonging to the thiazolidinedione and mostly used as 
anti-diabetic drugs and anti-cancer reagents (van Beekum, Fleskens et al. 2009, Peymani, 
Ghoochani et al. 2013). When activated, it forms a complex with the 9-cis retinoic X receptor 
(RXR), enters the nucleus and binds to the peroxisome proliferator response element (PPRE) 
(van Beekum, Fleskens et al. 2009). In the nucleus, PPARγ initiates the transcription of genes 
but can also be inhibited. PPARγ inhibition is due to constitutivly active RAS, which leads to the 
permanent activation of MEK-1. This in turn leads the export of PPARγ from the nucleus to the 
cytosol (Burgermeister, Chuderland et al. 2007) and to the phosphorylation of ERK 1/2, which 
phosphorylates PPARγ at serine 84/114 (in humans), resulting in inhibition of its transactivating 
potential on target gene promoters (Seger and Krebs 1995). 
 
PPARγ has a contradictory role on tumorigenicity. On the one hand a tumorigenic role has been 
described in several cancer types like bladder cancer, liposarcoma, mammary adenocarcinoma 
or hepatic tumors (Srivastava, Kollipara et al. 2014, Wu, Yang et al. 2016, Yousefnia, 
Momenzadeh et al. 2018). On the other hand, nuclear PPARγ has been associated with good 
prognosis, higher survival rates and a less aggressive and metastatic phenotype in colorectal 
cancer patients (Ogino, Shima et al. 2009, Pancione, Forte et al. 2009). Thus, the MTMR7-
PPARγ-complex could be a druggable target for the treatment of KRAS-mutated CRC patients. 
1.3. Aim of the thesis 
The most important difficulty in treating colorectal cancer, is the intrinsic and/or acquired 
resistance to chemotherapeutic drugs or targeted therapies. This unresponsiveness to therapy 
with antibodies directed against the epidermal growth factor receptor (Karapetis, Khambata-Ford 
et al. 2008), is often due to mutations in the KRAS gene, leading to constitutive activation of the 
RAS signaling pathway and in turn to the proliferation and survival of the tumor cells.  
Thus, targets downstream of mutant RAS hold the promise to overcome therapy resistance in this 
patient group.  
 
This thesis is focused on the lipid phosphatase MTMR7, which was first characterized by Majerus 
et al. to be specifically expressed in brain, neuronal cells, liver, kidney and the testis.  
MTMR7 has been localized to granules close to the nucleus and the cytosol, and is found in a 
soluble form in the cytosol, where it uses free inositol-1,3-bisphosphate (Ins(1,3)P2) as substrate 
(Mochizuki and Majerus 2003). MTMR7 was found as a novel binding partner of the peroxisome 
proliferator activated-receptor gamma (PPARγ) (Söhn, Weidner et al., unpublished). The 
expression of PPARγ is correlated with a good prognosis in CRC patients and it is one of the 
candidates to inhibit RAS through the upregulation of Ras-inhibitory proteins like PTEN, DOK1 or 
Caveolin-1. 
 
As already published, the lipid phosphatase MTMR7 inhibits the two major pathways RAF-
MEK1/2-ERK1/2 and AKTmTORC1/2 downstream of mutant KRAS, indicating an essential role 
in colorectal carcinoma (Weidner, Söhn et al. 2016). Thus, this thesis aimed to elucidate, if the 
MTMR7-PPARγ-complex could be a druggable target for the treatment of KRAS-mutated CRC 
patients. 
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This should be achieved by (i) assessing whether the enzymatic activity of MTMR7 is modified by 
the activation of PPARγ, using pharmacological ligands, (ii) determining if the PPARγ-MTMR7 
complex formation results in changes in the phosphorylation status of its lipid or protein 
substrates, iii) investigating if these changes lead to a change in KRAS expression levels, iv) 
examining, if the intrinsic unresponsiveness of KRAS mutant cells may be circumvented by the 
combination of PPARγ-ligands (such as the antidiabetic drug rosiglitazone) with kinase inhibitors 
like RAF-inhibitors (sorafenib, vemurafenib) and mTOR-inhibitors (everolimus) downstream of 
mutant KRAS. 
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2. Material and Methods 
2.1. Materials and Equipment 
Table 1: General chemicals 
Name Company Order number 
4',6-diamidino-2-phenylindole Roth GmbH 6335.1 
1,4- Dithiothreitol (DTT) Roth GmbH 6908.1 
2-Mercaptoethanol Sigma-Aldrich Chemie GmbH M7522 
2-Propanol Merck KGaA 1096341000 
Acetic acid ≥ 99,0 % (T) Sigma-Aldrich Chemie GmbH 45740 
Ammoniumperoxodisulfate Roth GmbH 9592,3 
Ampicillin > 99 % Roth GmbH K029.1 
Antigen unmasking solution Vector Laboratories H-3300 
Biozym LE Agarose Biozym Scientific GmbH 840004 
Boric Acid Sigma-Aldrich Chemie GmbH B6768 
Bromphenol Blue Sigma-Aldrich Chemie GmbH B-5525 
Complete Mini Protease inhibitor cocktail 
tablets Roche Diagnostics GmbH 04693124062 
Dithiothreitol (DTT) Roth GmbH 1.114.740.004 
Dual-Luciferase® Reporter Assay System Promega Cooperation E1910 
DH5 alpha competent cells Invitrogen GmbH 18265-017 
Ethanol, absolute, ≥ 98 % (GC) Sigma Aldrich  24194-5L R 
Ethanol technical, 96 % Roth GmbH 46139 
Ethidium bromide (10mg/ml) Sigma-Aldrich Chemie GmbH 15585-011 
Eukitt Sigma-Aldrich Chemie GmbH 03989 
Fluorescent mounting medium Dako North America S302380-2 
Formaldehyde 37 % ROTIPURAN Roth GmbH  4979.2 
Glycerol 99 % Sigma-Aldrich Chemie GmbH  200-289-5 
Glycine PUFFERAN ≥ 99 % p.a. Roth GmbH  3908.3 
Hemalum (Meyer) Roth GmbH T865.1 
HEPES Sigma-Aldrich Chemie GmbH 9105.3 
Hydrochloric acid (1N) Merck KGaA 1.090.571.000 
Hydrochloric acid (37 %) Sigma-Aldrich Chemie GmbH 435570 
LB-Agar Roth GmbH X965.1 
LB-Medium Roth GmbH X964.1 
Magnesium chloride Merck KGaA 5833 1000 
Methanol ≥ 99,8 % (GC) Sigma-Aldrich Chemie GmbH  32213 
Milk powder Sigma-Aldrich Chemie GmbH T145.2 
PBS Dulbecco Merck KGaA L182-50 
Power SYBR Green PCR Master Mix Applied Biosystems 4368577 
Protein A/G Plus Agarose  Santa Cruz Biotechnology sc-2003 
Protein G Plus/Protein A-Agarose Merck KGaA IP05 
Rotiphorese® Gel 30 (37,5 : 1) Roth GmbH 3029.2 
Roti®-Mark TRICOLOR Roth GmbH 8271.1 
Sodium Dodecyl Sulfate (SDS, ultra-pure 
≥99.5 %) Roth GmbH  2326.1 
Sodium chloride Sigma-Aldrich Chemie GmbH 31434-500G-R 
Sodium orthovanadate (Na3VO4) Sigma-Aldrich Chemie GmbH S6508 
TEMED (N,N,N’,N’-Tetramethylethane-
1,2-diamin 99 % Roth GmbH  2367.3 
Top10 one shot competent cells Invitrogen GmbH C404010 
TRIS PUFFERAN ≥ 99,9 % Ultra Roth GmbH  5429.3 
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Triton® X-100 Sigma-Aldrich Chemie GmbH 1.122.980.101 
Tween® 20 Roth GmbH 9127.1 
Western Bright Sirius HRP substrate Advansta Inc K-12043-D10 
X-Gal (5-bromo-4-chloro-indolyl--D-
galactopyranoside Sigma-Aldrich Chemie GmbH G5160 
Xylol (mixture of isomers) Roth 9713.1 
 
Table 2: Cell culture reagents 
Name Company Order number 
Dimethyl sulfoxide, minimum 99,5 % GC Sigma-Aldrich Chemie GmbH D8418 
Dulbecco’s Modified Eagle Medium Invitrogen GmbH 41966-052 
Hyclone Fetal bovine serum Invitrogen GmbH SV 30 160.03 
L-Glutamine Invitrogen GmbH 25030-024 
PBS phosphate buffered saline pH 7,4 Invitrogen GmbH 10010-056 
Penicillin-Streptomycin Invitrogen GmbH 15140-122 
RPMI-1640 Invitrogen GmbH 21875-091 
Thiazol Blue Tetrazolium Bromide (MTT) Sigma-Aldrich Chemie GmbH M 5655-1G 
Trypan Blue stain (0.4 %) Invitrogen GmbH 15250-061 
Trypsin-EDTA (0.25 %), phenol red Invitrogen GmbH 25200-056 
TurboFect® in vitro transfection reagent Fermentas GmbH R0531 
 
Table 3: Human cell lines 
Name Disease Company 
AGS Gastric Adenocarcinoma European Collection of Authenticated Cell Cultures (ECACC) 
Caco2 Human colorectal adenocarcinoma European Collection of Authenticated Cell Cultures (ECACC) 
DLD1 Human colorectal adenocarcinoma 
Deutschen Sammlung von 
Mikroorganismen und Zellkulturen 
GmbH (DSMZ) 
HCT116 Human colorectal carcinoma European Collection of Authenticated Cell Cultures (ECACC) 
HT29 Human colorectal adenocarcinoma European Collection of Authenticated Cell Cultures (ECACC) 
HEK293T Human embryonic kidney 
Deutschen Sammlung von 
Mikroorganismen und Zellkulturen 
GmbH (DSMZ) 
Lovo Human colorectal adenocarcinoma 
Deutschen Sammlung von 
Mikroorganismen und Zellkulturen 
GmbH (DSMZ) 
PATU8902 pancreas adenocarcinoma 
Deutschen Sammlung von 
Mikroorganismen und Zellkulturen 
GmbH (DSMZ) 
SW480 Human colorectal adenocarcinoma European Collection of Authenticated Cell Cultures (ECACC) 
 
Table 4: Antibodies 
Primary Antibodies   
Name Company Order number 
MTMR7 (Full-length) Abcam plc. ab121222 
cMTMR7 Abcam plc. ab150458 
MTMR7 MyBiosource MBS#1497385 
ERK1/2  Cell Signaling Technology 9101S 
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pERK1/2 (WB) Cell Signaling Technology 9101 
pERK1/2 (IHC) Cell Signaling Technology 4370 
HSP90 Santa Cruz Biotechnology sc-7942 
AKT2 Cell Signaling Technology 3063S 
pAKT473 Cell Signaling Technology 4058 
pAKT308 Cell Signaling Technology 2965S 
PPARγ Cell Signaling Technology 2435 
PPARγ (H100) Santa Cruz Biotechnology Sc-7196 
GFP Roche Diagnostics GmbH 11814460001 
HA Roche Diagnostics GmbH 11867423001 
Flag Sigma-Aldrich Chemie GmbH A2220 
Flag Cell Signaling Technology 2368S 
Pan-RAS Santa Cruz Biotechnology Sc-166691 
KRAS Abcam plc. 172949 
KI67 Novus Biologicals NB600-1252 
Lamin Santa Cruz Biotechnology Sc-20681 
EGFR Cell Signaling Technology 4267S 
Rab5 Cell Signaling Technology 3547 
Rab9 Thermo Fisher Scientific MA3-067 
Calnexin Cell Signaling Technology 26798 
   
Secondary Antibodies   
Alexa Fluor 488 Phalloidin Thermo Fisher Scientific A12379 
Alexa Fluor 594 Phalloidin Thermo Fisher Scientific A12381 
Alexa Fluor 488 donkey anti-rabbit Thermo Fisher Scientific A21206 
Alexa Fluor 594 donkey anti-mouse Thermo Fisher Scientific A21203 
Alexa Fluor 594 donkey anti-rabbit Thermo Fisher Scientific A21207 
Anti-rabbit IgG, HRP-linked Antibody Cell Signaling Technology 7074 
Anti-mouse IgG, HRP-linked Antibody GE Healthcare Europe GmbH NA-931V 
 
 
Table 5: Primer-sequences 
mouse RT-qPCR primer   
Gene Forward 5‘-3‘ Revers 3‘-5‘ 
Aco caggaagagcaaggaagtgg cctttctggctgatcccata 
B2m atgggaagccgaacatactg  cagtctcagtgggggtgaat 
Cyclind1 gcgtaccctgacaccaatct atctccttctgcacgcactt 
Hras atggcatcccctacattgaa acagcacacatttgcagctc 
Kras  tgcaatgagggaccagtaca  ccaggaccataggcacatct  
Mtmr7 ctgcagggaaaggctatgag cagcctgagttctccagtcc 
Mtmr9 cgaagcacttcggaaggtag ttctcgtcttccttgcacct 
Nras  tgacttgccaacaaggacag  aaaaggcatcctccacacc  
p21 cggtggaactttgacttcgt cagggcagaggaagtactgg 
Tff3 tctggctaatgctgttggtg ctcctgcagaggtttgaagc 
   
human RT-qPCR primer   
ACO ctgtgaggcaccagtctgaa gttcactcaggtccccttga 
B2M tgctgtctccatgtttgatgtatct  tctctgctccccacctctaagt  
CYCLIND1 gatcaagtgtgacccggact  tcctcctcttcctcctcctc  
HRAS ggaagcaggtggtcattgat atggcaaacacacacaggaa 
KCA3.1 catcacattcctgaccatcg acgtgcttctctgccttgtt 
KRAS  tgtggtagttggagctggtg tgacctgctgtgtcgagaat 
N-MTMR7 tgacggctacccatgtcata aatgattagggaggcccatc 
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C-MTMR7 tctgtcagccaacagtgacc cagtgagaaacacggcttca 
Central-MTMR7 tgcagaaaatgctggaagtg cactgcctttgcaatgaaga 
MTMR9 ccaccacttgatcctgtcct ttcaagcattcctccattcc 
NRAS ccaagaccagacagggtgtt ccctgagtcccatcatcact 
P21 gacaccactggagggtgact caggtccacatggtcttcct 
TFF3 ctccagctctgctgaggagt  gcttgaaacaccaaggcact  
 
Table 6: Enzymes 
Name Company Order number 
BamHI restriction enzyme Promega cooperation R6021 
EcoRI restriction enzyme Promega cooperation R6011 
GoTaq® Green Master Mix Promega cooperation M 7121 
HindIII restriction enzyme Promega cooperation R6041 
JumpStart™ RedTaq Ready 
Mix™ PCR Reaction Mix Sigma-Aldrich Chemie GmbH 
P0982  
NotI restriction enzyme Promega cooperation R6431 
T4 Ligase 5 u/µl New England Biolabs GmbH 15224017 
RNase-free DNAse Set QIAGEN GmbH 79254 
 
Table 7: Kits 
Name Company Order number 
BCA™ Protein Assay Kit Thermo Fisher Scientific 23225 
DAB Peroxidase Substrate 
Kit 
Vector Laboratories SK-4100 
Duolink® in Situ PLA Olink Bioscience DUO92101 
HighSpeed® Plasmid Midi Kit QIAGEN GmbH 12643 
QIAquick Gel Extraction Kit QIAGEN GmbH 28704 
PureYield™ Plasmid Mini 
Prep 
Promega cooperation A1222 
PeqGold Total RNA Kit Peqlab 12-6834-02 
TOPO® TA Cloning® Kit Invitrogen GmbH 450641 
Vectastain® ABC kit 
peroxidase rabbit/mouse IgG 
Vector Laboratories PK-4000 
Verso™ cDNA Kit Thermo Fisher Scientific AB-1453/B 
 
Table 8: Stimulants 
Name Company Order number 
17-DMAG Invivogen ant-dgl-25 
Amiloride Sigma-Aldrich Chemie GmbH A 7410 
Cetuximab Merck KGaA UMM pharmacy 
Chloroquine Sigma-Aldrich Chemie GmbH C6628 
Everolimus Cayman Chemical 11597 
hEGF, lyophilized Roche Diagnostics GmbH 000000011376454001 
MG-132 Sigma-Aldrich Chemie GmbH SML1135 
Rosiglitazone Cayman Chemical 71740 
Sorafenib Cayman Chemical 10009644 
 
Table 9: Consumable material 
Name Company Order number 
Blue-Cap-Greiner 15 ml Greiner bio-one  188 261 
Blue-Cap-Greiner 50 ml Greiner bio-one  227 261 
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Cellstar cell culture flask 
75 mm3 
Greiner bio-one  658 175 
Cellstar cell culture flask 
25 mm3 
Greiner bio-one  690 175 
Cellstar cell culture dishes 
10 cm 
Greiner bio-one  664 160 
Cellstar cell culture dishes 
14,5 cm 
Greiner bio-one  639 160 
Cellstar cell culture dishes 
6 cm 
Greiner bio-one  628 160 
Cellstar 6-well cell culture 
plate 
Greiner bio-one  657 160 
Cellstar 12-well cell culture 
plate 
Greiner bio-one  665 180 
Cellstar 24-well cell culture 
plate 
Greiner bio-one  662 160 
Cellstar 96-well cell culture 
plate 
Greiner bio-one 655 180 
Coverslips Menzel GmbH & Co. KG 631-1580 
10 µl pipette filter tips Starlab S1121-3810 
200 µl pipette filter tips Starlab S1120-8810 
1000 µl pipette filter tips Starlab S1126-7810 
5 ml serological pipette Greiner bio-one  606 180 
10 ml serological pipette Greiner bio-one  607 180 
25 ml serological pipette Greiner bio-one  760 180 
50 ml serological pipette Greiner bio-one  768 160 
Kimwipes-Science  Roth AA63.1 
1.5 ml microcentrifuge tubes Eppendorf AG 0030120086 
2.0 ml microcentrifuge tubes Eppendorf AG 0030120094 
200 µl PCR tubes Sarstedt AG & Co 72.737.002  
Petri dish BD Biosciences 351058 
Superfrost® plus microscope 
Slides 
Menzel GmbH & Co. KG 6310108 
 
Table 10: Equipment 
Machine Company 
Axiovert 40 CFL Microscope Carl Zeiss MicroImaging 
Centrifuge 3K12  Sigma 
Centrifuge 5804R Eppendorf AG 
Centrifuge 5415D Eppendorf AG 
Disperser T10 basic Package  IKA®-Werke GmbH & Co. KG 
Fusion Solo 
GelIX Imager 
PeqLab (VWR) 
INTAS 
GeneAmp® PCR System 9700 Thermo Fisher Scientific 
HERAcell® 240 Incubator Heraeus 
Hera safe Heraeus 
Mastercycler personal Eppendorf AG 
Mini-PROTEAN® 3 Cell Bio-Rad Laboratories GmbH 
Mini-Sub® Cell GT Bio-Rad Laboratories GmbH 
Mini Trans-Blot® Electrophoretic Transfer 
Cell Bio-Rad Laboratories GmbH 
NanoDrop® Spectrophotometer ND-1000 PEQLAB Biotechnologie GmbH 
Peqstar Light cycler Peqlab 
pH-Meter 766 calimatic Knick 
Pipettes Eppendorf AG 
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Power Supply EV245  Consort 
PowerPac Basic Bio-Rad 
Real Time machine 7900HT Sequence 
Detection System Applied Biosystems 
Shaker Certomat HK B. Braun Biotech international 
Table-cool centrifuge Eppendorf AG 
Tecan Infinite M200 microplate reader TECAN Group Ltd. 
Tube Rotator  
Vortexer Reax 2000 Heidolph 
Water bath Certomat WR B. Braun 
Water system ELGA  Millipore 
 
2.2. Software and Bioinformatics 
Software Manufacturer 
Image J Wayne Rasband 
Prism 7 GraphPad 
Office 2010 Microsoft 
 
2.3. Cell culture 
2.3.1. Growth conditions 
Human embryonic kidney (HEK293T), DLD1, Lovo, and PATU8902 cell lines were from the 
German Collection of Microorganisms and Cell Cultures (DMSZ). HT29, Caco2, SW480 und 
HCT116 were from the European Collection of Authenticated Cell Cultures (ECACC). All cell lines, 
except DLD1, were cultured at 37 °C in a humidified atmosphere of 5 % CO2 and 95 % air in high-
glucose Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10 % (v/v) fetal calf 
serum (FCS), 20 mM glutamine and penicillin / streptomycin (1000 units/ml; all from Invitrogen). 
For the DLD1 RPMI 1640 medium was used with the same supplements as for the other cell lines. 
Adherent cells were detached by using Trypsin-EDTA (0.25 %). 
2.3.2. Transient transfection of human cell lines 
Cells were seeded into 6-well plates and grown to 70 % confluency. The cells were then 
transiently transfected in DMEM medium with 2 μg DNA/well using TurboFectTM (Thermo Fisher) 
or 500 ng shRNA (Qiagen) according to the manufacturer`s instructions. As a negative control, 
cells were transfected with either EV control or a control shRNA. Cells were transfected for 6 
hours and the medium was changed thereafter. 
2.3.3.  Cell stimulation 
MTT 
The MTT assay is a colorimetric assay for assessing cell viability. Enzymes called NAD(P)H-
dependent cellular oxidoreductase are supposed to reflect the number of viable cells present per 
well. These enzymes reduce 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 
tetrazolium dye) to insoluble formazan (purple color). These assays can be used to study cell 
proliferation (cell growth under different conditions) or cytotoxicity, e.g. a loss of viable cells, 
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because of potential medical agents and toxic materials. In this thesis we only used proliferation 
assays, hereafter referred to as “viability-assays”. 
 
Sorafenib/Everolimus 
For viability assay cells were seeded into a 6-well plate transfected with an empty vector (EV) 
control, MTMR7 and MTMR9 (2 µg DNA/well) as described in 2.3.2. 24 h after seeding, cells were 
reseeded into 96-well plates (2000 cells/well). The next day, cells were treated with sorafenib (0, 
0.1, 0.3, 0.6, 1, 3, 6, 10 µM)/ everolimus (0, 0.01, 0.1, 1, 6, 10, 30, 50 µM). Concentrations had to 
be adapted for HEK293T cells (sorafenib (0, 10, 30, 60, 100, 300, 600, 1000 nM)/everolimus (0, 
0.1, 0.3, 0.6, 1, 3, 6, 10 nM)). Viability was measured for 7 days. 
 
Knockdown 
For viability assay cells were seeded into a 6-well plate, transfected with plasmids for control-
shRNA-control or MTMR7-shRNA (1:1:1:1 mixture of four clones, 500 ng/well, Qiagen) as 
described in 2.3.2. 24 h after seeding, cells were reseeded into 96-well plates (2000 cells/well). 
Viability was measured for 7 days. 
 
Peptide 
For viability assay 2000 cells/well were seeded into a 96-well plate. The next day, cells were 
incubated with either a control peptide or a MTMR7 peptide (0, 0.01, 0.1, 0.5, 1, 10 µM). Important 
modifications were a myristic acid at the N-terminus for anchoring at the cell membrane and the 
amidation at the C-terminus. Viability was measured for 7 days.  
 
MTMR7 peptide sequence: 
LMAVKEETQQLEEELEALEERLEKIQKVQL 
2.4. Protein preparation and analyses 
2.4.1. Total cell lysate 
To prepare total cell lysates, cells were transfected as described before (2.3.2). After 48 hours (h) 
cells were washed once with ice-cold PBS and 500 µl SDS-lysis buffer (50 mM Tris-HCl, pH = 
7.4, 1 % (w/v) SDS, 1 mM sodium orthovanadate (Na3VO4), 1 mM dithiothreitol (DTT), Protease 
Inhibitor Complete®) was added to the dish on ice. After scraping the cells, they were incubated 
on ice for 10 min, lysate was transferred to a 1.5 ml tube on ice and sonified with a stick sonicator. 
In the end, cells were centrifuged for 10 min at 4 °C (max. speed), and the supernatant was again 
transferred to a 1.5 ml tube and stored at -80 °C. 
2.4.2. Total tissue lysate 
To isolate proteins from tissue, approximately 3 mm3 of frozen tissue were cut off the block with 
a clean scalpel and put into a 2.0 ml tube with 5 x volumes of ice-cold tissue protein lysis buffer 
(20 mM HEPES, pH 7.4, 1 mM EDTA, 50 mM β-glycerophosphate, 10 % (v/v) Glycerol, 1 % (v/v) 
Triton X-100, 1 mM Na3VO4, 1 mM DTT, Protease Inhibitor Complete®). The tissue was then 
homogenized with a polytron homogenizer (Ultraturrax) for 10 sec. until no pieces remained. The 
lysates were incubated on ice for 1 h followed by centrifugation for 10 min at maximum speed in 
an Eppendorf centrifuge at 4 °C. Supernatant was collected and frozen at  
- 80 °C. 
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2.4.3. Subcellular fractionation of cells 
For subcellular fractionation, the cells were lysed by hypotonic lysis (HL-buffer: 20 mM Tris-HCl, 
pH 7.4, 2 mM EDTA, 2 mM MgCl2, 1 mM Na3VO4, 1 mM DTT, Protease Inhibitor Complete®). 
The nuclei were extracted in 150 μl of high salt buffer (HL buffer supplemented with 450 mM 
NaCl) on ice for 30 min with frequent vortexing for complete lysis. The remaining pellet containing 
all kinds of membranes/matrix components (endoplasmic reticulum, plasma membrane, nuclear 
matrix & membrane, chromatin) was subjected to extraction in 150 μl SDS lysis buffer (50 mM 
Tris HCl, pH 7.6, 2 % SDS (w/v)) for 5 min and sonication (10 sec, 35 %, Soniplus). 
2.4.4. Coimmunoprecipitation  
Coimmunoprecipitation (CoIP) is used to investigate protein-protein-interactions. For CoIP 
experiments, cells were seeded into a 10 cm dish and grown to 70 % confluence. On the next 
day, cells were transfected with 4 µg plasmid DNA for 48 h. Thereafter, cells were harvested by 
hypotonic lysis (10 mM Tris-HCl, pH 7.4, 2 mM EDTA, 2 mM MgCl2, 1 mM Na3VO4, 1 mM DTT, 
Protease Inhibitor Complete®) and incubated on ice for 20 min. Cell lysates were then scraped, 
transferred to a 2.0 ml tube, pipetted up and down until foaming and centrifuged at 4 °C, maximum 
speed. Supernatant was transferred into a new 1.5 ml tube, 10 µl agarose beads were added for 
preclearing, and the samples were incubated for 1 h at 4 °C on a rotator. After the incubation, 
cells were centrifuged again for 10 min at 4 °C, at maximum speed. Lysates were then separated 
into three tubes: 1) without antibody (-) (AB), 2) with AB (+) 3) input. Antibodies were added to 
the (+) samples, and the samples were incubated on the rotator over night at 4 °C. The next day, 
60 µl of agarose beads were added followed by incubation on the rotator for 2 h at 4 °C. 
Afterwards, cells were washed 3 times, eluted with 50 µl 100 mM Glycine (pH 2.2) for 2 min. 
Reaction was stopped by adding 10 μl 1.5 mM Tris-HCl, pH 8.8. After centrifugation for 1 min at 
maximum speed at 4 °C, the eluate was collected. Then, 20 µl SDS loading dye were added to 
the samples as well as the collected input. All samples were incubated at 99 °C for 10 min to 
perform Western blot analysis. 
2.4.5. Ras pulldown activity assay 
RAS pulldown assays were performed according to the manufacturer’s protocol (Biocat). In detail, 
cells were seeded into a 10 cm dish and grown to 70 % confluence. On the next day, cells were 
transfected with 4 µg plasmid DNA for 48 hours. Cells were washed once with ice cold PBS and 
harvested by adding 1X assay/lysis Buffer (125 mM HEPES, pH 7.5, 750 mM NaCl, 5 % NP-40, 
50 mM MgCl2, 5 mM EDTA, 10 % Glycerol) provided by the kit. Plates were incubated on ice for 
20 min, cells were scraped and put into a 1.5 ml tube. Lysates were cleared by centrifugation for 
10 min (14.000 xg at 4 °C) and the supernatant was taken into a new 1.5 ml tube.  
40 μl of resuspended RAF1 RBD Agarose beads were added to each tube followed by incubation 
at 4 °C for 1 h on a rotator. To pellet the beads, samples were centrifuged for 10 sec at 14.000 xg. 
The beads were washed 3 times with 0.5 ml of 1X Assay Buffer by centrifuging and aspirating 
each time. After the last washing step, the beads were pelleted, and the supernatant was carefully 
removed. The bead pellet was resuspended in 40 μl of 1 M Tris-HCL (pH 7.4) and 20 µl of SDS-
PAGE loading dye (62.5 mM Tris-base, pH 10, 10 % (w/v) SDS, 5 % (v/v) β-mercaptoethanol, 
50 % (v/v) glycerol, bromphenol blue). Samples were then boiled for 5 min at 99 °C and 
centrifuged for 10 sec at 14.000 xg. 
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2.4.6. Western Blot 
Western blotting is an important technique used in cell and molecular biology to identify specific 
proteins extracted from cells or tissue. This is reached within three steps. First, the proteins are 
separated by size (SDS-gel electrophoresis), followed by the transfer to a solid 
support/membrane, and finally target proteins are detected using a primary and secondary 
antibody (Liu, Mahmood et al. 2014). 
 
Sample preparation: 
Proteins were isolated (see 2.4.1, 2.4.2), and the concentrations were measured with the BCATM 
Protein Assay Kit (Thermo Fisher) according to the manufacturer’s protocol. Samples were diluted 
in dH2O to the same concentrations and boiled in 5 x SDS loading dye (62.5 mM Tris-base, pH 
10, 10 % (w/v) SDS, 5 % (v/v) β-mercaptoethanol, 50 % (v/v) glycerol, bromphenol blue) for 
10 min at 99 °C. After boiling, the samples were centrifuged and freshly loaded on a SDS-gel. 
 
SDS-Gelelectrophoresis 
 
To separate the protein samples by size, 30 ng protein were loaded onto either a 12.5 % or 10 % 
SDS-gel (Table 11). 
 
Table 11: Components of SDS-Gels 
Reagent Separating gel Stacking gel 
 12.5 % 10 % 4 % 
    
H2O 2.59 ml 3.29 ml 1.53 ml 
Acrylamide 30 %/0.8 % 3.5 ml 2.8 ml 333 µl 
Tris-HCL 1.5 M pH 8,8 stock 2.1 ml 2.1 ml  
Tris-HCL 0.5 M pH 6,8 stock - - 625 µl 
SDS 10 % stock 83 µl 83 µl 25 µl 
APS 10 % stock 42 µl 42 µl 12.5 µl 
Temed 2.8 µl 2.8 µl 2.5 µl 
 
 
After loading, gels were run in a Mini-PROTEAN® 3 Cell system (Bio-Rad Laboratories) at 30 mA 
(constant) in running buffer (192 mM glycine, 25 mM TRIS-base, 0.1 % (w/v) SDS). 
 
Transfer and detection 
After the gel run, proteins were transferred to a nitrocellulose membrane (Whatman) using the 
Mini Trans-Blot® Electrophoretic Transfer Cell (Bio-Rad Laboratories) for 1 h at 100 V in transfer 
buffer (192 mM glycine, 25 mM Tris-base, 20 % (v/v) Methanol). 
After the transfer, membranes were stained with Ponceau S and blocked in either 5 % (w/v) milk 
or BSA in T-PBS (Table 12) for 1 h under gentle agitation at room temeprature (RT). The 
membrane was then incubated overnight with primary antibody (1:1000) at 4 °C in either 5 % (w/v) 
milk or BSA in T-PBS or just in T-PBS with gentle shaking. The next day, membranes were 
washed 3x15 min with T-PBS before adding horseradish peroxidase-labelled (HRP-labelled) 
secondary antibody (1:5000) in either 5 % (w/v) milk or BSA in T-PBS for one hour at RT. 
Membranes were washed again 3x15 min with T-PBS. Immunodetection was performed using 
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ECL Detection Reagent (Western Bright Sirius HRP substrate) according to the manufacturer`s 
protocol. The membrane was placed into a darkroom (Fusion Solo, blot imager) for the respective 
exposure time, and pictures were taken with a digital camera. 
 
Table 12: Antibody conditions. 
Antibody Blocking 1st antibody 2nd antibody 
H-100 (55 kDa) 2 % BSA 1:1000, T-PBS 1:5000, T-PBS 
Pan-RAS (21 kDa) 5 % milk 1:1000, T-PBS 1:5000, T-PBS 
Lamin (70 kDa) 5 % milk 1:1000, T-PBS 1:5000, T-PBS 
Tubulin (55 kDa) 5 % milk 1:1000, T-PBS 1:5000, T-PBS 
EGFR (175 kDa) 5 % milk 1:1000, 5 % BSA 1:5000, 5 % milk 
Flag rb 5 % milk 1:1000, 5 % milk 1:5000, 5 % milk 
GFP 5 % milk 1:1000, 5 % milk 1:5000, 5 % milk 
MTMR9 (63 kDa) 2 % BSA 1:1000, T-PBS 1:5000, T-PBS 
MTMR7 (75 kDa) 5 % milk 1:1000, 5 % milk 1:5000, 5 % milk 
p-ERK 1/2 (42/44 kDa) 5 % BSA 1:1000, 5 % BSA 1:5000, 5 % BSA 
ERK 1/2 (42/44 kDa) 5 % milk 1:1000, T-PBS 1:5000, T-PBS 
p-AKT Ser 473 (60 kDa) 5 % BSA 1:1000, 5 % BSA 1:5000, 5 % BSA 
AKT 2 (60 kDa) 5 % milk 1:1000, 5 % milk 1:5000, 5 % milk 
 
2.4.7. Luciferase reporter gene assay (SRE, PPRE) 
Reporter gene systems like the serum response element (Lefebvre, Chen et al.) or the PPARγ 
(PPRE) response element are used in cell biology to study gene expression as well as other 
cellular events coupled to gene expression, like receptor activity, intracellular signal transduction, 
protein folding and protein-protein interactions. 
In the currently applied Luciferase Assay System, light is produced by converting the chemical 
energy of luciferin oxidation through an electron transition, forming the product molecule 
oxyluciferin. This reaction is catalyzed by firefly luciferase, a monomeric 61 kD protein, which 
oxidizes luciferin to oxyluciferin by using ATP•Mg2+ as a cosubstrate. 
 
To perform PPRE (PPAR activity) assay, HEK293T, HCT116, and SW480 cells were seeded into 
a 6-well plate, transiently cotransfected with PPRE/EV and PPRE/MTMR7 plasmids for 24 h. 
Cells transfected with 3xPPRE-TK-luc (for PPARγ activity) (from Fa. Hoffmann-La Roche AG) 
were stimulated with rosiglitazone (0, 1, 10, 100 µM) over night. After aspirating the medium, 
100 μl of 1 x passive lysis buffer (Promega) was added. Cells were incubated for 10 min at RT on 
a shaker. Cells were transferred into 1.5 ml tubes and centrifuged for 10 min at 4 °C and maximum 
speed. Supernatant was transferred into a new tube, and the luciferase activity was measured by 
the Steady Glo luciferase assay system (Promega). To this end, 35 µl of “Luciferase Assay 
Reagent” were mixed with 10 µl of lysate. The light emission was measured using a Tecan reader 
(TECAN Group Ltd.). The data was normalized to the protein content of each sample. 
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2.5. Nucleic acid preparation and analysis 
2.5.1. RNA extraction and purification of cells 
Cells were seeded in 6-well plates and transfected or stimulated as required. After 48 h, medium 
was removed, and 350 μl lysis buffer (provided by the kit) was added to each well. Cells were 
scraped and transferred to columns containing a silica membrane from the Total RNA Kit 
(PeqGold). RNA was extracted according to the manufacturer`s protocol. By adding DNase I 
(QiagenN) for 20 min, free DNA was digested, and pure RNA was eluted in 35 µl RNase-free 
water at RT. 
2.5.2. RNA extraction and purification of tissue 
To isolate RNA from tissue approx. 3 mm3 of frozen tissue were cut off the block with a clean 
scalpel and put into a 1.5 ml tube with 350 μl lysis buffer (provided by the kit). The tissue was 
then homogenized with a polytron homogenizer (Ultraturrax) for 10 sec until no pieces remained. 
The lysates were transferred to a silica membrane from the from the Total RNA Kit (PeqGold). 
RNA was extracted according to the manufacturer`s protocol. By adding DNase I (Qiagen) for 
20 min, free DNA was digested, and pure RNA was eluted in 35 µl RNase-free water at RT. 
2.5.3. cDNA-synthesis 
Reverse transcription, e.g. cDNA-synthesis was performed with 1 µg of RNA using the VersoTMC 
Kit (Thermo Fisher) according to manufacturer’s protocol. After synthesis, H2O was added to a 
final volume of 50 µl. 
2.5.4. qPCR 
Quantitative real-time PCR was used for the analysis of gene expression. The reaction mix for 
one sample consisted of the following substances:  
 
Reagent Volume 
DNA 2 µl 
Power SYBR-green Master Mix (Qiagen) 10 µl 
Forward Primer 10 µM 1 µl 
Reverse Primer 10 µM 1 µl 
dH2O 6 µl 
 
 
The PCR was performed in a 96-well plate. Each well was filled with 2 µl of cDNA and mixed with 
18 µl of master mix. After spinning the plate for 1 min at 1000 rpm, the PCR was performed on a 
Real Time Machine 7900HT Sequence Detection System (Applied Biosystems) using the 
following program:  
 
Stage 1: 95 °C 10 min      1 cycle 
Stage 2: 95 °C 0:15 min; 60 °C 1:00 min    40 cycles 
Stage 3: 95 °C 0:15 min; 60 °C 0:15 min; 95 °C 0:15 min  1 cycle 
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During the PCR, the fluorescent dye SYBRgreen binds to the double stranded DNA which results 
in a fluorescence signal. Thus, an increase in the amount of DNA leads to an increase in 
fluorescence which can be measured for each cycle. After the PCR, the results were analyzed 
using the SDS 2.4 software (Applied Biosystems). To quantify the DNA amount, cycle thresholds 
(Ct-values) were exported to an Excel file. Afterwards, the mean value of the Ct was calculated 
for the same samples (duplicates), and the mean of the Ct value of the housekeeping gene (β2M) 
was subtracted (ΔCt). Then, the “calibrator” was calculated by taking the mean value of all ΔCt 
values for one gene under different conditions (e.g. stimulation; different individuals like patients 
or mice). The calibrator was then subtracted from the ΔCt leading to the ΔΔCt value. Finally, fold 
induction was calculated using the following term: 2-ΔΔCt. 
 
Regular PCR 
1 µg of RNA were transcribed into cDNA. For the PCR the GoTag®Green Master Mix (Promega) 
was used. The reaction mix for one sample consisted of the following substances: 
 
Reagent Volume 
cDNA 2 µl 
GoTag®Green Master Mix (Promega) 10 µl 
Forward Primer 10 µM 1 µl 
Reverse Primer 10 µM 1 µl 
dH2O 6 µl 
 
2.5.5. Agarose gelelectrophoresis 
PCR samples were analyzed on 1 % (w/v) agarose gels. Agarose (Biozym) was added to 1 x TAE 
buffer (40 mM Tris-base, 1 mM EDTA pH 8.0, 20 mM acetic acid), boiled for a few seconds and 
0.25 μg/ml ethidium bromide were added. The gel run was performed for 30 min at 100 V. For the 
detection of the DNA, a gel documentation device (Gel iX 20 Imager) and the software INTAS 
were used. 
 
2.6. Immunohistochemical methods 
2.6.1. Preparation of mouse tissue 
For immunohistochemical staining mouse tissue had to be embedded in paraffin cassettes. 
Mouse tissue, e.g. Ileum, Colon and Cecum, was inserted in embedding cassettes and fixed 
overnight in 4 % (w/v) paraformaldehyde in PBS at 4 °C. Afterwards, tissue was dehydrated in an 
autotechnicon and embedded in paraffin. Blocks had to be transferred to -20 °C before being cut 
into 2-3 µm slices with a microtome (Leica RM 2145).  
Tissue was also snap-frozen in liquid nitrogen using cryotubes (Sarstedt) and stored at -80 °C for 
later RNA or protein isolation. For analysis, frozen tissue was cut with a scalpel and RNA or 
protein was isolated as described in (2.4.1, 2.4.2). 
2.6.2. Immunofluorescence staining of cells 
Immunofluorescence is a technique which can be used on cells and tissue sections. It allows 
visualization of the distribution of your target protein within a cell. The technique uses specific 
antibodies which bind to their antigen present on your protein of interest. Secondary antibodies 
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coupled to fluorescent dyes are used to bind the Fc part of the primary antibody. After staining, 
samples can be viewed and analyzed with a fluorescence microscope. 
For fluorescence staining, 300.000 cells were seeded on coverslips. The next day, cells were 
transfected with MTMR-GFP plasmid for 48 h. Cells were then fixed with 4 % formaldehyde for 
20 min, washed with PBS (3x5 min), and blocked with 100 % of FCS for 30 min to avoid unspecific 
binding of the antibody. For intracellular staining, cells had to be permeabilized with 0.1 % Triton-
X 100 (v/v) in PBS for another 10 min. Then, the first antibody was added and incubated at 4 °C 
overnight.  
Coverslips were washed with PBS (3x5 min) and incubated with the secondary antibody (1:500) 
for one hour at RT in the dark. After another washing step, the coverslips were incubated with 
DAPI for 10 min at RT in the dark. Then, they were again washed with PBS and mounted onto 
glass-slides. After drying, stained cells could be visualized with a fluorescence microscope 
(Zeiss). (Antibody conditions are shown in Table 13). 
 
Table 13: Conditions for immunofluorescent staining 
Antibody 1st Ab dilution 
2nd AB 
dilution 
Order 
number 
Company 
Flag 1:500 1:500 F7425 Sigma-Aldrich Chemie GmbH 
cMTMR7 1:500 1:500 ab-150458 Abcam plc 
pan-RAS 1:500 1:500 sc-166691 Santa Cruz Biotechnology 
PPARγ 1:500 1:500 2435 Cell Signaling Technology 
RAB5 1:200 1:500 3547 Cell Signaling Technology 
RAB9 1:500 1:500 MA3-067 Thermo Fisher Scientific 
 
2.6.3. Immunofluorescence staining of tissue 
For immunofluorescence staining, paraffin sections were deparaffinized in Xylol (mixture of 
isomers) and rehydrated in the following steps: 96 % EtOH (6 min), 80 % EtOH (6 min), 70 % 
EtOH (6 min) and dH2O (2 min). Antigen retrieval was performed in unmasking solution 
(10 mmol/L citrate buffer, pH = 6.0; Vector Laboratories, Inc.). Sections were heated without 
boiling for 10 min in a microwave and afterwards cooled to RT for 30 min. After a washing step 
(3x5 min), slides were blocked with 100 % of FCS for 1 h to avoid unspecific binding of the 
antibody. Then, the first antibody diluted in 0.3 % Triton-X 100 (v/v) was added, and slides were 
incubated at 4 °C overnight. 
Slides were washed with PBS (3x5 min) and incubated with the secondary antibody (1:350) for 
one hour at RT in the dark. After another washing step, the slides were incubated with DAPI for 
10 min at RT in the dark. Then, they were again washed with PBS and mounted using mounting 
medium from DAKO. After drying, stained tissue sections could be visualized with a fluorescence 
microscope (Zeiss). (Antibody conditions are shown in Table 13).  
2.6.4. Immunohistochemistry 
Immunohistochemistry (IHC) is used to detect and localize proteins in cells of a tissue sections 
(Ramos-Vara et al, 2014). To understand the localization and the distribution of biomarkers and 
differentially expressed proteins, immunohistochemistry is often used in basic research. 
Furthermore, it’s used in the diagnosis of abnormal cells in cancerous tissue. For 
immunohistochemical staining, paraffin sections were deparaffinized in Xylol (mixture of isomers) 
and rehydrated in the following steps: 96 % EtOH (6 min), 80 % EtOH (6 min), 70 % EtOH (6 min) 
and dH2O (2 min). Antigen retrieval was performed in unmasking solution (10 mmol/L citrate 
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buffer, pH = 6.0; Vector Laboratories, Inc.). Sections were heated without boiling for 10 min in a 
microwave and afterwards cooled to RT for 30 min. Before quenching the endogenous 
peroxidase activity with 3 % (v/v) H2O2 in PBS, cells were washed in PBS (3x2 min). After 
quenching, slides were blocked with 5 % (v/v) normal goat serum in 1 % (w/v) BSA in PBS for 1 h 
at RT in a humidity chamber. Blocking solution was removed from the slides, primary antibody 
(1:100) was added, and the slides were incubated over night at 4 °C in a humidity chamber. Slides 
were washed 3x2 min in PBS and incubated with a biotinylated secondary rabbit (Vectastain® 
ABC Kit peroxidase rabbit IgG, Vectastain Laboratories, Inc.) antibody (1:500) in 1 % (w/v) BSA 
for 1 h at RT in a humidity chamber. After another washing step, slides were incubated in ABC-
Mixture (Vector Laboratories, Inc.) for 30 min. Slides were washed additionally before adding 
DAB-mixture from the DAB peroxidase substrate Kit (Vectastain Laboratories, Inc.) for 1-5 min 
until the tissue turned slightly brown. Afterwards, slides were 3x1 min washed in dH2O to stop the 
reaction and counterstained in “Mayer’s Hämalaum” (Merck) for a few seconds. Slides were 
washed for 10 min under tap water to get rid of the excessive color. Afterwards, slides were 
dehydrated using the following steps: 70 % EtOH (6 min), 80 % EtOH (6 min), 96 % EtOH (6 min) 
and Xylol (mixture of isomers) (6 min) and mounted with eukitt mounting medium using a glass 
coverslip. (Antibody conditions are shown in Table 14) 
 
Table 14: conditions for immunohistichemical staining 
Antibody 
Antigen 
retrieval Dilution 
Order 
number 
Company 
KI67 Citrate/EDTA 1:100 NB600-1252 Novus Biologicals 
KRAS Citrate/EDTA 1:100 Ab-172949 Abcam plc 
cMTMR7 Citrate/EDTA 1:100 ab-150458 Abcam plc 
 
Immunohistochemical staining was either evaluated by scoring (0 = negative, 1 = weak positive, 
2 = moderate positive and 3 = strong positive) or counting the cells (cells/ area). For the latter, 
positive cells per area were counted. In detail, at least of 5 images of normal tissues from 
Apcmin/+ x Cav1-KO mice ("adjacent normal") were selected, area of crypts was measured 
(5 crypts), and the positive cells in each crypt were counted. For tumors of the Apcmin/+ x Cav1-
KO mice, the area of the tumor was measured and the positive cells in this area were counted.  
2.7. Proximity ligation assay 
Proximity ligation assay (PLA, Duolink®) is a highly specific and sensitive technology to detect 
protein interactions and modifications. 
Two antibodies of the proteins of interest were used to bind the antigens in the cell which were 
tested for their potential colocalization. The secondary oligonucleotide labeled antibodies, so 
called “PLA probes”, bind to the primary antibodies. If the PLA probes are in close proximity (< 
40 nm) the DNA strands can interact, and the oligonucleotides are ligated and amplified in a rolling 
circle mechanism using oligonucleotides labeled with a fluorescent dye. These fluorescent 
oligonucleotides can be viewed in a fluorescent microscope as bright red fluorescent spots. PLA 
was performed according to the manufacturer’s protocol and all solutions were provided by the 
kit. For assay performance, HEK293T cells were grown on 18 mm2 coverslips placed in a 6-well 
plate. Cells were then washed with PBS (3x5 min), fixed with 4 % formaldehyde for 20 min, 
washed again with PBS (3x5 min), and incubated with blocking solution (provided by the kit) for 
30 min at 37 °C (dry incubator) in a humidity chamber to avoid unspecific binding of the antibody. 
Cells were then permeabilized with 0.1 % Triton-X 100 (v/v) in PBS for 10 min. Thereafter the 
primary antibody (1:250 in antibody diluent; provided by the kit) was added and incubated at 4 °C, 
overnight. Coverslips were washed in 1x Wash Buffer A (2x5 min) and incubated with the PLA 
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probe solution for 1 h at 37 °C in a humidity chamber. After another washing step in Wash Buffer A 
(2x5 min), coverslips were incubated with the Ligation-Ligase solution for 30 min at 37 °C. 
Afterwards, coverslips were washed twice in 1x Wash Buffer A for 2 min and then incubated with 
Amplification Polymerase solution for 100 min at 37 °C in the dark. After amplification, coverslips 
were washed once with Wash Buffer B for 10 min and stained with Phalloidin (1:500) in 1 x Wash 
Buffer B for 10 min. After an additional washing step with Wash Buffer B for 10 min, coverslips 
were washed in 0.01 x Wash Buffer B for 2 min, dried at RT in the dark and mounted on glass 
slides using Duolink in Situ Mounting Medium with DAPI. 
2.8. Molecular cloning 
For overexpression of huMTMR7 and huMTMR9 in cells, the human cDNA provided as 
commerical MGC clones from Thermofisher Scientific for both proteins were inserted into the 
pTarget vector (Promega). The cDNAs were amplified by PCR with the following setup: 
 
Reagent Volume 
cDNA 2 µl 
GoTag®Green Master Mix (Promega) 10 µl 
Forward Primer 10 µM 1 µl 
Reverse Primer 10 µM 1 µl 
dH2O 6 µl 
 
The PCR-program was as follows: 
94 °C 5 min,  
(94 °C 30 sec; 55 °C 60 sec; 72 °C 120 sec) x 35 Cycles 
72 °C 120 sec 
 
After the purification of the PCR-products on a 1 % agarose gel, bands with the size of 1,7 kb 
(MTMR9) and 2,0 kb (MTMR7) were cut with a clean scalpel under a UV-transilluminator, followed 
by DNA extraction using the QIAquick Gel Extraction Kit (Qiagen) according to the manufacturer`s 
protocol. Purified PCR products were used for TOPO TA Cloning® (Invitrogen) according to the 
manufacturer`s protocol. Reaction was setup as follows: 
 
Reagent Volume 
Purified linear PCR product 0.5 µl - 4 µl 
Salt Solution (provided by Kit) 1 µl 
dH2O (double distilled H2O) add to total volume of 5 µl 
linear TOPO vector (provided by Kit) 1 µl 
TOTAL volume 6 µl 
 
The TOPO-reaction was incubated for 5 min at RT. Afterwards, 1 µl of the TOPO reaction was 
immediately transferred into competent OneShot® TOP10 E.coli and mixed gently. Bacteria then 
were incubated for 30 min on ice, followed by a heat shock for 45 sec at 42 °C and incubation for 
2 min on ice. Then 500 µl SOC-Medium was added and the bacteria were incubated for 1 h at 
37 °C gently shaking at 300 rpm. Afterwards, bacteria were plated on LB agar plates containing 
100 μg/ml ampicillin and 40 mg/ml X-Gal (5-Brom-4-chlor-3-indoxyl-β -D-galactopyranoside, 
Sigma) and incubated overnight at 37 °C. The next day, positive white colonies (TOPO plasmid 
with correctly inserted PCR product) were picked and colony-PCR was performed. For the PCR, 
one colony was picked with a white pipette tip, transferred to another LB agar plate (“back up 
plate”) followed by incubation of the tip in 100 μl LB medium for 1 h at 37 °C under gentle shaking 
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at 300 rpm. After incubation, 5 µl of the bacteria suspension was used to perform the PCR 
reaction with the same setup as described before. The PCR products were again purified on a 
1 % agarose gel. If a positive band was detected, clones from the “back up plate” were incubated 
overnight in 5 ml LB containing 100 μg/ml ampicillin. The plasmid was purified using the 
PureYield™ Plasmid Mini Kit (Promega) according to the manufacturer`s protocol and sequenced 
by GATC Biotech AG. Clones with the correct MTMR7/MTMR9 sequence were then used for 
subcloning into the pTarget vector. The next step was the preparative restriction of the recipient 
vector by double digesting the DNA using the BamHI and NotI restriction enzymes (Promega) for 
pTarget and MTMR7/MTMR9_Topo. This reaction had the following setup: 
 
Reagent Volume 
pTarget/Topo plasmid  2 μg  
BamHI / NotI 0.5 μl  
Buffer D  1 μl  
dH2O  total 10 μl  
 
The digested product was loaded on a 1 % (w/v) agarose gel. The insert and pTarget vector were 
cut and purified as described before. Then, insert and vector were subjected to ligation in a ratio 
3 to 1. 
 
Reagent Volume 
T4 ligase  1 μl  
T4 buffer  1 μl  
insert  30 ng  
vector  10 ng 
 
The reaction was incubated overnight at 11 °C in a PCR cycler, and then 1 μl of the ligation mix 
was added to 50 μl of OneShot® TOP10 E.coli. The reaction was performed as described before, 
followed by a colony-PCR on the next day. For the PCR, forward primer in pTarget vector and 
reverse primer in the insert were used. Positive clones were again picked for PureYield™ Plasmid 
Mini Preparation and sequenced by GATC company. 
2.9. Patch-clamp 
Patch-clamp experiments were performed in cooperation with Dr. Xiaobo Zhou, First Department 
of Medicine, Medical Faculty Mannheim, University of Heidelberg.  
For patch-clamp meassurements cells were seeded into 3.5 cm dishes (10.000 HCT116/ 
20.000 SW480) and transfected with either MTMR7-GFP or an EV control for 48 hours. The 
patch-clamp measurements were performed and analyzed by X. Zhou according to the following 
protocol. 
Standard patch-clamp recording techniques are used to measure currents in the whole-cell 
configuration. 
Patch electrodes were pulled from borosilicate glass capillaries (MTW 150F; World Precision 
Instruments, Inc.) using a DMZ-Universal Puller (Zeitz-Instrumente Vertriebs GmbH). The 
electrodes were filled with pre-filtered pipette solution (126 mM KCl, 6 mM NaCl, 1.2 mM MgCl2, 
5 mM EGTA, 11 mM glucose, 1 mM MgATP, 0.1 mM Na3GTP, and 10 mM HEPES adjusted to 
pH 7.2 with KOH). Currents were recorded at RT with an EPC-8 amplifier (HEKA Elektronik) 
connected via a 16 bit A/D interface to a pentium IBM clone computer. Before digitization to 5 kHz 
the signals are low-pass filtered (1 kHz). Data acquisition and analysis were performed using an 
ISO-3 multitasking patch-clamp program (MFK M. Friedrich). For whole cell recordings, the bath 
was superfused with physiological saline solution (PSS: 130 mM NaCl, 5.9 mM KCl, 2.4 mM 
8 µl 
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CaCl2, 1.2 mM MgCl2, 11 mM glucose, 10 mM HEPES, pH 7.4 with NaOH) and the pipette 
resistance ranged from 2-3 MΩ and the electrode offset potentials are always zero-adjusted 
before a Giga-seal is formed.  
After obtaining a Giga-seal, the membrane under the pipette tip was disrupted by negative 
pressure so that the whole-cell configuration was established. Afterwards, the membrane 
capacitance and series resistance were compensated (60-80 %), and whole-cell currents were 
elicited by applying 300 ms step pulses to potentials ranging from -80 mV to +80 mV in 10 mV 
increments from a holding potential of -50 mV. Currents were recorded by ISO-3 and saved on 
the computer for data analysis. Measurements of the whole-cell currents took place at the end of 
each pulse and were normalized to cell capacitance to calculate the current density (pA/pF) which 
was then plotted versus the respective voltages, yielding the activation (I/V) curves of channels 
in the cell.  
SK4 channel blocker, TRAM 34 or clotrimazole were applied to cells by a perfusion pipette. The 
blocker-sensitive currents were separated from Im as SK4 channel currents (ISK4). 
2.10. Ubiquitin Immunoblotting and Proteasome Activity 
These assays were performed in cooperation with Dr. Norbert Ponelies, Division of Experimental 
Surgery Center, Medical Faculty Mannheim, University of Heidelberg.  
To measure the proteasome activity and the ubiquitin status of the cells, SW480 cells were 
seeded to 80 % of confluency into 15 cm dishes. The next day, cells were transfected with either 
MTMR7 or an EV control. After 24h, cells were lysed by addition of lysis buffer 
(3 mM KH2PO4/K2HPO4 pH 7.4). The lysates were immediately frozen in liquid nitrogen followed 
by three to five freeze and thaw cycles. Lysates were then centrifuged at 4 °C for 30 min at 
40.000 g to clear the lysates from particulate and membranous material. The analysis was 
performed by N. Ponelies according the following protocols.  
 
Ubiquitin Immunoblotting 
 
The supernatants (30 µg per lane) were separated by SDS-PAGE and the expression of ubiquitin 
was evaluated by a rabbit anti-ubiquitin antiserum (1:500, (v/v); Sigma) using a horseradish 
peroxidase-labeled secondary anti-rabbit antibody (1:20.000, (v/v); Jackson ImmunoResearch). 
For quantification of free and conjugated ubiquitin, a standard was used in one of the lanes 
containing 100 ng ubiquitin. For the detection (SuperSignal West Femto Maximum Sensitivity 
Substrate; Pierce Biotechnology) was used. Analysis and quantification were accomplished by 
imaging software (Image-Master TotalLab 1.11; Amersham Biosource). A rabbit anti-mitogen-
activated protein kinase (MAPK) p44/42 Ab (Cell Signaling Technology) served as a protein 
loading control.  
 
Proteasome Activity 
 
To determine the main hydrolytic activities (LLE—caspase-like, LVY— chymotrypsin, ARR—
trypsin-like) fluorogenic substrates like carbobenzoxy-Leu-Leu-Glu-α-7-amido-4-methylcoumarin 
(Z-LLE-AMC), succinyl-Leu-Leu-Val-Tyr-AMC (Suc-LLVY-AMC), and carbobenzoxy-Ala-Arg-Arg-
AMC (Z-ARR-AMC) were used (all from Calbiochem/Merck). Reactions were performed in 
microtiter plates using 50 μl/well volumes which contained 15 μg protein extract and assay buffer 
(50 mM Tris–HCl, 1 mM DTT, 5 mM ATP, 5 mM MgCl2, pH 8.0). To differentiate peptidase- and 
proteasome-specific activities, inhibition by epoxomicin (10 μM) and Ada-(Ahx)3-(Leu)3-vinyl 
sulfone (10 μM) (Biomol International LP) was used. Fluorescence (excitation/ emission—
360 nm/465 nm) was detected at time intervals of 15 min for 1 h at 30 °C (Genios; Tecan) after 
adding substrates like Z-LLE-AMC (100 μM), Suc-LLVY-AMC (100 μM), and Z-ARR-AMC 
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(200 μM). Proteolytic activity was calculated as pkat/mg total protein from the mean of three 
identical tests (Bergstraesser, Hoeger et al. 2012). 
2.11. Data collection and Statistics 
Imaging devices were used to collect optical densities (OD) of bands from Western blots (Fusion 
Solo, VWR). For Western blot, bands in gels were quantified with Image J (imagej.nih.gov/ij). For 
normalization, OD values of proteins of interest were devided by housekeeping proteins (HSP90, 
ERK 1/2). Each normalized value was then divided by the normalized value of the control (EV, 
untreated). Subsequently, the mean was calculated from at least three independent experiments 
(independent experiments = each experiment was performed with a different passage of the 
cells). Results for the real-time PCR were calculated as described in 2.5.4. Immunohistochemical 
staining was evaluated as mentioned in 0. 
Statistical analysis was performed using GraphPad Prism (version 7.0). For pair-wise 
comparisons, p-values were calculated using Student’s t-test or Mann Whitney test. For multipe 
comparisons, regular ANOVA or Kruskal-Wallis test were used (all unpaired and two-sided). 
For Western blot and PCR, quantitative results are expressed as means or -fold-change ± S.E.  
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3. Results 
3.1. Expression of MTMR7 in colorectal cancer cell lines and tissues 
The endogenous expression of MTMR7 was investigated on protein as well as on mRNA levels 
in human CRC cell lines, a normal non-cancer cell line, and in mouse tissues by RT-PCR and 
Western blot.  
3.1.1. mRNA expression in human CRC cell lines and mouse organs 
To analyze the endogenous expression of MTMR7 and its inactive binding partner MTMR9, total 
RNA was extracted from CRC cell lines. RT-qPCR was performed with a primer set for MTMR9 
and three different primer sets for MTMR7 (N-, C-terminal and the central region of the full-length 
MTMR7 cDNA). The results are shown in Figure 6 and Figure 7.  
 
 
Figure 6: Expression of endogenous MTMR7/MTMR9 in human CRC cell lines. Detection of MTMR7/MTMR9 cDNA in total RNA 
extracted from human cell lines. Primers were designed for MTMR9 and the N-terminal, central and C-terminal regions of MTMR7. 
Representative agarose gels of RT-PCR (35 x cycles) are shown together with the quantitative analyses. CT-values from RT-qPCRs 
on total RNA were normalized to beta2-microglobulin (B2M) and calculated as -fold ± S.E. (n=3 per cell line; Kruskal Wallis test). 
Legend: 1 = HEK293T, 2 = SW480, 3 = HT29, 4 = Caco2, 5 = HCT116, 6 = NTC = non-template control (water) control without specific 
bands. Expected sizes of amplification products: MTMR7 = 134 bp, MTMR9 = 174 bp and B2M = 85 bp. 
 
MTMR7 showed a low expression in SW480 and HT29 cells, a medium expression in HCT116 
and Caco2 cells, and a high expression in Lovo, DLD1 CRC cells, and in non-cancer HEK293T 
cells. MTMR9 mRNA was highly expressed in HCT116, Lovo and DLD1 cells, moderately in 
Caco2 cells and low in SW480, HT29 and HEK293T cells (Figure 6).  
 
To examine the endogenous expression of MTMR7 and its inactive binding partner MTMR9, total 
RNA was extracted from frozen mouse organs. RT-qPCR was performed with primer sets for the 
central region of full-length Mtmr7 cDNA and Mtmr9. The results are shown in Figure 7. 
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Figure 7: Expression of endogenous Mtmr7/Mtmr9 mRNA in mouse tissues. Detection of Mtmr7/Mtmr9 cDNA in total RNA 
extracted from frozen mouse tissues. Primers were designed for Mtmr9 and the central region of Mtmr7. Representative agarose gels 
of RT-PCR (35 x cycles) are shown together with the quantitative analyses. CT-values from RT-qPCRs on total RNA were normalized 
to beta2-microglobulin (B2m) and calculated as -fold ± S.E. (n=3 per organ; *p<0.05 liver vs. brain; Kruskal Wallis test). Legend: 1 = 
ovary, 2 = small intestine, 3 = colon, 4 = liver, 5 = kidney, 6 = brain, 7 = heart, 8 = spleen, 9 = muscle, 10 = cecum, 11 = forestomach, 
12 = stomach, 13 = non-template control (water) control without specific bands. Expected sizes of amplification products: Mtmr7 = 
172 bp, Mtmr9 = 147 bp and B2m = 170 bp. 
 
Furthermore, RT-qPCR analysis revealed that Mtmr7 and Mtmr9 cDNA was abundantly 
expressed in different mouse organs. However, the amount between the organs differed. Both 
cDNAs were low expressed in ovary, liver and spleen, whereas there was a moderate expression 
in the colon, the small intestine, kidney, heart, muscle, cecum and stomach. Expression in brain 
tissue was very high as already shown by Majerus et al. in 2003 and served as control (Figure 7). 
 
To conclude, MTMR7/Mtmr7 and MTMR9/Mtmr9 mRNA were expressed in 12 mouse 
gastrointestinal tissues, in human non-cancer cells (HEK293T) and in six human CRC cell lines 
(SW480, HT29, Caco2, HCT116, Lovo, DLD1). 
3.1.2.  Protein expression in human colorectal cancer cell lines and mouse organs 
To investigate endogenous protein expression of MTMR7 (76 kD), protein was isolated from CRC 
cell lines, and Western blot was performed using an MTMR7 antibody, detecting the full-length 
MTMR7 protein. HEK293T cells transfected with a MTMR7 full-length plasmid (pT-MTMR7-FL) 
served as positive control compared to an empty vector (EV) control (Figure 8). 
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Figure 8: Expression of endogenous MTMR7 protein in human CRC cell lines and mouse tissues. A. Detection of MTMR7 
(76 kD) protein in total cell lysates extracted from human cell lines using an MTMR7 Ab (ab121222) is shown together with the 
quantitative analyses. HEK293T cells were transfected with pT-MTMR7-FL and EV expression plasmids for 48 h. Transfected cells 
served as positive (HEK293T/MTMR7) and negative (HEK293T/EV) controls. OD values of bands in gels were normalized to beta-
actin or HSP90 and calculated as means ± S.E. (n=3 per cell line; *p<0.05 vs. EV; Kruskal Wallis test). Legend: 
1 = HEK293T/MTMR7, 2 = HEK293T/EV, 3 = SW480, 4 = HCT116, 5 = HT29, 6 = Caco2, 7 = DLD1, 8 = Lovo. B. Detection of 
MTMR7 (55 kD) protein in total cell lysates extracted from a panel of mouse organs using the cMTMR7 Ab (ab150458) are shown 
together with the quantitative analyses. OD values of bands in gels were normalized to beta-actin or HSP90 and calculated as 
means ± S.E. (n=3 per organ; *p<0.05 vs. brain; Kruskal Wallis test). Legend: 1 = ovary, 2 = small intestine, 3 = colon, 4 = liver, 
5 = kidney, 6 = brain, 7 = heart, 8 = muscle, 9 = cecum, 10 = stomach. 
 
The endogenous protein expression differed between the cell lines. The colorectal cancer cell 
lines SW480, Caco2, HT29, as well as the non-cancer cell line HEK293T showed a very low 
endogenous MTMR7 expression. In contrast, the CRC cell lines DLD1 and Lovo showed a 
moderate expression of endogenous MTMR7 and HCT116 a high expression of endogenous 
MTMR7 (Figure 8A). 
 
Furthermore, proteins were isolated from a panel of mouse organs, and Western blot was 
performed using an antibody against the c-terminal region of MTMR7. Brain tissue served as a 
positive control. Western blot analysis revealed that the expression of MTMR7 varied between 
the different mouse organs. There was a low expression in the muscle, a moderate expression in 
ovaries, liver, cecum, heart and stomach, whereas it was highly expressed in the colon, the small 
intestine, the kidney and brain (Figure 8B).  
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3.2. Subcellular localization of MTMR7 
The subcellular localization of the MTMR7 protein was investigated in immunofluorescence 
experiments. First, the localization of endogenous MTMR7 under different conditions was 
examined. HCT116 cells were starved overnight and treated with 50 ng/ml EGF, 20 % FCS, 1 µM 
rosiglitazone (rosi), a pharmacological PPARγ-agonist, or a physiological PPARγ-agonist, 1 µM 
linoleic acid for 1 hour before staining for the actin cytokeleton using Phalloidin and the nuclei 
using DAPI and an antibody against MTMR7.  
 
 
Figure 9 Subcellular localization of MTMR7. Starved HCT116 cells were treated with rosi (1 µM), linoleic acid (1 µM), EGF 
(50 ng/ml) and FCS (20 %) for 1 h before fixing and staining for immunofluorescence microscopy. MTMR7 was localized in sub-
membranal spots and no difference between the treatment could be seen. Colors: red = MTMR7, green = phalloidin, blue = DAPI, 
Magnification 400x. 
 
The results showed sub-membranal or cytoplasmic-nuclear spots in the starved cells and the 
EGF, FCS and rosi treated cells. The localization of MTMR7 was dependent on the number of 
cells on the slide. For single cells, nuclear localization was seen. However, cytoplasmic 
localization was observed, if the cells were grown confluent (Figure 9). 
 
To further characterize the localization of MTMR7, double-color staining using specific markers 
for the cytoskeleton (phalloidin), the ER (calnexin) or for the early endosomes (RAB5) were used. 
The results did not show any colocalization of overexpressed pT-MTMR7-Flag with RAB5 or 
calnexin, but to some extent with phalloidin in the focal adhesions. Moreover, MTMR7 was 
recognized as small dots which may be colocalized with sub-membranal vesicles at the late 
endosomes or lysosomes. To further examine the localization of MTMR7, co-staining of late 
endosomal markers like RAB9 together with endogenous MTMR7 were performed. Here, a 
colocalization between RAB9 and MTMR7 was seen, so that MTMR7 may be located at vesicles 
that mark the late endosomal compartment (Figure 10). 
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Figure 10: MTMR7 colocalizes with the late endosomal marker RAB9. Cycling cells were fixed and stained for 
immunofluorescence microscopy. A. HEK293T cells were transfected with pT-MTMR7-Flag and co-stained with antibodies for 
phalloidin, calnexin (ER marker) or RAB5 (early endosomal marker) together with an antibody against a FLAG-tag. No colocalization 
was seen for calnexin or RAB5 whereas MTMR7 partially colocalized with phalloidin in the focal adhesions. Colors: red = MTMR7, 
green = organelle Marker, blue = DAPI, Magnification 400x. B. Endogenous MTMR7 was co-stained with RAB9 (late endosomal 
marker) and a colocalization was seen. Colors: red = RAB9, green = MTMR7, blue = DAPI, Magnification 400x. 
3.3. Interaction between PPARγ and MTMR7 
3.3.1. MTMR7 forms a complex with PPARγ 
Since MTMR7 was identified as a new binding partner of PPARγ in the cytosol by a MALDI-MS 
proteomic interaction screen (Söhn, Weidner et al., unpublished), the interaction between the two 
proteins was further investigated using CoIP experiments on endogenous levels in HCT116 as 
well as with MTMR7-GFP transfected HEK293T cells. For both the endogenous and the 
overexpressed CoIPs, the IP was performed using polyclonal antisera against PPARγ followed 
by detection of endogenous or overexpressed MTMR7 by Western blot (IB) using an antibody 
directed against MTMR7.  
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Figure 11: MTMR7 forms a complex with PPARγ. A. CoIP of FL MTMR7 and PPARγ from total cell lysates of endogenous HCT116 
and transiently transfected HEK293T cells. Immunoprecipitation (“IP”) was performed using a PPARγ or no Ab (bead control). 
Coprecipitated proteins were detected by Western blot (“IB”) using an antibody against MTMR7 (ab121222). Results are means ± 
S.E; endogenous (n=8; *p<0.05 complex vs. no complex; Unpaired t test) and overexpressed (n=9; p=0.0567 complex vs. no complex; 
Mann Whitney test). B. pT-MTMR7-Flag transfected HEK293T cells were fixed and co-stained for endogenous PPARγ (2435, CS) 
and overexpressed MTMR7-Flag. Colocalization of the two proteins was seen in the cytosol. Colors: red = MTMR7-Flag, green = 
PPARγ, blue = DAPI, Magnification 400x. 
 
Statistical analysis showed, that the MTMR7-PPARγ-complex was detectable in 80 % of all 
performed CoIPs. However, the complex-formation was stronger on the endogenous level in 
HCT116 cells, whereas significance could not be reached in HEK293T cells after overexpression 
(Figure 11A).  
In addition to CoIP experiments, immunofluorescence staining was performed in HEK293T cells. 
The cells were transfected with a pT-MTMR7-Flag plasmid for 48 hours and co-stained for 
endogenous PPARγ and overexpressed MTMR7-Flag (Figure 11B). Fluorescent microscopy 
revealed cytosolic colocalization of the two proteins. 
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To verify the CoIP-results and immunofluorescence staining, proximity ligation assay (PLA) was 
performed. HEK293T cells were co-transfected with PPARγ together with MTMR7-GFP plasmid 
or an EV control for 24 hours and PLA assay was performed using GFP- and PPARγ-antibodies. 
This assay uses secondary oligonucleotide labeled antibodies (“PLA probes”). These probes bind 
to the primary antibodies and generate red spots, if the two proteins are near to each other. 
Interaction could be seen in the transfected cells compared to the untransfected cells (Figure 12). 
 
 
Figure 12: Proximity ligation assay (PLA). HEK293T cells were transiently transfected with PPARγ together with MTMR7-GFP 
plasmid or an EV control for 24 h. Immunofluorescence staining was done with anti-GFP and PPARγ (2435, CS) antibodies. Using a 
single Ab served as negative control. Colors: red dots = MTMR7–PPARγ colocalization, green = actin/ MTMR7-GFP, blue = nuclei; 
magnification 400x. 
 
3.3.2. MTMR7 reduces nuclear amount of phosphorylated PPARγ protein  
To further elucidate the MTMR7-PPARγ interaction, effects of MTMR7 on nuclear PPARγ were 
assessed. For this purpose, subcellular fractionation was performed to examine the localization 
of PPARγ in different cell compartments upon MTMR7 overexpression. HEKT293T cells were 
transfected either with MTMR7 or an EV control and stimulated with 1 µM rosi or 20 % FCS for 
1 hour. After cell lysis, Western blot was performed, looking for general PPARγ and 
phosphorylated (“P”)-PPARγ expression. β-tubulin and lamin served as loading controls (Figure 
13).  
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Figure 13: Decrease of nuclear P-PPARγ upon MTMR7 transfection. HEK293T cells were transiently transfected with MTMR7 or 
an EV control for 48 h. Cells were starved overnight and treated with rosi (1 µM) or FCS (20 %) for 1 h before subcellular fractionation. 
Detection of PPARγ/ P-PPARγ (55 kD) protein in cytosol and nucleus is shown together with quantitative analyses. Lamin and β-
tubulin served as loading controls. OD values of bands in gels were normalized to Lamin or β-tubulin and calculated as means ± S.E. 
(n=4; *p<0.05 MTMR7 vs. EV; Mann Whitney test). 
 
The results confirmed, that the amount of PPARγ did not change upon MTMR7 transfection in the 
cytosolic cell compartment. Furthermore, nuclear P-PPARγ was significantly downregulated by 
30 % ± 8 % in MTMR7 transfected cells compared to an EV control in unstimulated cells. 
However, no changes were seen in cells stimulated with rosi or FCS. In addition, no influence of 
MTMR7 on PPARγ localization could be seen. 
3.3.3. MTMR7 activates transcriptional response of PPARγ 
To elucidate if MTMR7 promotes the transcriptional activity of PPARγ in the nucleus, luciferase 
reporter assays using a PPRE-LUC plasmid were performed. For this assay, cells were transiently 
co-transfected with PPRE (PPARγ-responsive-element)-driven luciferase reporter plasmid 
together with either MTMR7 or an EV control for 24 hours and then incubated with increasing 
concentrations (0, 0.1, 1, 10 µM) of rosi for additional 24 hours. Luciferase activity was measured 
in total cell lysates and normalized to protein content (Figure 14).  
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Figure 14: MTMR7 activates transcriptional response of PPARγ. Cells were co-transfected with PPRE reporter plasmid and 
MTMR7 or an EV control for 24 h. After transfection, cells were treated with rosi (0-10 µM) for 24 h. Luciferase activity in total cell 
lysates was normalized to protein content and calculated as -fold ± S.E. (n=9; *p<0.05 MTMR7 vs. EV; Two-way ANOVA). 
 
All three cell lines showed a significant increase of PPARγ activation upon MTMR7 transfection. 
Transcriptional PPRE activity was significantly enhanced (9.5-fold) in SW480 cells transfected 
with MTMR7 compared to the EV transfected cells at 0.1 µM rosi. In HCT116 cells, the activity 
was 8.5 times higher in the MTMR7 transfected cells compared to the controls at 0.1 µM rosi. 
HEK293T showed a 14 times higher activity upon MTMR7 transfection and stimulation with 
0.1 µM rosi.  
 
Taken together, the results confirmed that MTMR7 enhanced the transcriptional activity of PPARγ 
in KRAS-mutated SW480 and HCT116 cells with high pan-RAS activity as well as in HEK293T 
non-cancer cells. 
3.3.4. MTMR7 enhances PPARγ target gene expression 
To check the effect of transient MTMR7 overexpression on the nuclear PPARγ response, RT-
qPCR for quantification of cognate (or bona fide) PPARγ-target genes like phosphatase and 
tensin homolog (PTEN), trefoil factor 3 (TFF3), acyl-CoA oxidase (ACO), phosphoenolpyruvate 
carboxykinase (PEPCK) and cluster of differentiation 3 (CD36) was performed. HCT116 and 
HEK293T cells were transfected with either MTMR7 or an EV control and stimulated with 1 µM 
rosi for 48 h before extraction of total RNA. RT-qPCR was conducted using primer for PTEN, 
TFF3, ACO, PEPCK and CD36 (Table 5, material and methods). Results are shown in Figure 15. 
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Figure 15: MTMR7 increases PPARγ-target gene expression. Cells were transfected with MTMR7 plasmid or an EV control for 48 
h. Cells were treated with rosi (1 µM) or DMSO (vehicle control) for 24 h. CT-values from RT-qPCRs on total RNA were normalized 
to beta2-microglobulin (B2M) and calculated as -fold ± S.E. (n=3 per cell line; *p<0.05 rosi vs. DMSO; Mann Whitney test). 
 
RT-qPCR analysis on the cDNA pools showed that MTMR7 had no influence on PTEN, ACO, 
PEPCK and CD36 but significantly increased TFF3 mRNA expression levels by ~ 43 % in rosi 
stimulated HEK293T cells. For unstimulated HCT116 cells a trend in upregulation of TFF3 mRNA 
upon MTMR7 transfection was seen but did not reach statistical significance. However, this trend 
could not be exceeded by stimulation with the PPARγ ligand rosi.  
 
Taken together, these results showed that MTMR7 does not influence PPARγ localization but that 
it promotes transcriptional activity of PPARγ in KRAS-mutated and HEK293T cells.  
3.3.5. MTMR7 promotes membrane retention of EGFR and reduces nuclear EGFR  
MTMR7 enhances the transcriptional activity of PPARγ in KRAS-mutated SW480 cells with high 
pan-RAS activity. The next step was to find out if enhancement takes place by direct interaction 
between MTMR7 and PPARγ or via inhibition of the negative regulatory pathway of PPARγ, 
namely the EGFR-RAS-RAF-MEK1/2-ERK1/2 pathway.  
To answer this, subcellular fractionation was performed, and cell fractions together with total cell 
lysates were analyzed by Western blot. SW480, HCT116 and HEK293T cells were transfected 
with either MTMR7 full-length plasmid or an EV control for 48 h. Before harvesting, cells were 
starved overnight and stimulated for 0, 15, 30, 60, 120 and 180 minutes with 20 % FCS to trigger 
GFR endocytosis, recycling, or degradation routes (Burgermeister, Höde et al. 2017). For 
subcellular fractionation, the cells were lysed by hypotonic lysis (cytosolic fraction). The nuclei 
were extracted in high salt buffer, and the remaining pellet containing membranes/matrix 
components (ER, plasma membrane, nuclear matrix & membrane, chromatin) was subjected to 
extraction in SDS lysis buffer and sonication. The samples were then analyzed by Western blot 
using an antibody against EGFR and pan-RAS to see whether those proteins are influenced by 
MTMR7 (Figure 16). 
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Figure 16: MTMR7 promotes membrane retention of EGFR and reduces nuclear EGFR in SW480 cells. Cells were transiently 
transfected with MTMR7 or an EV control for 48 h. After transfection, cells were starved overnight and treated with FCS (20 %) for 0-
180 min before subcellular fractionation. Detection of EGFR (170 kD) protein in the insoluble and nuclear fraction is shown together 
with quantitative analysis. Lamin served as loading control. OD values of bands in gels were normalized to lamin and calculated as 
means ± S.E. (n=3 per cell line; *p<0.05 MTMR7 vs. EV; Kruskal-Wallis test). 
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The results showed that MTMR7 promotes membrane retention of EGFR in SW480 cells. 
Thereby, nuclear EGFR expression (NUC), which has been associated with tumor progression 
and worse survival prognosis for several human cancers, was significantly reduced by 90 ± 11 % 
upon MTMR7 transfection and FCS stimulation for 180 minutes. A trend in the reduction (by 
40 ± 15 %) of nuclear EGFR was also seen in HEK293T cells after 120 minutes of stimulation, 
whereas the HCT116 cells were not responsive (Figure 16).  
 
For all cell lines, a trend in decreasing pan-RAS protein upon MTMR7 transfection (~ 10 – 30 %) 
could be seen in the insoluble fraction (INS). Interestingly, the reduction was seen after about 
30 minutes of stimulation in the colorectal cancer cell lines HCT116 and after 60 minutes in 
SW480, whereas HEK293T cells already responded after about 15 minutes of stimulation. In 
addition, no massive translocation to other compartments was observed (Figure 17). 
 
 
Figure 17: MTMR7 reduces pan-RAS protein levels. Cells were transiently transfected with MTMR7 or an EV control for 48 h. After 
transfection cells were starved overnight and treated with FCS (20 %) for 0-180 min before subcellular fractionation. Detection of pan-
RAS (21 kD) protein is shown together with quantitative analyses. Results are means ± S.E. (n=3; n.s.; Mann Whitney test (HEK293T, 
SW480) or Two-way Anova (HCT116)). 
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3.3.5.1. MTMR7 influences EGFR and pan-RAS protein expression 
In addition to subcellular fractionation, the effect of MTMR7 on EGFR and pan-RAS expression 
was evaluated in total cell lysate samples. SW480 cells were transfected and treated as above, 
harvested after indicated time points, and total cell lysates were analyzed by Western blot using 
an antibody against EGFR and pan-RAS to evaluate if those proteins are influenced by MTMR7 
(Figure 18).  
 
 
Figure 18: MTMR7 reduces pan-RAS protein levels. SW480 cells were transiently transfected with MTMR7 or an EV control for 48 
h. After transfection cells were starved overnight and treated with FCS (20 %) for 0-180 min before lysis. Detection of pan-RAS (21 
kD) protein is shown together with quantitative analyses. Results are means ± S.E. (n=3; *p<0.05 MTMR7 vs. EV; Two-way ANOVA, 
Bonferroni n.s.). 
 
A reduction of 75 ± 25 % of the EGFR, which did not reach significance, was detected after 
60 minutes upon MTMR7 transfection in SW480 cells. The receptor expression was increased 
again after 120 minutes, suggesting a recycling or regeneration of the EGFR. As seen above, 
cells transfected with MTMR7 full-length plasmid showed a ~30 % lower pan-RAS expression 
than cells transfected with the EV control. However, this effect did not reach significance. 
 
To conclude, MTMR7 promotes membrane retention of EGF-Receptor and reduces nuclear 
EGFR. Furthermore, an inhibitory effect of MTMR7 on total RAS-protein expression has been 
stated.  
3.4. Down-regulation of KRAS by MTMR7 
3.4.1. MTMR7 reduces the activity and total protein levels of pan-RAS in KRAS-mutated 
CRC cells 
To further characterize the molecular mechanisms of RAS down-regulation by MTMR7, a pan-
RAS pulldown assay provided by Cell Biolabs was performed to see if MTMR7 not only reduces 
the total protein level but also the GTPase activities of RAS proteins. Different CRC cell lines 
(SW480, HCT116, Lovo, DLD1), one pancreatic cancer cell line (PATU8902), and one gastric 
cancer cell line (AGS, data not shown), all KRAS-mutated, were transfected with MTMR7 full 
length plasmid and an EV control for 48 h. The cells were harvested, and RAS pulldown assay 
was performed according to the manufacturer’s protocol. The samples were then analyzed by 
Western blot using an antibody against pan-RAS to detect the amounts of active pan-RAS 
proteins (Figure 19). 
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Figure 19: MTMR7 reduces the activity of pan-RAS in KRAS-mutated CRC cells. Cells were transfected with MTMR7 plasmid or 
an EV control for 48 h before performance of GST-pulldown assay. Detection of active pan-RAS (21 kD) protein is shown together 
with the quantitative analyses. Results are -fold ± S.E. (n=3 per cell line; *p<0.05 MTMR7 vs. EV; Unpaired t test (HCT116, Lovo, 
SW480) / One sample t test (DLD1, PATU8902). 
 
The quantitative analysis showed a significant downregulation of active as well as total pan-RAS 
protein by MTMR7 in SW480 cells (active: by 40 ± 15 %; total: by 55 ± 7 %). The significant 
decrease in mutant pan-RAS was also seen in HCT116 (by 55 ± 27 %), Lovo (by 23 ± 4 %) cells 
and a pancreatic cell line (by 18 ± 8 %). However, in contrast to the SW480 cells the effect on the 
total protein level was not seen in these cell lines. The colorectal cancer cell line DLD1 showed a 
trend in active RAS reduction (by 33 ± 18 %) which did not reach significance. 
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Since MTMR7 was inhibiting active-mutant RAS, the effect on RAS was determined in total cell 
lysates of human colorectal cancer cell lines. HCT116, SW480 and KRAS wildtype HEK293T (as 
control) cells were transfected with either a MTMR7 plasmid or an EV control for 1-3 days and 
Western blot was performed using a pan-RAS antibody (Figure 20).  
 
 
Figure 20: MTMR7 reduces total protein levels of pan-RAS. Cells were transfected with MTMR7 plasmid or an EV control for 1-3 
days. Pan-RAS protein levels were reduced upon MTMR7 transfection. OD values of bands in gels were normalized to ERK 1/2 or 
HSP90 and calculated as means ± S.E. (n≤3 per cell line; *p<0.05 MTMR7 vs. EV; Unpaired t test). 
 
The statistical analysis confirmed a significant downregulation of RAS protein in SW480 by 
14 ± 4 % after 1 day and in HEK293T cells after day 1 (by 18 ± 5 %) and 2 (by 144 ± 88 %). For 
HCT116 cells no trend in RAS inhibition could be seen.  
The same experiment was done on mRNA level, but no effect was seen at all (Figure 44, 7.3).  
3.4.2. RAS is not degraded by the proteasome 
To further elucidate the mechanism of RAS inhibition by MTMR7, inhibitors of the proteasome 
(MG132) and lysosomal acidification (chloroquine) were used. To test for proteasomal 
degradation, SW480 cells were transfected with MTMR7 or an EV control. During transfection, 
cells were incubated in presence or absence of the proteasomal inhibitor MG132 (3 µM) for 8, 16, 
24 and 32 hours. Cells were harvested after indicated time points and pan-RAS protein was 
detected by Western blotting.  
 
 
Figure 21: RAS is not degraded via the proteasome. SW480 cells were transfected with MTMR7 plasmid or an EV control. During 
transfection, cells were incubated in presence or absence of the proteasomal inhibitor MG132 (3 µM) for 8-32 h. Detection of pan-
RAS (21 kD) protein in TCL is shown together with the quantitative analyses. OD values of bands in gels were normalized to ERK 1/2 
and calculated as -fold ± S.E. (n=3; n.s.; Two-way ANOVA). 
 
The statistical analysis showed, that RAS down-regulation was seen in cells transfected with 
MTMR7 plasmid after 16 h. A regeneration of RAS protein was seen after 16 and 32 h in MTMR7-
transfected cells treated with MG132. However, it did not reach significance (Figure 21). 
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To critically test these results with a more specific method, an ubiquitination and proteasome 
assay were performed in cooperation with Dr. Norbert Ponelies, Division of Experimental Surgery 
Center, Medical Faculty Mannheim, University of Heidelberg. To perform the assay, SW480 cells 
were transfected with MTMR7 or an EV control and harvested after 24 hours. 
 
 
Figure 22: Detection of endogenous ubiquitin in cell lysates by immunoblotting. SW480 cells were transfected with MTMR7 
plasmid or an EV control for 24 h before performance of ubiquitin/ proteasome assay. A-C. Detection of anti-ubiquitin in MTMR7-
transfected (Lane 1,3,6,8)/ EV-transfected (Lane 2,4,7,9) cell lysates (30 µg/ lane) is shown together with the quantitative analyses; 
Lane MM –protein marker (Spectra Multicolor). No influence on the ubiquitinationrate and on the intracellular ubiquitin level upon 
MTMR7 transfection could be seen. D. The membrane was reprobed with an anti-MAPK 1/ 2 (p44/42) antibody as a protein loading 
control. E. Measurement of proteasomal activity in MTMR7-transfected cells compared to EV controls. Results are -fold ± S.E. (n=7; 
n.s.; Unpaired t test). 
 
The experiment showed no influence on the ubiquitination rate and on the intracellular ubiquitin 
level upon MTMR7 transfection (Figure 22A, B).  
 
Furthermore, proteasomal activity of the proteases’ active sites that perform the proteolysis 
reactions was measured. Each of the three subunits has a slightly different proteolytic activity: β1 
cleaves the peptide chain of the unfolded protein to acidic amino acids (caspase-like activity, C-
like), β2 cleaves for basic amino acids (trypsin-like activity, T-like), and β5 cleaves for hydrophobic 
amino acids (chymotrypsin-like activity, CT-like).  
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The results did not show any difference in the caspase- and trypsin-like protease activity. 
However, a tendency that the chymotrypsin-like proteasomal activity was decreased from 1.7-fold 
in EV transfected cells to 1.5-fold in MTMR7 transfected cells was seen (Figure 22E).  
This confirmed previous findings which showed that MTMR7 has no influence on proteasomal 
degradation of pan-RAS (Figure 21).  
Taken together, these results confirmed that RAS is not degraded via the proteasome. 
3.4.3. RAS is not degraded by the lysosome 
To elucidate if RAS protein might be degraded through lysosomal acidification, SW480 cells were 
transfected with MTMR7 and an EV control for 6 h. Directly after transfection, cells were cultivated 
in presence or absence of chloroquine (100 µM) for 24, 48 and 72 hours. Similar experiment was 
done in a short-term time frame with transfection for 6 hours. After transfection, cells were 
cultivated for 48 hours and then starved overnight. After starvation, cells were pre-incubated with 
chloroquine (100 µM) for 30 minutes and re-stimulated for 0, 60 and 180 minutes with 20 % FCS. 
Cells were harvested after the indicated time points and samples were analyzed by Western blot 
using an antibody against pan-RAS. 
 
 
Figure 23: RAS is not degraded via the lysosome. A. SW480 cells were transfected with MTMR7 plasmid or an EV control for 6 h. 
After transfection, cells were treated with the lysosomal inhibitor chloroquine (100 µM) for 1-3 days. Detection of pan-RAS (21 kD) 
protein in TCL is shown together with the quantitative analyses. OD values of bands in gels were normalized to ERK 1/2 and calculated 
as -fold ± S.E. (n=3; n.s.; Two-way Anova). B. SW480 cells were transfected with MTMR7 plasmid or an EV control for 6 h. After 
transfection, cells were cultivated for 48 h and then starved overnight. After starvation, cells were preincubated with the lysosomal 
inhibitor chloroquine (100 µM) for 30 min before re-stimulation with 20 % FCS for 0-180 min. Detection of pan-RAS (21 kD) protein in 
TCL is shown together with the quantitative analyses. OD values of bands in gels were normalized to ERK2 and calculated as -fold ± 
S.E. (n=3; n.s.; Two-way Anova). 
 
The results showed, that RAS inhibition could not be stopped by blocking the lysosomal 
degradation pathway in a long-term time frame. In contrast, the effect was enhanced upon 
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chloroquine treatment, meaning that RAS is not degraded via lysosomal acidification, but the 
reduction can be further promoted using a lysosomal inhibitor (Figure 23A). Notably, MTMR7 
expression was also diminished in chloroquine treated cells, meaning that the used 
concentration might have been too high for the long-term treatment. In a short-term time frame, 
no loss of pan-RAS protein upon MTMR7 transfection or chloroquine treatment could be observed 
(Figure 23B). 
3.4.4. Changes in membrane potential promote RAS down-regulation  
3.4.4.1. KCl promotes RAS reduction and P-ERK 1/2 inhibition in colorectal cancer cell 
lines 
Subcellular fractionation showed that MTMR7 prevents the recruitment of RAS proteins to 
membranes. As shown by Hancock et al, changes in the membrane potential promote 
detachment of RAS nanoclusters at the plasma membrane and internal membranes like 
endosomes (Zhou, Wong et al. 2015). Thus, modulators of ion channels (TRAM34, KCl) were 
used to study their effect on RAS. HEK293T, SW480 and HCT116 were transfected with either 
MTMR7 and an EV control for 6 h. Directly after transfection, cells were treated for a long-term 
time frame of 1-3 days with 100 mM KCl (SW480) or 50 mM KCl (HEK293T, HCT116).  
A similar experiment was done in a short-term time frame with transfection for 6 hours. After 
transfection, cells were cultivated for 48 hours and then starved overnight. After starvation, cells 
were treated for a short-term time frame (0-30 minutes) with 100 mM KCl (SW480) or 50 mM KCl 
(HEK293T, HCT116). Cells were harvested after the indicated time points and samples were 
analyzed by Western blot using an antibody against pan-RAS and P-ERK 1/2. 
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Figure 24: KCl promotes RAS down-regulation in colorectal cancer cell lines in a long-term time frame. Cells were transfected 
with MTMR7 plasmid or an EV control for 6 h. After transfection cells were directly treated with 100 mM KCl (SW480) or 50 mM KCl 
(HCT116/ HEK293T) for 1-3 days. Detection of pan-RAS (21 kD) protein in TCL is shown together with the quantitative analyses. OD 
values of bands in gels were normalized to HSP90 and calculated as -fold ± S.E. (n=3 per cell line; *p<0.05 MTMR7 vs. EV; Kruskal-
Wallis test; n.s. Dunn's multiple comparisons test). 
 
The results of the long-term time frame experiment showed that RAS down-regulation was 
significantly promoted from 13 % reduction upon MTMR7 transfection to 40 % reduction upon 
MTMR7 transfection combined with increasing extracellular KCl concentrations in SW480 cells 
on day 3. The same trend was seen in HEK293T cells but not as strong as for the SW480 cells 
(Figure 24). 
 
For the short-term stimulation with KCl the results confirmed a significant downregulation of pan-
RAS protein by 37 ± 14 % in SW480 and by 14 ± 9 % in HEK293T cells, but not for the HCT116 
cells. Furthermore, ERK 1/2 phosphorylation was significantly inhibited by increasing extracellular 
KCl concentrations in HEK293T (by 68 ± 20 %) and HCT116 (by 32 ± 3 %) cells after 30 minutes 
of stimulation. However, this inhibition could not be seen in SW480 cells (Figure 25). 
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Figure 25: KCl promotes reduction of pan-RAS protein and P-ERK 1/2 inhibition in colorectal cancer cell lines in a short-term 
time frame. Cells were transfected with MTMR7 plasmid or an EV control for 6 h. After transfection cells were cultivated for 48 h and 
then starved overnight. After starvation cells were treated with 100 mM KCl (SW480) or 50 mM KCl (HCT116/ HEK293T) for 0, 5, 10 
and 30 minutes. Detection of pan-RAS (21 kD) protein and P-ERK 1/2 in TCL is shown together with the quantitative analyses. OD 
values of bands in gels were normalized to HSP90 or ERK 1/2 and calculated as -fold ± S.E. (n=3 per cell line; *p<0.05 MTMR7 vs. 
EV; Two-way ANOVA (SW480, HEK293T) or Kruskal-Wallis test (HCT116)). 
 
Taken together, these results indicated that RAS down-regulation may be at least in part due to 
membrane depolarization, thus a biophysical mechanism. 
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To further elucidate if pan-RAS protein is reduced by a biophysical mechanism, “patch-clamp” 
technologies were used. Experiments were performed on a sodium-dependent potassium 
channel (KCA3.1, SK4) in cooperation with Dr. Xiaobo Zhou, First Department of Medicine, 
Medical Faculty Mannheim, University of Heidelberg. This channel plays an important 
physiological role in the regulation of the membrane potential and calcium signaling in many cell 
types (Srivastava, Li et al. 2005). RT-PCR results showed that this channel was highly expressed 
in HCT116 and SW480 cells and weakly in Caco2 and HT29 cells (Figure 26). 
 
 
Figure 26: Expression of KCA3.1 channel in colorectal cancer cell lines. Detection of KCA3.1 cDNA in total RNA extracted from 
human cell lines. Representative agarose gel of RT-PCR (35 x cycles) is shown. Expected sizes of amplification products: KCA3.1 = 
159 bp B2M = 85 bp (n=3 per cell line). 
 
Furthermore, the KCA3.1 channel has been reported to be inhibited by MTMR6. Since MTMR6, 
MTMR7 and MTMR8 belong to the same subgroup of MTMs, the question was if MTMR7 can 
also influence that channel and thereby change the membrane potential (Srivastava, Li et al. 
2005). 
 
To examine this, SW480 and HCT116 cells were transfected with MTMR7-GFP or an GFP-tagged 
EV control for 48 hours. The GFP-tag was indispensable to distinguish between the transfected 
and untransfected cells. After incubation, ”patch-clamp” measurements were performed by Dr. 
Xiaobo Zhou. Whole cell currents were evoked by pulses from -80 - 80 mV with a holding potential 
of -50 mV. Two KCA3.1 channel blockers, TRAM34 or clotrimazole, were applied to the cells by 
a perfusion pipette. 
 
 
Figure 27: Overexpression of MTMR7 did not influence the KCA3.1 channel in SW480 and HCT116 cells. Whole cell currents 
(Im) were evoked by pulses from -80 to +80 mV with the holding potential of -50 mV. KCA3.1 channel blocker, TRAM 34 (1 µM) or 
clotrimazole (3 µM) was applied to cells by a perfusion pipette. The blocker-sensitive currents were separated from Im as KCA3.1 
channel currents (ISK4). A. Representative Im traces in absence (control) and presence of 1 µM TRAM 34 in SW480 cells expressed 
with GFP (left) or MTMR7-GFP (right). B. Representative Im traces in absence (control) and presence of 3 µM clotrimazole in SW480 
cells expressed with GFP (left) or MTMR7-GFP (right). C. Representative Im traces in absence (control) and presence of 1 µM TRAM 
34 in HCT116 cells expressed with GFP (left) or MTMR7-GFP (right). D. Representative Im traces in absence (control) and presence 
of 3 µM clotrimazole in HCT116 cells expressed with GFP (left) or MTMR7-GFP (right) (n = 10). 
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Figure 27, also kindly provided by Dr. Xiaobo Zhou, shows representative currents in presence 
or absence of 1 µM TRAM34 (Figure 27A, C) and 3 µM clotrimazole (Figure 27B, D) in cells 
transfected with EV-GFP (left) or MTMR7-GFP (right). These data showed that MTMR7 did not 
influence the KCA3.1 channel or the membrane currents. 
 
To further prove if RAS is degraded by a biophysical mechanism, an epithelial sodium channel 
(ENaC) blocker called amiloride was used. It directly blocks the channel and thereby inhibits 
sodium reabsorption without depleting potassium, thus hyperpolarizes the plasma membrane. 
For this experiment, HEK293T cells were transfected with either MTMR7 and an EV control for 
6 h. Directly after transfection, cells were treated with 0.1 mM amiloride for a long-term time frame 
of 1-3 days.  
A similar experiment was done in a short-term time frame with transfection for 6 hours. After 
transfection, cells were cultivated for 48 hours and then starved overnight. After starvation, cells 
were treated with 0.1 mM amiloride for a short-term time frame (0-30 minutes). 
Cells were harvested after the indicated time points and samples were analyzed by Western blot 
using an antibody against pan-RAS and P-ERK 1/2 (Figure 28). 
 
 
Figure 28: Amiloride prevents RAS down-regulation and P-ERK 1/2 inhibition in HEK293T. A. Cells were transfected with 
MTMR7 plasmid or an EV control for 6 h. After transfection cells were directly stimulated with 0.1 mM amiloride for 1-3 days. Detection 
of pan-RAS (21 kD) protein in TCL is shown together with the quantitative analyses. B. Cells were transfected with MTMR7 plasmid 
or an EV control for 6 h. After transfection cells were cultivated for 48 h and then starved overnight. After starvation cells were 
stimulated with 0.1 mM amiloride 0, 5, 10 and 30 minutes. Detection of pan-RAS (21 kD) protein and P-ERK 1/2 in TCL is shown 
together with the quantitative analyses. Neither RAS down-regulation nor P-ERK 1/2 inhibition was seen. OD values of bands in gels 
were normalized to HSP90 and calculated as -fold ± S.E. (n=3; n.s.; Two-way ANOVA). 
 
The results showed that MTMR7-mediated RAS reduction was prevented by treating the cells in 
a long- and short-term time frame. In addition, phosphorylation of ERK 1/2 was not inhibited. 
These data from two drugs affecting membrane polarisation indicate that MTMR7-mediated RAS 
down-regulation may be due to biophysical changes in membrane potential. 
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3.4.5. PPARγ drug agonist does not promote MTMR7-mediated RAS down-regulation 
Since MTMR7 inhibited RAS activity and forms a complex with PPARγ which is druggable by 
PPARγ agonist the effect on RAS reduction was determined by treating SW480, HCT116 and 
HEK293T cells with rosi. For this purpose, cells were transfected with MTMR7 full-length plasmid 
and an EV control for 6 h. After transfection, cells were stimulated with 10 µM rosi for 1, 2, 3 days. 
Cells were harvested after indicated time points, and Western blot analysis was performed using 
an antibody against pan-RAS (Figure 29). 
 
 
 
 
Figure 29: Rosiglitazone does not increase MTMR7 mediated RAS degradation in HEK293T cells. Cells were transfected with 
MTMR7 plasmid or an EV control for 6 h. After transfection cells were stimulated with 10 µM rosi for 1, 2, 3 days. Detection of pan-
RAS (21 kD) protein in TCL is shown together with the quantitative analyses. OD values of bands in gels were normalized to ERK 1/2 
and calculated as -fold ± S.E. (n=3 per cell line; *p<0.05 MTMR7 vs. EV; Two-way ANOVA). 
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The results confirmed that the reduction of RAS protein in HEK293T cells was significantly 
decreased by 40 % ± 7.6 % upon MTMR7 transfection, no additional effect of rosi treatment was 
detected. However, reduction was neither seen for HCT116 nor for SW480 cells. Thus, treatment 
with PPARγ ligand rosi did not further facilitate RAS down-regulation. 
3.5. Effect of MTMR7 on therapy-resistance 
3.5.1. Knockdown of MTMR7 promotes proliferation of human colorectal cancer cell lines 
We have shown previously, that HCT116 and SW480 cells stably transfected with MTMR7 
displayed a reduced proliferation rate within 5 days compared to cells transfected with an EV 
control (Weidner, Söhn et al. 2016).  
To prove if these findings were due to MTMR7 overexpression, a knock-down of endogenous 
MTMR7 protein with MTMR7-shRNA plasmid in KRAS-mutant cells (HCT116, Lovo, SW480; 
DLD1) and in KRAS-WT cells (Caco2, HT29, HEK293T) was performed. Cell viability was 
measured using MTT assay. Cells transfected with a control shRNA plasmid served as control 
(Figure 30).  
 
 
Figure 30: MTMR7 knockdown promotes cell growth. SW480, HCT116, Lovo, DLD1, Caco2, HT29 and HEK293T cells were 
transfected with either shRNA control or shRNA MTMR7 plasmid for 24 h. Viability was measured in MTT assay 2 days after 
transfection. OD values were calculated as -fold ± S.E. (n=3 per cell line; *p<0.05 MTMR7-shRNA vs. control-shRNA; Unpaired t test) 
compared with day 0. 
 
For KRAS-mutant HCT116 cells the results showed a significantly increasing cell viability upon 
transfection of MTMR7-shRNA compared with cells receiving control shRNA plasmid (sh MTMR7 
3.4 ± 0.6 % vs. sh Control 1.3 ± 0.1 %). Similar results were found for Lovo (sh MTMR7 2.3 ± 0.4 
% vs. sh Control 1.6 ± 0.1 %) and SW480 (sh MTMR7 3.3 ± 0.6 % vs. sh Control 1.1 ± 0.01 %) 
cells whereas KRAS-WT cells Caco2, HT29, HEK293T were less sensitive to MTMR7 knockdown 
(Figure 30). (Data already published in (Weidner, Söhn et al. 2016)).  
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3.5.2. MTMR7 sensitizes human KRAS-mutated CRC cells to mTOR-/RAF kinase-
inhibitors 
Since MTMR7 acts as a dual inhibitor of the RAS-RAF-MEK1/2-ERK1/2 and PI3K-AKT-mTOR-
S6K signaling pathways, the idea was to assess whether this inhibiting effect can be mimicked 
by combining two approved drugs, a multi-kinase inhibitor (sorafenib), inhibiting the RAF-kinase 
and several tyrosine kinases of the VEGF signaling pathway, together with an mTOR-inhibitor 
(everolimus), to inhibit proliferation and survival of KRAS-mutated human CRC. 
MTT viability assays with different concentrations of sorafenib and everolimus in presence and 
absence of MTMR7 were performed in SW480, HCT116 and HEK293T cells to figure out effective 
drug concentrations. MTMR9 was an additional control as it is an inactive binding partner of 
MTMR7. Results are shown in Figure 31. 
 
 
Figure 31: Effect of kinase inhibitors on colorectal cancer cell lines. SW480, HCT116 and HEK293T cells were transfected with 
either an EV control or MTMR7 plasmid for 24 h. The next day, cells were reseeded into 96-well plates (2000 cells/well). After additional 
24h, cells were treated with either sorafenib (upper panel) or everolimus (lower panel) at different concentrations. Viability was 
measured in MTT assay after 96 h of treatment. OD values were calculated as -fold ± S.E. (n=3 per cell line; n.s.; MTMR7 vs. EV; 
Two-way Anova) compared with day 0. 
 
The results demonstrated, that low drug concentrations in the nanomolar range were needed for 
KRAS-WT cells e.g. HEK293T cells. In these cells, a synergistic effect of the drugs and MTMR7 
transfection could not be seen. Nethertheless, HEK293T cells proliferated slower under drug 
treatment and thus showed no resistance against sorafenib or everolimus. 
 
For the KRAS-mutated HCT116 and SW480 cells, very high concentrations (micromolar range) 
of the drugs were needed, and no synergistic effect of the drugs and MTMR7 was seen. Thus, 
the KRAS-mutated cells showed a resistance against both drugs.  
 
To assess whether the resistance can be circumvented by combining these two kinase inhibitors, 
MTT assays were performed using a combination of sorafenib and everolimus (Figure 32). 
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Figure 32: Combination therapy breaks resistance in colorectal cancer cell lines. SW480, HCT116 and HEK293T cells were 
transfected with either an EV control or MTMR7 plasmid for 24 h. The next day, cells were reseeded into 96-well plates 
(2000 cells/well). After additional 24h, cells were treated with a sorafenib/ everolimus combination. Viability was measured in MTT 
assay after 96 h of treatment. OD values were calculated as -fold ± S.E. (n=2 per cell line; *p<0.05 MTMR7 vs. EV; Friedman test) 
compared with day 0. 
 
The combination therapy showed that in presence of MTMR7 and the two drugs, proliferation of 
the cells was much slower as in the single therapy, whereas resistance remained in the absence 
of MTMR7. Proliferation was significantly inhibited in HCT116 and SW480 cells upon drug 
treatment and MTMR7 transfection (HCT116: MTMR7 3.5 ± 1.5 % vs. EV 4.5 ± 1.5 %; SW480: 
MTMR7 1.9 ± 1.0 % vs. EV 2.5 ± 0.4 % at a concentration of 10/ 3 µM). The effect was also seen 
in HEK293T cells, but it was not as strong as in the two colorectal cancer cell lines. 
 
To examine if the inhibiting effect of MTMR7 can be enhanced by additional treatment with PPARγ 
ligand, cells were treated with the combination of the two kinase inhibitors -/+ rosi. However, rosi 
did not further inhibit cell growth (data not shown).  
 
In sum, MTMR7 inhibited proliferation of KRAS-mutated CRC cells with high pan-RAS activity 
(SW480) more efficiently than the kinase inhibitors alone, MTMR7 augmented the efficacy of the 
drugs, while the addition of rosi did not further influence growth inhibition.  
3.5.3. Influence of MTMR7 on cetuximab treatment 
To assess, whether the benefit of cetuximab treatment is dependent on the presence or absence 
of MTMR7 in cells, two KRAS-mutant CRC cell lines (HCT116, SW480) and one KRAS-WT cell 
line (HEK293T) were transfected with MTMR7 plasmid or an EV control for 24 hours and treated 
with cetuximab concentrations ranging from 0 to 1000 µg/ml in a long-term time frame of 6 days 
(Figure 33). 
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Figure 33: Benefit of cetuximab treatment is not dependent on the presence of MTMR7. SW480, HCT116 and HEK293T cells 
were transfected with either an EV control or MTMR7 plasmid for 24 h. The next day, cells were reseeded into 96-well plates 
(2000 cells/well). After additional 24h, cells were treated with 1000 µg/ml cetuximab. Viability was measured in MTT assay 1-6 days. 
OD values were calculated as -fold ± S.E. (n=3 per cell line; n.s. Two-way Anova) compared with day 0. 
 
The results showed that, MTMR7 did not promote cetuximab treatment in any cell line. However, 
a different effect could be seen in the three cell lines. The SW480 and HCT116 cells were resistant 
to cetuximab treatment at all, even in the highest used concentration.  
 
For the HEK293T cells no differences could be seen upon MTMR7 transfection and cetuximab 
treatment. However, these cells are not KRAS mutated and should respond at least to cetuximab 
treatment alone (without MTMR7 transfection). This indicates that the antibody was not 
functioning properly, which might be due to the use of antibody remnants of the clinic. 
3.5.4. MTMR7 peptide inhibits proliferation of human KRAS-mutated CRC cell lines  
Since MTMR7 is lost in many colorectal cancer patients, the idea was to resupply it to patients. 
To this end, Dr. Elke Burgermeister designed a docking site peptide which mainly consists of the 
coiled-coil domain of MTMR7. This domain is an amphipathic leucine-rich helix which is 
responsible for the binding of MTMR9 which in turn enhances the MTMR7 phosphatase activity. 
A scrambled peptide served as control. 
 
To assess, whether the MTMR7 peptide can imitate signaling inhibition by MTMR7 
overexpression, a series of 7 human cancer cell lines (SW480, HCT116, DLD1, Lovo, HEK293T, 
AGS, PATU8902) were grown for 7 days in presence of either 0.5 µM MTMR7-peptide or 
scrambled peptide, and cell viability was measured each day by MTT assay (Figure 34).  
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Figure 34: MTMR7 peptide inhibits cell growth. SW480, HCT116, Lovo, DLD1, PATU8902, AGS and HEK293T cells were treated 
with either 0.5 µM MTMR7-peptide or control-peptide. Viability was measured in MTT assay after 1-3 days. OD values were calculated 
as -fold ± S.E. (n=3 per cell line; *p<0.05 MTMR7-peptide vs. control-peptide; Two-way ANOVA) compared with day 0. 
 
The results revealed that MTMR7 peptide significantly inhibited cell growth already after 1 - 2 
days in SW480 (MTMR7 peptide 1.3 ± 0.1 % vs. control peptide 2.8 ± 0.5 %), HCT116 (MTMR7 
peptide 1.7 ± 0.4 % vs. control peptide 2.8 ± 0.7 %) and PATU8902 (MTMR7 peptide 1.6 ± 0.1 % 
vs. control peptide 2.6 ± 0.3 %) cells. Furthermore, a trend for reduced proliferation was seen in 
AGS cells whereas the response in Lovo, DLD1 and HEK293T cells was not as effective.  
3.5.4.1. Effect of MTMR7 peptide on RAS-ERK 1/2 signaling 
To study the effect of MTMR7-peptide on AKT-mTOR and ERK 1/2 signaling pathways 
downstream of KRAS, SW480, HCT116, and HEK293T cells were incubated with either MTMR7-
peptide or a control-peptide. After 24 hours, cells were starved for 16 h and stimulated with EGF 
(50 ng/ml) for 0-30 minutes, and samples were analyzed by Western blot using an antibody 
against pan-RAS, P-AKT and P-ERK 1/2 (Figure 35).  
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Figure 35: MTMR7 peptide promotes RAS down-regulation. SW480, HCT116 and HEK293T cells were incubated with MTMR7-
peptide or a control-peptide. After 24 h cells were starved for 16 h and stimulated with 50 ng/ml EGF for 0-30 min. Detection of pan-
RAS (21 kD) and P-ERK 1/2 protein in TCL is shown together with the quantitative analyses. MTMR7-peptide promoted RAS down-
regulation in all cell lines but did not influence P-ERK 1/2 expression. OD values of bands in gels were normalized to ERK 1/2 and 
calculated as -fold ± S.E. (n=3; n.s.; Two-way Anova). 
 
A tendency for down-regulation of pan-RAS protein levels by about 30 % after 30 minutes of 
stimulation was seen in SW480 and HEK293T cells. However, this effect could not be seen more 
downstream in ERK 1/2 phosphorylation. Here, all cell lines showed a significant change in P-
ERK 1/2 expression over time, but not between MTMR7-/control-peptide treatment.  
Furthermore, P-AKT expression was not influenced by MTMR7-peptide (data not shown). 
3.5.4.2. MTMR7-peptide reduces serum response element activation 
Furthermore, functionality of the MTMR7-peptide was determined by measuring the 
transcriptional activation of the serum response element (SRE) (Lefebvre, Chen et al.) using 
luciferase reporter assays as a readout. SW480, HCT116 and HEK293T cells were incubated 
with either MTMR7-peptide or a control-peptide. After 24 and 48 hours, luciferase activity of SRE 
was measured (Figure 36). 
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Figure 36: MTMR7 peptide inhibits SRE-reporter gene activity. SW480, HCT116 and HEK293T cells were treated with either 1 µM 
MTMR7-peptide or control-peptide for 24/48 h. Luciferase activity in total cell lysates was normalized to protein content and calculated 
as -fold ± S.E. (n=3; *p<0.05 MTMR7-peptide vs. control peptide; Two-way ANOVA) compared with day 0. 
 
All three cell lines showed a significant decrease of SRE activation upon MTMR7-peptide 
treatment after 48 hours, indicating that the peptide is active and inhibits RAS-ERK 1/2 signaling. 
 
SRE activity was significantly decreased by 35 % in HCT116 cells treated with the MTMR7 
peptide compared to the control-peptide.  
In SW480 cells, the activity was inhibited by 20 % in the peptide treated cells compared with the 
untreated controls.  
HEK293T cells did not show a difference between the MTMR7-peptide and the control-peptide 
treatment. However, a significant decrease in SRE activity by 35 % upon MTMR7-peptide 
treatment was seen on the second day, compared with the first day. 
 
The effect was stronger in HCT116 cells, carrying the weaker KRAS G13D mutation, than in 
SW480 cells with the KRAS G12V mutation. 
3.6. In vivo analysis of KRAS signaling in Apcmin/+ x Cav1-KO mice 
3.6.1. Therapy of Apcmin/+ x Cav1-KO mice with an HSP90 inhibitor  
CoIP experiments showed, that MTMR7 is not only forming a complex with PPARγ and MTMR9, 
but also with the Heat-shock protein 90 (Hsp90) (Figure 43, 7.1). In addition, MTMR7 lowered 
HSP90 protein levels significantly in rosi treated cells (Weidner 2016). 
Hsp90 is a molecular chaperone which is involved in maturation, stabilization and nuclear 
translocation of a large (> 200 proteins) set of substrate proteins, known as client-proteins. These 
clients include many oncogenes, hormone receptors (e.g. PPARγ) and kinases (Prince 2011). 
Thus, the idea was to target these clients with an Hsp90 inhibitor and to determine if Hsp90 is 
also involved in the stabilization of MTMR7 using an Apcmin/+ x Cav1-KO mouse model. Mice 
(at an age of 6 months) were randomized into treatment and control groups (n=3) and treated 
with 17-DMAG, a water-soluble derivative of geldanamycin, via i.p. injection ((12,5 mg/kg); 4 x 
times per week) for 4 weeks. At 7 months of age, mice were sacrificed, and drug response was 
analyzed. The HE-staining and macroscopic analysis revealed a diminished lesion size of about 
50 % in the treated mice compared to the untreated ones. Furthermore, microscopic analysis 
showed a lower tumor amount in the colon of the treated Apcmin/+ x Cav1-KO mice compared to 
the untreated Apcmin/+ x Cav1-KO mice (Figure 37).  
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Figure 37: HE-staining of Apcmin/+ x Cav1-KO mice treated with an Hsp90 inhibitor. Apcmin/+ x Cav1-KO mice were treated 
with the Hsp90 inhibitor 17-DMAG (i.p., 12,5 mg/kg, 4 x per week, n=3 per group) for 4 weeks. Representative HE (adenomas) images 
are shown. Macroscopic analysis of tumor therapy (lesions size: 0=none; 1= small white adenoma (< 5 mm); 2= large “red” 
vascularized colorectal adenoma/tumor (> 5 mm) (*p<0.05; Kruskal-Wallis test or ANOVA). 
 
3.6.2. Therapy influence on PPARγ-target gene expression 
Due to quantitative reasons, tissue of the ileum (100 % penetrance of lesions) was used to 
investigate the expression of PPARγ target genes such as Tff3, p21 and CyclinD1, using RT-
qPCR (Figure 38).  
 
 
Figure 38: Influence of 17-DMAG therapy on PPARγ target gene expression. Gene expression was measured in total RNA 
extracted from frozen mouse tissues. CT-values from RT-qPCRs on total RNA were normalized to beta2-microglobulin (B2m) and 
calculated as -fold ± S.E. (n=3 per organ; n.s.). 
 
RT-qPCR showed an upregulation of Tff3 in the treated mice compared to the untreated mice 
(WT and Apcmin/+ x Cav1-KO mice).  
Same was true for the cell cycle inhibitors (CDKIs), CyclinD1, and P21, indicating that the Hsp90 
inhibitor promotes senescence in these mice. 
 
In contrast, no changes were found in the samples of colon tissue (data not shown). 
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Furthermore, immunohistochemical staining of KRAS and KI67 (Figure 39) was performed. 
 
 
 
 
Figure 39: KI67 and KRAS staining in 17-DMAG treated Apcmin/+ x Cav1-KO mice. A. Representative images are shown together 
with statistical analysis after counting of positive cells (see 2.6.4). Magnification 200x. Results were calculated as -fold ± S.E. 
(untreated n=6; treated n=6; n.s.; Two-way Anova). B. Representative images are shown together with statistical analysis after scoring 
(see 2.6.4). Magnification 200x. Results were calculated as -fold ± S.E. (untreated n=6; treated n=6; n.s.; Two-way Anova). 
 
Immunohistochemical staining demonstrated that the expression of KI67 is not significanlty 
changed under therapy. Notably, adjacent normal tissue had a higher proliferation rate than the 
adenoma tissue, indicative of a possible senescence in these lesions which did not progress to 
adenocarcinoma (Figure 39A). 
For KRAS no difference could be seen between the adjacent normal tissue and tumor tissue. In 
addition, 17-DMAG treatment had no impact on KRAS expression in the Apcmin/+ x Cav1-KO 
mice (Figure 39B). 
3.6.2.1. 17-DMAG therapy decreases P-ERK 1/2 levels in Apcmin/+ x Cav1-KO mice 
In addition to immunohistochemical staining of KRAS and KI67, P-ERK 1/2 and pan-RAS levels 
were examined. Proteins were extracted from frozen tissue samples of the colon, and Western 
blots were performed using antibodies against P-ERK 1/2, pan-RAS and p-AKT proteins. The 
antibodies for AKT-2 and ERK 1/2 served as controls (Figure 40). 
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Figure 40: Western blot analysis of Apcmin/+ x Cav1-KO mice treated with a Hsp90 inhibitor. Apcmin/+ x Cav1-KO mice were 
treated with the Hsp90 inhibitor 17-DMAG (i.p., 12,5 mg/kg, 4 x per week, n=3 per group) for 4 weeks. Detection of P-ERK 1/2 (42/44 
kD), pan-RAS (21 kD), P-AKT protein in TCL is shown together with the quantitative analyses. 17-DMAG treatment reduced pan-RAS 
protein levels and influenced P-ERK 1/2 expression. OD values of bands in gels were normalized to ERK 1/2 or AKT2 and calculated 
as -fold ± S.E. (n=3; *p<0.05 treated vs. untreated; Two-way ANOVA). 
 
Western blot experiments demonstrated a significant decrease in P-ERK 1/2 expression in tissue 
of untreated WT compared with untreated Apcmin/+ x Cav1-KO mice.  
For pan-RAS expression, an expected significant increase of 30 % ± 5 % was seen in the 
untreated Apcmin/+ x Cav1-KO mice compared with the untreated WT mice. In addition, a 
downregulation by 35 % of pan-RAS protein was seen in the treated Apcmin/+ x Cav1-KO mice 
compared with the untreated Apcmin/+ x Cav1-KO mice. In contrast, no changes between 
untreated WT mice compared with treated WT mice was detected. 
Examination of P-AKT expression revealed no changes, neither between the untreated nor 
between the treated WT and Apcmin/+ x Cav1-KO mice. 
 
Taken together, these in vivo data suggest that Hsp90 may be important for stabilizing 
PPARγ/MTMR7 complex. However, this experiment needs to be repeated with a minimum of n = 
5-10 per group due to the limited case number. 
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3.6.3. Therapy of Apcmin/+ x Cav1-KO mice with rosiglitazone 
To establish the effect of rosi treatment on the expression level of KRAS, immunohistochemical 
staining was performed. Paraffin blocks of a Apcmin/+ x Cav1-KO mice therapy with rosi (provided 
by Teresa Friedrich (Friedrich, Richter et al. 2013)) were used. The Apcmin/+ x Cav1-KO mice 
received a chow diet supplemented with 0.02 % (w/w) rosi (~25 mg/kg*day) for 4 months and 
were sacrificed at 7 months of age (Figure 41). 
 
Figure 41: Loss of KRAS staining in rosiglitazone-treated Apcmin/+ x Cav1-KO mice. Representative pictures are shown 
together with statistical analysis after scoring (see 2.6.4). Magnification 100x Results were calculated as -fold ± S.E. (untreated n=6; 
treated n=5; n.s.; Two-way ANOVA).  
 
Immunohistochemical staining revealed a reduction of KRAS staining in tumor tissue compared 
with adjacent normal tissue in the untreated and the treated Apcmin/+ x Cav1-KO mice. Although, 
no difference between the treated and the untreated Apcmin/+ x Cav1-KO mice was detected. 
Generally, KRAS level was lower in APC mutant mice irrespective of treatment compared to WT 
mice (data not shown).  
Due to low case numbers, this experiment is a preliminary impression of rosi impact on KRAS 
expression in Apcmin/+ x Cav1-KO mice.  
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4. Discussion 
The major aim of the thesis was to characterize the role and function of the lipid phosphatase 
MTMR7 in colorectal cancer in vivo and in vitro. MTMR7 was found as a novel binding partner of 
PPARγ (Söhn, Weidner et al., unpublished). Since mutations in RAS genes (KRAS, NRAS) cause 
intrinsic unresponsiveness of colorectal cancer (CRC) patients to therapy with antibodies directed 
against the epidermal growth factor receptor (Karapetis, Khambata-Ford et al. 2008), targets 
downstream of mutant RAS hold the promise to overcome therapy resistance in this patient group. 
The already published inhibiting effect of the phosphatase MTMR7 on the two major pathways 
RAF-MEK1/2-ERK1/2 and AKTmTORC1/2 downstream of mutant KRAS indicated that the lipid 
phosphatase MTMR7 plays an essential role in colorectal carcinoma (Weidner, Söhn et al. 2016). 
Thus, this thesis aimed to elucidate, if the MTMR7-PPARγ-complex could be a druggable target 
for the treatment of KRAS-mutated CRC patients. 
 
 
With respect to tissue expression, this work completed the expression analysis in murine tissue 
performed in the initial description by Majerus et al. 2003. As reported, expression of MTMR7 is 
found in neuronal tissue, liver, and kidney tissues on the mRNA level. A further agreement can 
be found in the quantitative evaluation of the mRNA content, in which the high expression in brain 
tissue was confirmed. In addition to the earlier MTMR7 expression analyses, MTMR7 mRNA 
could also be detected in muscle tissue and in all sections of the gastrointestinal tract in this work. 
Moreover, MTMR7 mRNA is expressed in several colorectal cancer cell lines, indicating a 
potential role of the phosphatase in the disease of colorectal carcinoma. 
 
In line with the findings on mRNA level and in contrast to Majerus et al. 2003, the protein 
expression pattern of MTMR7 could be extended by heart, lung, liver, kidney, muscle, and all 
parts of the gastrointestinal tract in murine tissue. Furthermore, MTMR7 expression is found in 
human cell lines of colorectal cancer. 
 
 
Subcellular localization of MTMR7 revealed a colocalization with RAB9, a late endosomal marker. 
This result corroborated the suggestion of Majerus et al. 2003, that MTMR7 is enriched in 
endosomes or the Golgi apparatus, since RAB9 functions in transport between late endosomes 
and the trans Golgi network (Lombardi, Soldati et al. 1993), proposing a role of MTMR7 in 
membrane trafficking. Another indication that MTMR7 influences membrane trafficking, is the fact 
that it uses PI(3)P as substrates (Weidner, Söhn et al. 2016) and these, but not PI(3,5)P2,  are 
found in multivesicular bodies (Hnia, Vaccari et al. 2012).  
Furthermore, MTMR7 contains a conserved region of about 70 amino acids, the GRAM domain, 
which also exists in glucosyltransferases, GTPase-activating proteins of the RAB small GTPases, 
and other proteins associated with membrane-coupled processes (Doerks, Strauss et al. 2000). 
Interestingly, localization of MTMR7 was dependent on the number of cells on the slide: Nuclear 
localization for single cells and cytosolic localization for cells grown to confluency. This 
observation may further corroborate a possible role of MTMR7 in membrane trafficking. However, 
this hypothesis has to be further elucidated. 
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The peroxisome proliferator-activated receptor-gamma (PPARγ) is a ligand-activated 
transcription factor. PPARγ is involved in the regulation of several processes including, glucose 
and lipid metabolism (Polvani, Tarocchi et al. 2016), inflammation, wound healing, differentiation 
(e.g. of mesenchymal and epithelial cells) and cancer (Burgermeister and Seger 2007, 
Srivastava, Kollipara et al. 2014, Zurlo, Ziccardi et al. 2016). For instance, the expression of genes 
involved in differentiation and growth inhibition are controlled by PPARγ, and it is reported to be 
a negative regulator of the cell cycle (Grommes, Landreth et al. 2004). The nuclear receptor can 
be activated by its agonists like rosi- and pioglitazone, belonging to the thiazolidinedione family 
(van Beekum, Fleskens et al. 2009, Peymani, Ghoochani et al. 2013). Its activation inhibits 
proliferation of tumor cells derived from liposarcoma, breast adenocarcinoma (Rubin, Zhao et al. 
2000), prostate carcinoma, colorectal carcinoma, non-small-cell lung carcinoma, pancreatic 
carcinoma, bladder cancer, gastric carcinoma, and glial tumors of the brain (Chattopadhyay, 
Singh et al. 2000). Furthermore, the tumor suppressor PTEN and the cyclin-dependent kinase 
inhibitor P21 are induced by thiazolidinediones, which contributes to their antiproliferative activity.  
However, pharmacological activation of the nuclear receptor is not only beneficial for malignant 
and inflammatory diseases (Rubin, Zhao et al. 2000, Tyagi, Gupta et al. 2011). For example, 
cardiovascular side effects (Erdmann, Charbonnel et al. 2007) and a pro-carcinogenic impact in 
bladder cancer (Neumann, Weill et al. 2012, Bosetti, Rosato et al. 2013), but not in colorectal 
cancer has been demonstrated for therapy with pioglitazone. Interestingly, there was a modest 
risk reduction of colorectal cancer in relation to thiazolidinediones and an inverse association 
particularly with rosi (Bosetti, Rosato et al. 2013). 
Hence, PPARγ specific agonists are currently in clinical trials as a combination therapy with 
conventional chemotherapeutics (Peters, Shah et al. 2012). Efatutazone therapy, for example, 
significantly reduced the size of pancreatic, colon, anaplastic thyroid carcinoma (Shimazaki, 
Togashi et al. 2008), and esophageal carcinoma (Sawayama, Ishimoto et al. 2014) in xenograft 
models. However, the combination of efatutazone with FOLFIRI in a phase II study showed no 
evidence of clinical efficacy (Marshall, Shuster et al. 2014). Furthermore, a phase II study in 
chronic myeloid leukemia revealed that the combination of pioglitazone with imatinib was well 
tolerated and yielded a favorable 56% response rate (Prost, Relouzat et al. 2015, Rousselot, 
Prost et al. 2017). 
To better understand the discrepancy between preclinical and clinical efficacies of PPARγ, we 
studied its molecular regulation mechanisms. Its regulation is dependent of its subcellular 
localization (Zhang, Berger et al. 1996, Camp and Tafuri 1997, van Beekum, Fleskens et al. 
2009).It has been shown that the export of PPARγ to the cytosol is due to mitogenic stimulations. 
These stimulations were correlated with the nuclear export signal (NES) in the mitogen‑activated 
protein kinase kinase 1/2 (MEK1/2). This nuclear export leads to the reduced ability of PPARγ to 
activate nuclear target genes and thus inhibits its genomic function (Burgermeister, Chuderland 
et al. 2007). 
 
All these data and the fact that PPARγ is forming a cytosolic complex with MTMR7 in human 
KRAS-mutated colorectal cancer cell lines (Söhn, Weidner et al., unpublished) gave evidence 
that this complex might be a druggable target in anti-cancer therapy.  
 
Therefore, this thesis followed the investigations of P. Weidner (Weidner, Söhn et al. 2016) to 
further examine the molecular mechanism of PPARγ-MTMR7 complex formation and its 
consequences.  
CoIP experiments confirmed that the MTMR7-PPARγ complex is located in the cytosol and it is 
being formed endogenously in HCT116 as well as in HEK293T cells after MTMR7 
overexpression. These results were verified by immunofluorescence microscopy and proximity 
ligation assay, where endogenous PPARγ and overexpressed MTMR7 were localized in the 
cytoplasm. This finding was unexpected, as PPARγ alone is usually found in the nucleus.  
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We previously showed a reduced ERK 1/2 phosphorylation after MTMR7 overexpression 
(Weidner, Söhn et al. 2016) and assumed that this could be a new mechanism of a positive 
amplification loop of cytosolic PPARγ on the transcriptional activity of the receptor in the nucleus. 
In detail, cytosolic PPARγ seems to activate the lipid phosphatase MTMR7, which inhibits ERK 
1/2 signaling and thereby activates PPARγ activity in the nucleus (Söhn, Weidner et al., 
unpublished).  
To test this hypothesis, subcellular fractionation was performed in the present work to analyze 
the nuclear and cytosolic distribution of the nuclear receptor PPARγ. There was no cytosolic 
change in PPARγ after MTMR7 overexpression, even after stimulation with 20 % FCS and rosi. 
In contrast, a decrease in phosphorylated (inhibited) PPARγ in the nuclear fraction could be 
detected after MTMR7 transfection, while the unphosphorylated nuclear receptor amount 
remained unaltered.  
However, an increased activity of the PPARγ-response-element was found, which indicates 
activation of the nuclear receptor by MTMR7. This fact could also be underlined by upregulation 
of TFF3, a secretory protein in the gastrointestinal mucosa and a PPARγ-target gene.  
Thus, MTMR7 failed to evoke a massive translocation of PPARγ to the nucleus, which was also 
demonstrated by immunofluorescence staining, suggesting that its positive effect on PPARγ 
transcriptional activity might be via prevention of its inhibitory phosphorylation by the RAS-
ERK 1/2 pathway. 
 
Based on these data, the following mechanisms, how MTMR7 augments the transcriptional 
activity of PPARg, can be proposed: 1) by EGFR endocytosis routes or 2) by RAS down-
regulation followed by reduced ERK 1/2 activity. 
 
It is well known that the levels of EGFR (Keohavong, DeMichele et al.) at the cell surface are 
strictly regulated by a complex endocytotic machinery. After internalization, EGFR is either 
recycled back to the cell surface or transported to the late endosome or lysosome for degradation 
(Chi, Cao et al. 2011).  
Phosphatidylinositol(3)phosphate (PI(3)P) also plays an important role in determining the flux of 
receptors toward the degradation and recycling pathways and is required for EGFR trafficking 
and degradation and, therefore, is a key regulator of endosomal morphology and function 
(Simonsen, Wurmser et al. 2001, Fili, Calleja et al. 2006). It has been shown that either the 
depletion of PI(3)P (Futter, Collinson et al. 2001, Lu, Hope et al. 2003, Petiot, Faure et al. 2003, 
Tsujita, Itoh et al. 2004) or increased levels of the phospholipids (Cao, Backer et al. 2008) 
impaired endosomal EGFR sorting, indicating that a tightly coordinated balance of overall PI(3)P 
is essential for proper growth factor receptor endocytosis and sorting. 
Notably, these PI(3)Ps link the myotubularins to the EGF receptor. Cao et al. showed that the 
depletion of MTM1 or MTMR2 increased PI(3)P levels and slowed down EGFR degradation in 
two different keratinocyte cell lines, but EGFR internalization in response to ligand stimulation 
was unaffected by MTM depletion (Cao, Backer et al. 2008). 
The present work showed that MTMR7 promoted membrane retention of EGFR in colorectal 
cancer cells and thereby reduced accumulation of EGFR in the nucleus (Burgermeister, Höde et 
al. 2017). The latter had been associated with highly proliferative tissue by Shiaw-Yih Lin et al., 
showing that nuclear EGFR is highly expressed in the uterus of mice on day 6 of pregnancy, in 
basal cells of human normal oral mucosa, and in breast cancer samples (Shiaw-Yih Lin 2001). In 
addition, nuclear EGFR expression has been associated with tumor progression and worse 
survival prognosis in cancer of the breast, ovary, oropharynx, esophagus, and non-small cell lung 
cancer (Lo, Xia et al. 2005, Psyrri, Yu et al. 2005, Hoshino, Fukui et al. 2007, Traynor, Weigel et 
al. 2013). Moreover, its nuclear expression is highly linked to an enhanced resistance to radiation, 
chemotherapy, and the anti-EGFR therapies gefitinib and cetuximab (Brand, Iida et al. 2013).  
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The data cited above suggest that MTMR7-mediated reduction of nuclear EGFR might lead to 
inhibition of proliferation and a better response to anti-EGFR therapies in colorectal cancer 
patients. Thus, MTMR7 may play an important role in colorectal cancer and EGFR sorting and it 
could be a possible future druggable target for overcoming therapy resistance in colorectal cancer 
patients.  
 
As mentioned before, RAS-proteins (K-RAS, H-RAS and N-RAS) are the most frequently mutated 
proteins in cancers, including pancreatic (65 %), colorectal (33 %), and lung cancer (16 %) (Data 
from COSMIC v84 release, (Forbes, Bindal et al. 2011)). They are involved in the regulation of 
many cellular processes, including the control of cell proliferation, transformation, differentiation, 
and survival (Malumbres and Barbacid 2003, Ahearn, Haigis et al. 2011). The activity state of 
RAS proteins is in turn controlled by binding of growth factors to upstream receptor tyrosine 
kinases (RTKs), resulting in the recruitment of guanine nucleotide exchange factors which then 
catalyze the switch from the inactive, guanosine diphosphate (GDP)-bound to the active, 
guanosine triphosphate (GTP)-bound states (Downward 2003, Ahearn, Haigis et al. 2011).  
Mutations in RAS proteins occur predominantly at the amino acids in the CDS (coding sequence) 
at position G12, G13, and Q 61 (Buhrman, Holzapfel et al. 2010). Due to a defect in hydrolysis of 
GTP to GDP, these mutations result in a persistent GTP-bound state of RAS, leading to a 
constitutive activation of downstream signaling (Scheffzek, Ahmadian et al. 1997, Scheidig, 
Burmester et al. 1999). 
In the present work, a reduced pan-RAS activity as well as a reduced total amount of pan-RAS 
protein, but not of mRNA, was found upon MTMR7 transfection in KRAS mutated colorectal 
cancer cell lines. However, no translocation to other cell compartments like the cytosol or the 
nucleus was detected.  
Notably, the impact of MTMR7 on RAS down-regulation was higher in SW480 cells carrying the 
G12V, than in HCT116 carrying the G13D KRAS mutation. This might be due to the lower pan-
RAS activity of the G13D mutation compared to the G12V, and the high endogenous expression 
level of MTMR7 in HCT116 cells compared to the low level in SW480 cells. 
 
Thus, MTMR7 overexpression reduced the amount of pan-RAS protein in colorectal cancer cells. 
Since this was only observed on the protein level and not on the mRNA level, an effect on 
transcription or mRNA stability could be excluded. Thus, RAS protein might be down-regulated 
by MTMR7, e.g. by inhibition of translation or reduction of protein stability ("degradation"). 
 
RAS degradation was already described by others. However, the mode of RAS degradation 
remains controversial. Zeng et al. found that the E3 Ligase Nedd4-1 downregulates RAS in 
normal cells through the lysosomal pathway (Zeng, Wang et al. 2014). In addition, Shukla et al. 
reported, that the loss of Smad ubiquitination regulatory factor 2 (SMURF2) leads to mutant KRAS 
degradation by the lysosome and thereby inhibits survival and growth of lung and colorectal 
cancer cell lines, whereas wild type KRAS protein levels remained almost unaffected (Shukla, 
Allam et al. 2014). Furthermore, Lu et al. reported that KRAS degradation is carried out through 
the lysosome (Lu, Hope et al. 2003), which was also shown by others, reporting a lysosome-
mediated degradation after 4-hydroxy-tamoxifen treatment (Kohli, Kaza et al. 2013).  
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In contrast, Jeong et al. provided evidence for a proteasomal mechanism of RAS degradation 
(Jeong, Yoon et al. 2012). Pan et al., developed a recombinant chimeric protein, which induces 
cell death in mutant KRAS-expressing pancreatic tumor cell lines and a tumor mouse model of 
pancreatic cancer exemplifying that RAS protein can also be degraded through the proteasomal 
system (Pan, Zhang et al. 2016).  
 
Here, the two major mechanisms of degradation were considered, namely lysosomal protein 
degradation and the ubiquitin-proteasome system. The lysosome was discovered in rat liver in 
1953 by Christian de Duve as vacuolar structure containing hydrolytic enzymes which function 
optimally in an acidic pH (De Duve, Gianetto et al. 1953, Gianetto and De Duve 1955). Lysosomal 
degradation starts with the intake of exogenous proteins and particles as well as endogenous 
proteins and cellular organelles. Exogenous proteins are digested via receptor-mediated 
endocytosis and pinocytosis, exogenous particle via phagocytosis, and endogenous proteins and 
cellular organelles via micro- and macro-autophagy.  
The ubiquitin-proteasome system was discovered 30 years later by Aaron Ciechanover, Avram 
Hershko und Irwin Rose and rewarded for the Nobel Prize for chemistry in 2004. They found that 
proteins are continuously marked for degradation by ubiquitin, generating a polyubiquitin chain, 
which serves as the binding and degradation signal for the 26S proteasome, a multi subunit 
protease complex (Ciechanover 2005).  
 
However, these two major pathways of protein degradation, i.e. lysosomal or proteasomal, did 
not clarify the mechanism of RAS down-regulation upon MTMR7 overexpression. In contrast, loss 
of RAS protein level was enhanced upon chloroquine treatment, meaning that RAS is not 
degraded via lysosomal acidification, but RAS can be further diminished using a lysosomal 
inhibitor. Furthermore, no regeneration of RAS protein was seen in MTMR7-transfected cells 
treated with MG132, indicating that RAS is not degraded via the proteasomal pathway.  
 
Thus, alternative mechanism next to protein degradation may be involved here: For example, 
membrane association of KRAS is still not fully clarified and remains to be evaluated. Publications 
commonly suggest that RAS is attached to membranes by binding of its polybasic domain to the 
negatively charged phospholipids at the inner leaflet of the plasma membrane and the weak, 
lipophilic association through CAAX-sequence modulations. In addition, there must be other 
mechanisms to keep RAS attached to membranes (Willumsen, Christensen et al. 1984, Schmick, 
Vartak et al. 2014, Schmick, Kraemer et al. 2015). One described mechanism is the PDEδ-Arl-2 
delivery system which continuously shuffles KRAS back to the plasma membrane. This process 
is as fast as the KRAS dissociation from membranes, leading to a constant steady-state level of 
KRAS at the plasma membrane (Schmick, Kraemer et al. 2015).  
 
Since RAS seemed not to be degraded via the lysosome or the proteasome, literature research 
suggested a possible down-regulation through a biophysical mechanism.  
Hancock et al. suggest an alternative mechanism of RAS post-translational regulation that 
involves changes in the membrane potential. They report membrane assembling of RAS proteins 
via nanoclusters, containing about six RAS proteins (Zhou and Hancock 2015). The stability of 
these clusters is enhanced by plasma membrane depolarization upon increased extracellular K+ 
concentrations and in contrast disrupted by hyperpolarization, achieved by expressing Kv2.1, a 
voltage-gated K+ channel (Zhou, Prakash et al. 2017).  
Meanwhile, the results obtained in the present work showed the opposite effect. Instead of 
preventing loss of RAS using high extracellular K+ concentrations, down-regulation of RAS was 
promoted. In contrast, hyperpolarization blocking the influx of Na+ ions into the cytosol using 
amiloride prevented MTMR7-induced loss of RAS protein. 
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One possible explanation of RAS down-regulation upon MTMR7 transfection is its substrate 
specificity for PI(3)P. By dephosphorylation of PI(3)P to PI, the membrane also depolarizes, and 
RAS might get unstable due to the lost, negative charge of the inner leaflet of the plasma 
membrane. This idea, though, is not supported by available literature. Instead, there are two 
alternatives: 1) phosphatidylserine, but not PI(3)P is part of RAS nanoclusters (Zhou, Prakash et 
al. 2017), 2) the amount of all available PIPs at the plasma membrane is less than 10 % (Robinson 
and Dixon 2006). Thus, the contribution of MTMs to the overall membrane potential remains 
elusive. 
 
Currently, the RAS down-regulation mechanism upon MTMR7 overexpression is still unclear. It 
might be due to multiple mode of actions including changes in translational initiation or protein 
stability. Another possibility could be autophagy, since several MTMs play a role here. Hence, 
more detailed analysis is needed to resolve this issue.  
 
Nevertheless, the MTMR7-mediated activation of the nuclear receptor PPARγ is still possible 
through the RAS down-regulation pathway. If that would be true, it could also be an explanation 
why MTMR7 did not facilitate nuclear import of PPARγ like the inhibitors of RAS signaling Dok-1 
and Caveolin-1 (Burgermeister, Friedrich et al. 2011). Instead, MTMR7 inhibits RAS (its activity 
and protein level), leading to a lower ERK 1/2 activity, which results in the reduction of inhibitory 
PPARγ phosphorylation and in an increase of the transcriptional PPARγ activity, and finally 
culminating in the activation of tumor suppressor genes like Dok-1 and Caveolin-1.  
The mutual inhibition of the RAS-pathway and PPARγ is well known from the literature. PPARγ 
inhibition is due to constant active RAS, which leads to the permanent activation of MEK-1. This 
in turn inhibits PPARγ in two ways: 1) MEK-1 leads to a constant export of PPARγ from the 
nucleus to the cytosol (Burgermeister, Chuderland et al. 2007) and 2) MEK-1 leads to a constant 
phosphorylation of ERK 1/2, which phosphorylates PPARγ at serine 84/114 (in humans) (Zhang, 
Berger et al. 1996, Camp and Tafuri 1997, van Beekum, Fleskens et al. 2009). The RAS-pathway 
is inhibited by PPARγ-mediated up-regulation of tumor suppressors like PTEN and CDKIs (P21). 
Activated PTEN interrupts the PI3K-AKT/PKB- signaling pathway by dephosphorylating 
phosphatidylinositol phosphates (especially IP3) (Leslie, Kriplani et al. 2016). This negative 
feedback loops lead to inhibition of the RAS oncogenic driver pathways. 
 
In conclusion, the tumor suppressor MTMR7 reduces the cellular amount of RAS, which prevents 
nuclear export of PPARγ (Burgermeister, Chuderland et al. 2007), resulting in the activation of 
tumor suppressor genes (Burgermeister, Friedrich et al. 2011). Thus, the MTMR7-PPARγ 
crosstalk might be a new target for the treatment of colorectal cancer, where constantly mutant 
KRAS leads to treatment failure of EGFR therapy in colorectal cancer patients.  
 
 
There are currently no therapeutic approaches available to target mutant KRAS and there is a 
great need to identify effective druggable targets for KRAS mutated cancers.  
Previously published results showed reduced growth rates upon MTMR7 overexpression 
compared with cells that received EV controls. Moreover, knockdown of endogenous MTMR7 
showed an increase in tumor cell proliferation, consistent with the fact that MTMR7 is lost in 
colorectal cancer patients during tumor progression (Weidner, Söhn et al. 2016). Furthermore, 
our research evinced that proliferation is further inhibited by stimulating the cells with the PPARγ 
ligand rosiglitazone (Friedrich 2013, Weidner 2016).  
Thus, the intrinsic unresponsiveness of KRAS mutant cells to anti-EGFR therapy might be 
circumvented by the combination of PPARγ-ligands, such as rosiglitazone with kinase inhibitors, 
downstream of mutant KRAS, like a multi-kinase inhibitor (sorafenib), inhibiting the RAF-kinase 
and several tyrosine kinases of the VEGF signaling pathway and mTOR-inhibitors (everolimus). 
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These inhibitors are already approved in the clinic, sorafenib for Hepatocellular carcinoma (HCC) 
(Lang 2008), and everolimus for neuroendocrine tumors (NET) of gastrointestinal or lung origin 
(Liu and Kunz 2017). 
The results obtained showed that using MTMR7 together with either sorafenib or everolimus could 
not efficiently reduce the viability of colorectal cancer cells. Non-cancer cells, though, were 
sensitive to MTMR7 overexpression in combination with the inhibitors. In contrast, in presence of 
MTMR7 and the two drugs, proliferation of the cells was much slower as in respective 
monotherapies with each single drug, whereas resistance remained in the absence of MTMR7. 
The effect was also seen in non-cancer cells, but it was not as strong as in the two colorectal 
cancer cell lines. This indicates a potential specific effect of MTMR7 on RAS mutant cancer cells 
lines, consistent with the observation that MTMR7 down-regulates RAS protein. Another 
possibility might be the MTMR7-mediated inhibition of compensatory alternative signaling 
pathways (e.g. Wnt e.a.) that is activated if the RAF and mTOR signaling pathways are inhibited. 
However, the inhibiting effect of MTMR7 could not be further enhanced by additional treatment 
with the PPARγ ligand rosiglitazone, which might be due to the already profound inhibition of 
tumor cell growth upon MTMR7 transfection and by the two kinase inhibitors.  
 
 
Due to unwanted toxicity and side effects, the use of multiple inhibitors in clinical combination 
regimens often hinders therapy success. Concerning MTMR7 and its role in colorectal cancer 
patients, it is already published, that the lipid phosphatase is either present or completely absent 
in colorectal cancer tumor cells, which was shown in immunohistochemical staining on tissue 
microarrays (Weidner, Söhn et al. 2016). Additionally, MTMR7 positive tumor cells were 
associated with reduced local tumor growth, stage, and grade. This fact and the diminished 
MTMR7 mRNA expression in colorectal cancer patient samples indicated that MTMR7 is lost 
during tumor development and tumor growth (Weidner, Söhn et al. 2016). 
Hence, to resupply MTMR7 as a tumor suppressor and RAS-inhibitory protein to the cells might 
be a promising anti-tumor approach. Gene therapy in patients, though, is not feasible, and neither 
transgenic nor KO mice of MTMR7 are available to critically test this idea. Therefore, a docking 
site peptide corresponding to the coiled-coil domain of MTMR7 and a scrambled control-peptide 
were designed (by E. Burgermeister, unpublished) to test their effect on tumor cell proliferation.  
In fact, the peptide was effective and inhibited proliferation in a series of KRAS-mutated and 
KRAS-WT human cancer cell lines from the colon, stomach and pancreas, in the micromolar 
range (1-10 μM). Notably, a tendency of RAS-inhibition upon MTMR7-peptide treatment was 
seen, however, it did not affect ERK 1/2 phosphorylation. In line with this data, SRE activation 
was diminished upon MTMR7-peptide treatment, indicating that the peptide is active and inhibits 
RAS-ERK 1/2 signaling. These data indicated that therapy with this MTMR7-peptide might be 
feasible also in vivo.  
 
In general, peptides are highly effective and selective and therefore a good starting point for 
developing novel therapeutics (Fosgerau and Hoffmann 2015). In addition, they are associated 
with excellent safety and tolerability in humans, as well as with a shorter time to be developed 
and to get approved. Disadvantages in the past were their chemical and physical instability, their 
short half-time and their susceptibility to hydrolysis and oxidation (Fosgerau and Hoffmann 2015). 
Another obstacle is oral bioavailability, which is due to digestive enzymes that would break down 
amid bonds and thereby diminish the efficacy of the drug (Lau and Dunn 2017). Nevertheless, 
physicochemical properties of peptides could be improved by introducing chemical modifications 
like lactam bridges, stabilizing α-helices or salt bridge formations (Fosgerau and Hoffmann 2015).  
Presently, over 60 peptide drugs have been approved in Europe, the United States, and Japan, 
and there are about 150 in clinical development for several indications, including oncology (Lau 
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and Dunn 2017). For instance, Lupron™ from Abbott Laboratories is a peptide-based drug used 
for prostate cancer treatment (Kaspar and Reichert 2013, Fosgerau and Hoffmann 2015). 
Another one, Goserelin, targets the gonadotropin-releasing hormone receptor, and is used for 
palliative treatment of advanced prostate and breast cancer (Kaspar and Reichert 2013). 
 
In sum, there are several peptide drugs available which closely mimic natural pathways by adding 
back or supplementing peptides in cases where they are missing or inadequate endogenously. 
The most prominent one might be insulin, first therapeutically used in 1922 (Banting, Best et al. 
1922, Lau and Dunn 2017). If that could also be true for MTMR7 in the treatment of colorectal 
cancer patients, remains to be evaluated. 
 
To investigate expression and regulation of PPARγ and MTMR7 in vivo, we analyzed genetically 
modified mouse models (GEMMS) for CRC. 
In vivo therapies were carried out in a Apcmin/+ x Cav1-KO mouse model established previously 
by our research group (Friedrich, Richter et al. 2013). These mice mostly develop highly 
vascularized, distal colorectal tumors. Genetically, these mice show a downregulation of genes 
related to the transcription factor PPARγ and an upregulation of genes related to the RAS-
signature like Kras and Nras (Friedrich 2013).  
Since CoIP experiments showed that MTMR7 is not only forming a complex with PPARγ and 
MTMR9, but also with the Heat-shock protein 90 (Hsp90), Apcmin/+ x Cav1-KO mice were treated 
with 17-DMAG, a water-soluble derivative of the Hsp90 inhibitor geldanamycin, to investigate if 
Hsp90 is also involved in the stabilization of MTMR7.  
In line with the previous data (Friedrich, Richter et al. 2013), highly vascularized, distal colorectal 
tumors were found in the untreated mice. Nevertheless, the tumor size could be diminished by 
treating the Apcmin/+ x Cav1-KO mice with the Hsp90 inhibitor. Furthermore, Kras gene 
expression was higher in the untreated tumor Apcmin/+ x Cav1-KO mice than in the untreated 
WT mice, as expected (Friedrich 2013). Under therapy a downregulation of Kras was seen in the 
tumor group compared to the WT mice. This held true on protein level, where pan-RAS expression 
was diminished in the treated Apcmin/+ x Cav1-KO mice compared to the untreated Apcmin/+ x 
Cav1-KO mice. This effect could also be seen in the decrease in P-ERK 1/2 expression in tissue 
of treated WT and treated Apcmin/+ x Cav1-KO mice compared to the untreated WT control mice. 
In addition, Mtmr7 gene expression was higher in the treated WT and Apcmin/+ x Cav1-KO mice 
indicating a stabilization of Mtmr7 in the WT mice upon 17-DMAG treatment and an indirect impact 
of MTMR7 on KRAS expression. The therapy effect on protein-level could not be assessed due 
to a lack of commercially available antibody against mouse MTMR7 suitable for IHC. However, 
this would be of great importance since MTMR7 was shown to be regulated on the protein and 
not on the mRNA level (Weidner, Söhn et al. 2016). 
 
 
To evaluate the impact of pharmacological PPARγ-activation on KRAS expression, a cohort of 
rosiglitazone-treated Apcmin/+ x Cav1-KO mice was used (Friedrich, Richter et al. 2013). A 
decrease of KRAS protein was seen in tumor tissue compared with adjacent normal tissue in the 
untreated and the treated Apcmin/+ x Cav1-KO mice which was in accordance to previous 
obtained data on Kras mRNA level. Due to the lack of freshly frozen tissue, Mtmr7 expression 
could not be assessed in these mice, and, thus, no correlation between Mtmr7 and Kras 
expression could be established. However, upregulation of the RAS-inhibitory proteins and tumor 
suppressors Cav1 and Dok1 might suggest that this could also true for Mtmr7 (Friedrich 2013).  
 
Taken together, this thesis delineated the expression and function of the lipid phosphatase 
MTMR7 and its relation to the RAS signaling pathway and the therapy resistance in colorectal 
carcinoma.  
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Through down-regulation of total and active RAS protein, MTMR7 reduces the activity of ERK 1/2, 
a negative regulator of PPARγ, and thereby enhances transcriptional activity of the nuclear 
receptor (Figure 42, adapted from the DKFZ-MOST Ca158 proposal and progress reports by Dr. 
Elke Burgermeister).  
MTMR7 inhibited active mutant and total RAS protein and on the other hand enhanced 
transcriptional activity of PPARγ elevated the expression of PPARγ target genes. Furthermore, 
MTMR7 promoted membrane retention of EGFR in colorectal cancer cells and thereby reduced 
nuclear EGFR expression, which is associated with tumor progression in patients (Shiaw-Yih Lin 
2001). Its sensitizing effect on kinase inhibitor therapy and the fact that a synthetic MTMR7-
peptide inhibited proliferation of colorectal carcinoma cell lines proposed it as a potent target for 
therapeutic strategies against CRC in patients. Nevertheless, the exact mechanism of MTMR7-
mediated RAS-inhibition needs to be clarified in the future. Due to its absence in many colorectal 
carcinomas, which is independent of patient’s KRAS mutation status, MTMR7 could also be a 
potential marker for therapy resistance, although it would be important to clarify precisely at which 
stage the tumor suppressor is lost during carcinogenesis. 
 
 
Figure 42: Model for RAS inhibition by MTMR7. Oncogenic RAS leads to a constant export of the nuclear transcription factor 
PPARγ to the cytosol where it binds to MTMR7. MTMR7 down-regulates RAS, leading to the reduced ERK 1/2 activity, which results 
in the reduction of PPARγ phosphorylation, a decrease in PPARγ inhibition and in the activation of tumor suppressor genes like PTEN 
and finally in the inhibition of proliferation of KRAS-mutated CRC cells. Legend: Blue: tumor inhibitors; Red: tumor promoters; Yellow 
arrows-activation; Black arrows-inhibition. (adapted from Burgermeister (DKFZ-MOST, Ca158)) 
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4.1. Outlook 
The current thesis investigated the possible molecular and cellular mechanisms of MTMR7-
mediated RAS down-regulation on multiple levels and by means of a series of experimental 
approaches. However, it has not been achievable to conclusively clarify the exact mode of action. 
Therefore, it will be necessary in the future to investigate functional cross-talk of MTMR7 and 
RAS in depth. One approach would be to specifically block either the PI3K class 2 or the PI3K 
class 3 kinases to assess whether RAS down-regulation is indeed associated with the 
disappearance of the PI(3)P molecule from internal cellular membranes (e.g. endosomes). 
Moreover, successful cloning of a mutant KRAS plasmid tagged with RFP would be helpful to 
detect GFP-MTMR7 and RFP-RAS protein in normal cycling colorectal cancer cells using live cell 
imaging or immunofluorescence co-staining. Nethertheless, the understanding of MTMR7 as a 
KRAS regulator is indispensable to further validate and develop it as a potential future target for 
colorectal cancer therapy. 
 
In addition, it would be very important to examine the MTMR7-peptide efficacy in a Kras mutated 
mouse model in vivo, which was beyond the scope of this thesis, but might be an important 
milestone to elaborate the proof of concept if MTMR7 may be a druggable target to overcome 
therapy resistance in colorectal carcinoma patients.  
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5. Abbreviations 
AB Antibody 
ACO Acyl-CoA oxidase 
APC Adenomatous polyposis coli 
ARC Arcuate nucleus 
  
Bp Base pairs 
BSA Bovine serum albumin 
  
CAV-1 Caveolin-1 
cDNA Complementary DNA 
CD36 Cluster of differentiation 36 
CDS Coding sequence 
CIN Chromosomal instability 
CIMP CpG island methylator phenotype 
c-like Caspase-like activity 
CMS Consensus molecular subtypes 
CoIP Coimmunoprecipitation 
COX Cyclooxygenase 
CRC Colorectal cancer 
Ct-like Chymotrypsin-like activity 
CT-values cycle thresholds 
  
DAB 3,3′-Diaminobenzidine 
DAPI 4',6-diamidino-2-phenylindole 
DMEM Dulbecco’s modified eagles medium 
DMSO Dimethylsulfoxid 
DNA Deoxyribonucleic acid 
DOK-1 Docking protein-1 
  
EDTA ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
ENaC Epithelium sodium channel 
  
ER Endoplasmic reticulum 
ERK Extracellular signal related kinase 
EtOH Ethanol 
EV Empty vector 
  
FAB Familial adenomatous polyposis 
FCS Fetal calf serum 
FL Full-length 
FOLFIRI Folinic acid, fluorouracil, irinotecan 
FOLFOX Folinic acid, fluorouracil, oxaliplatin 
5-FU 5-Fluoruracil 
  
GDP Guanosine diphosphate 
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GEF Guanine nucleotide exchange factor 
GFP Green fluorescent protein 
GTP Guanosine triphosphate 
  
HEK Human embryonic kidney 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HNPCC Hereditary non-polyposis colorectal cancer 
H-RAS Harvey RAS 
HSP90 Heat shock protein 90 
  
IHC Immunohistochemistry 
INS insoluble 
IP Immunoprecipitation 
  
KCl Potassium chloride 
kD Kilo dalton 
K-RAS Kirsten Ras 
  
LB medium lysogeny broth medium 
LHA Lateral hypothalamic area 
LOH Loss of heterozygosity 
LV Leucovorin 
  
MEK mitogen-activated protein 
MMR Mismatch repair 
mRNA Messenger ribonucleic acid 
MSI Microsatellite instability 
MTMR Myotubularin-related 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
  
NES Nuclear export signal 
NRAS Neuroblastoma RAS 
NTC Non-template control 
NUC Nuclear 
  
OS Overall survival 
  
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PEPCK Phosphoenolpyruvate carboxykinase 
PH-GRAM Pleckstrin homology domain 
PI3P Phosphatidylinositol-3-phosphate 
PLA Proximity ligation assay 
PPARγ Peroxisome proliferator activated receptor gamma 
PPRE PPARγ response element 
PI Phosphatidylinositol 
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pT p-target (expression vector) 
PTEN Phosphatase and tensin homolog  
PVN Paraventricular nucleus 
  
RAF Rapidly accelerated fibrosarcoma 
RBD RAS binding domain 
RNA Ribonucleic acid 
Rosi rosiglitazone 
RT Room temperature 
RTK Receptor tyrosine kinases 
RXR 9-cis retinoid x receptor 
  
SDS sodium dodecyl sulfate 
shRNA Small hairpin RNA 
SID Set interaction domain 
SRE Serum response element 
  
TCL Total cell lysate 
TFF3 Trefoil factor 3 
T-like Trypsin-like activity 
TP53 Tumor protein 53 
TYS Thymidylate synthase 
  
Ub ubiquitin 
  
VEGF Vascular endothelial growth factor 
VAT Visceral adipose tissue 
  
WT Wild-type 
  
X-Gal 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
 
  References 
 
81 
6. References 
Ahearn, I. M., K. Haigis, D. Bar-Sagi and M. R. Philips (2011). "Regulating the regulator: post-translational 
modification of RAS." Nat Rev Mol Cell Biol 13(1): 39-51. 
 
Ahuja, N., A. L. Mohan, Q. Li, J. M. Stolker, J. G. Herman, S. R. Hamilton, S. B. Baylin and J. P. Issa (1997). 
"Association between CpG island methylation and microsatellite instability in colorectal cancer." Cancer 
Res 57(16): 3370-3374. 
 
Al-Sohaily, S., A. Biankin, R. Leong, M. Kohonen-Corish and J. Warusavitarne (2012). "Molecular pathways 
in colorectal cancer." J Gastroenterol Hepatol 27(9): 1423-1431. 
 
Andre, T., A. de Gramont, D. Vernerey, B. Chibaudel, F. Bonnetain, A. Tijeras-Raballand, A. Scriva, T. 
Hickish, J. Tabernero, J. L. Van Laethem, M. Banzi, E. Maartense, E. Shmueli, G. U. Carlsson, W. 
Scheithauer, D. Papamichael, M. Moehler, S. Landolfi, P. Demetter, S. Colote, C. Tournigand, C. Louvet, 
A. Duval, J. F. Flejou and A. de Gramont (2015). "Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in 
Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and 
Mismatch Repair Status of the MOSAIC Study." J Clin Oncol 33(35): 4176-4187. 
 
Arends, J. W. (2000). "Molecular interactions in the Vogelstein model of colorectal carcinoma." J Pathol 
190(4): 412-416. 
 
Azzedine, H., A. Bolino, T. Taieb, N. Birouk, M. Di Duca, A. Bouhouche, S. Benamou, A. Mrabet, T. 
Hammadouche, T. Chkili, R. Gouider, R. Ravazzolo, A. Brice, J. Laporte and E. LeGuern (2003). "Mutations 
in MTMR13, a new pseudophosphatase homologue of MTMR2 and Sbf1, in two families with an autosomal 
recessive demyelinating form of Charcot-Marie-Tooth disease associated with early-onset glaucoma." Am 
J Hum Genet 72(5): 1141-1153. 
 
Balla, T., M. Wymann and J. D. York (2012). Phosphoinositides I enzymes of synthesis and degradation. 
Subcellular biochemistry,. Dordrecht ; New York, Springer: 1 online resource (xv, 352 p.). 
 
Banting, F. G., C. H. Best, J. B. Collip, W. R. Campbell and A. A. Fletcher (1922). "Pancreatic Extracts in 
the Treatment of Diabetes Mellitus." Can Med Assoc J 12(3): 141-146. 
 
Baron, J. A., M. Beach, J. S. Mandel, R. U. van Stolk, R. W. Haile, R. S. Sandler, R. Rothstein, R. W. 
Summers, D. C. Snover, G. J. Beck, J. H. Bond and E. R. Greenberg (1999). "Calcium supplements for the 
prevention of colorectal adenomas. Calcium Polyp Prevention Study Group." N Engl J Med 340(2): 101-
107. 
 
Begley, M. J. and J. E. Dixon (2005). "The structure and regulation of myotubularin phosphatases." Current 
Opinion in Structural Biology 15(6): 614-620. 
 
Begley, M. J., G. S. Taylor, M. A. Brock, P. Ghosh, V. L. Woods and J. E. Dixon (2006). "Molecular basis 
for substrate recognition by MTMR2, a myotubularin family phosphoinositide phosphatase." Proc Natl Acad 
Sci U S A 103(4): 927-932. 
 
Begley, M. J., G. S. Taylor, S. A. Kim, D. M. Veine, J. E. Dixon and J. A. Stuckey (2003). "Crystal structure 
of a phosphoinositide phosphatase, MTMR2: insights into myotubular myopathy and Charcot-Marie-Tooth 
syndrome." Mol Cell 12(6): 1391-1402. 
 
Bennett, A. and M. Del Tacca (1975). "Proceedings: Prostaglandins in human colonic carcinoma." Gut 
16(5): 409. 
 
Berger, P., I. Berger, C. Schaffitzel, K. Tersar, B. Volkmer and U. Suter (2006). "Multi-level regulation of 
myotubularin-related protein-2 phosphatase activity by myotubularin-related protein-13/set-binding factor-
2." Hum Mol Genet 15(4): 569-579. 
 
Berger, P., S. Bonneick, S. Willi, M. Wymann and U. Suter (2002). "Loss of phosphatase activity in 
myotubularin-related protein 2 is associated with Charcot-Marie-Tooth disease type 4B1." Hum Mol Genet 
11(13): 1569-1579. 
 
References 
 
82 
Berger, P., C. Schaffitzel, I. Berger, N. Ban and U. Suter (2003). "Membrane association of myotubularin-
related protein 2 is mediated by a pleckstrin homology-GRAM domain and a coiled-coil dimerization 
module." Proc Natl Acad Sci U S A 100(21): 12177-12182. 
 
Berger, P., K. Tersar, K. Ballmer-Hofer and U. Suter (2011). "The CMT4B disease-causing proteins MTMR2 
and MTMR13/SBF2 regulate AKT signalling." J Cell Mol Med 15(2): 307-315. 
 
Bergstraesser, C., S. Hoeger, H. Song, L. Ermantraut, M. Hottenrot, T. Czymai, M. Schmidt, M. Goebeler, 
N. Ponelies, C. Stich, R. Loesel, G. Molema, M. Seelen, W. van Son, B. A. Yard and N. Rafat (2012). 
"Inhibition of VCAM-1 expression in endothelial cells by CORM-3: the role of the ubiquitin-proteasome 
system, p38, and mitochondrial respiration." Free Radic Biol Med 52(4): 794-802. 
 
Bertotti, A., E. Papp, S. Jones, V. Adleff, V. Anagnostou, B. Lupo, M. Sausen, J. Phallen, C. A. Hruban, C. 
Tokheim, N. Niknafs, M. Nesselbush, K. Lytle, F. Sassi, F. Cottino, G. Migliardi, E. R. Zanella, D. Ribero, 
N. Russolillo, A. Mellano, A. Muratore, G. Paraluppi, M. Salizzoni, S. Marsoni, M. Kragh, J. Lantto, A. 
Cassingena, Q. K. Li, R. Karchin, R. Scharpf, A. Sartore-Bianchi, S. Siena, L. A. Diaz, Jr., L. Trusolino and 
V. E. Velculescu (2015). "The genomic landscape of response to EGFR blockade in colorectal cancer." 
Nature 526(7572): 263-267. 
 
Bolino, A., M. Muglia, F. L. Conforti, E. LeGuern, M. A. Salih, D. M. Georgiou, K. Christodoulou, I. 
Hausmanowa-Petrusewicz, P. Mandich, A. Schenone, A. Gambardella, F. Bono, A. Quattrone, M. Devoto 
and A. P. Monaco (2000). "Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding 
myotubularin-related protein-2." Nat Genet 25(1): 17-19. 
 
Bonithon-Kopp, C., O. Kronborg, A. Giacosa, U. Rath and J. Faivre (2000). "Calcium and fibre 
supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European 
Cancer Prevention Organisation Study Group." Lancet 356(9238): 1300-1306. 
 
Bosetti, C., V. Rosato, D. Buniato, A. Zambon, C. La Vecchia and G. Corrao (2013). "Cancer risk for patients 
using thiazolidinediones for type 2 diabetes: a meta-analysis." Oncologist 18(2): 148-156. 
 
Botteri, E., S. Iodice, V. Bagnardi, S. Raimondi, A. B. Lowenfels and P. Maisonneuve (2008). "Smoking and 
colorectal cancer: a meta-analysis." JAMA 300(23): 2765-2778. 
 
Boyle, P. and J. S. Langman (2000). "ABC of colorectal cancer: Epidemiology." BMJ 321(7264): 805-808. 
 
Brand, T. M., M. Iida, N. Luthar, M. M. Starr, E. J. Huppert and D. L. Wheeler (2013). "Nuclear EGFR as a 
molecular target in cancer." Radiother Oncol 108(3): 370-377. 
 
Brinkmann, B., M. Klintschar, F. Neuhuber, J. Huhne and B. Rolf (1998). "Mutation rate in human 
microsatellites: influence of the structure and length of the tandem repeat." Am J Hum Genet 62(6): 1408-
1415. 
 
Buhrman, G., G. Holzapfel, S. Fetics and C. Mattos (2010). "Allosteric modulation of Ras positions Q61 for 
a direct role in catalysis." Proc Natl Acad Sci U S A 107(11): 4931-4936. 
 
Burgermeister, E., D. Chuderland, T. Hanoch, M. Meyer, M. Liscovitch and R. Seger (2007). "Interaction 
with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma." 
Mol Cell Biol 27(3): 803-817. 
 
Burgermeister, E., T. Friedrich, I. Hitkova, I. Regel, H. Einwachter, W. Zimmermann, C. Rocken, A. Perren, 
M. B. Wright, R. M. Schmid, R. Seger and M. P. A. Ebert (2011). "The Ras Inhibitors Caveolin-1 and 
Docking Protein 1 Activate Peroxisome Proliferator-Activated Receptor   through Spatial Relocalization at 
Helix 7 of Its Ligand-Binding Domain." Molecular and Cellular Biology 31(16): 3497-3510. 
 
Burgermeister, E., P. Höde, J. Betge, T. Gutting, A. Merkel, W. Wu, M. Tanzer, M. Mossner, D. Nowak, J. 
Magdeburg, F. Ruckert, C. Sticht, K. Breitkopf-Heinlein, N. Schulte, N. Hartel, S. Belle, S. Post, T. Gaiser, 
B. I. Heppner, H. M. Behrens, C. Rocken and M. P. A. Ebert (2017). "Epigenetic silencing of tumor 
suppressor candidate 3 confers adverse prognosis in early colorectal cancer." Oncotarget 8(49): 84714-
84728. 
 
  References 
 
83 
Burgermeister, E. and R. Seger (2007). "MAPK kinases as nucleo-cytoplasmic shuttles for PPARgamma." 
Cell Cycle 6(13): 1539-1548. 
 
Calvo, F., L. Agudo-Ibanez and P. Crespo (2010). "The Ras-ERK pathway: understanding site-specific 
signaling provides hope of new anti-tumor therapies." Bioessays 32(5): 412-421. 
 
Camp, H. S. and S. R. Tafuri (1997). "Regulation of peroxisome proliferator-activated receptor gamma 
activity by mitogen-activated protein kinase." J Biol Chem 272(16): 10811-10816. 
 
Canavan, C., K. R. Abrams and J. Mayberry (2006). "Meta-analysis: colorectal and small bowel cancer risk 
in patients with Crohn's disease." Aliment Pharmacol Ther 23(8): 1097-1104. 
 
Cao, C., J. M. Backer, J. Laporte, E. J. Bedrick and A. Wandinger-Ness (2008). "Sequential Actions of 
Myotubularin Lipid Phosphatases Regulate Endosomal PI(3)P and Growth Factor Receptor Trafficking." 
Molecular Biology of the Cell 19(8): 3334-3346. 
 
Cao, C., J. Laporte, J. M. Backer, A. Wandinger-Ness and M. P. Stein (2007). "Myotubularin lipid 
phosphatase binds the hVPS15/hVPS34 lipid kinase complex on endosomes." Traffic 8(8): 1052-1067. 
 
Chattopadhyay, N., D. P. Singh, O. Heese, M. M. Godbole, T. Sinohara, P. M. Black and E. M. Brown 
(2000). "Expression of peroxisome proliferator-activated receptors (PPARS) in human astrocytic cells: 
PPARgamma agonists as inducers of apoptosis." J Neurosci Res 61(1): 67-74. 
 
Chi, S., H. Cao, Y. Wang and M. A. McNiven (2011). "Recycling of the epidermal growth factor receptor is 
mediated by a novel form of the clathrin adaptor protein Eps15." J Biol Chem 286(40): 35196-35208. 
 
Cho, E., S. A. Smith-Warner, D. Spiegelman, W. L. Beeson, P. A. van den Brandt, G. A. Colditz, A. R. 
Folsom, G. E. Fraser, J. L. Freudenheim, E. Giovannucci, R. A. Goldbohm, S. Graham, A. B. Miller, P. 
Pietinen, J. D. Potter, T. E. Rohan, P. Terry, P. Toniolo, M. J. Virtanen, W. C. Willett, A. Wolk, K. Wu, S. S. 
Yaun, A. Zeleniuch-Jacquotte and D. J. Hunter (2004). "Dairy foods, calcium, and colorectal cancer: a 
pooled analysis of 10 cohort studies." J Natl Cancer Inst 96(13): 1015-1022. 
 
Chojnowski, A., N. Ravise, C. Bachelin, C. Depienne, M. Ruberg, B. Brugg, J. Laporte, A. Baron-Van 
Evercooren and E. LeGuern (2007). "Silencing of the Charcot-Marie-Tooth associated MTMR2 gene 
decreases proliferation and enhances cell death in primary cultures of Schwann cells." Neurobiol Dis 26(2): 
323-331. 
 
Christoforidis, S., M. Miaczynska, K. Ashman, M. Wilm, L. Zhao, S. C. Yip, M. D. Waterfield, J. M. Backer 
and M. Zerial (1999). "Phosphatidylinositol-3-OH kinases are Rab5 effectors." Nat Cell Biol 1(4): 249-252. 
 
Ciechanover, A. (2005). "Intracellular protein degradation: from a vague idea thru the lysosome and the 
ubiquitin-proteasome system and onto human diseases and drug targeting." Cell Death Differ 12(9): 1178-
1190. 
 
Clapper, M. L., W. C. Chang and N. J. Meropol (2001). "Chemoprevention of colorectal cancer." Curr Opin 
Oncol 13(4): 307-313. 
 
Cross, A. J., S. Boca, N. D. Freedman, N. E. Caporaso, W. Y. Huang, R. Sinha, J. N. Sampson and S. C. 
Moore (2014). "Metabolites of tobacco smoking and colorectal cancer risk." Carcinogenesis 35(7): 1516-
1522. 
 
Cunningham, D., W. Atkin, H. J. Lenz, H. T. Lynch, B. Minsky, B. Nordlinger and N. Starling (2010). 
"Colorectal cancer." Lancet 375(9719): 1030-1047. 
 
Cunningham, D., Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, D. Bets, M. Mueser, A. Harstrick, 
C. Verslype, I. Chau and E. Van Cutsem (2004). "Cetuximab monotherapy and cetuximab plus irinotecan 
in irinotecan-refractory metastatic colorectal cancer." N Engl J Med 351(4): 337-345. 
 
Davies, R. J., R. Miller and N. Coleman (2005). "Colorectal cancer screening: prospects for molecular stool 
analysis." Nat Rev Cancer 5(3): 199-209. 
 
References 
 
84 
Davies, R. L., V. A. Grosse, R. Kucherlapati and M. Bothwell (1980). "Genetic analysis of epidermal growth 
factor action: assignment of human epidermal growth factor receptor gene to chromosome 7." Proc Natl 
Acad Sci U S A 77(7): 4188-4192. 
 
De Duve, C., R. Gianetto, F. Appelmans and R. Wattiaux (1953). "Enzymic content of the mitochondria 
fraction." Nature 172(4390): 1143-1144. 
 
De Stefano, A. and C. Carlomagno (2014). "Beyond KRAS: Predictive factors of the efficacy of anti-EGFR 
monoclonal antibodies in the treatment of metastatic colorectal cancer." World J Gastroenterol 20(29): 
9732-9743. 
 
Doerks, T., M. Strauss, M. Brendel and P. Bork (2000). "GRAM, a novel domain in glucosyltransferases, 
myotubularins and other putative membrane-associated proteins." Trends Biochem Sci 25(10): 483-485. 
 
Dowling, J. J., S. E. Low, A. S. Busta and E. L. Feldman (2010). "Zebrafish MTMR14 is required for 
excitation-contraction coupling, developmental motor function and the regulation of autophagy." Hum Mol 
Genet 19(13): 2668-2681. 
 
Downward, J. (2003). "Targeting RAS signalling pathways in cancer therapy." Nat Rev Cancer 3(1): 11-22. 
 
Eaden, J. A., K. R. Abrams and J. F. Mayberry (2001). "The risk of colorectal cancer in ulcerative colitis: a 
meta-analysis." Gut 48(4): 526-535. 
 
El Zouhairi, M., A. Charabaty and M. J. Pishvaian (2011). "Molecularly targeted therapy for metastatic colon 
cancer: proven treatments and promising new agents." Gastrointest Cancer Res 4(1): 15-21. 
 
Erdmann, E., B. Charbonnel, R. G. Wilcox, A. M. Skene, M. Massi-Benedetti, J. Yates, M. Tan, R. 
Spanheimer, E. Standl, J. A. Dormandy and P. R. Investigators (2007). "Pioglitazone use and heart failure 
in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study 
(PROactive 08)." Diabetes Care 30(11): 2773-2778. 
 
Fares, H. and I. Greenwald (2001). "Genetic analysis of endocytosis in Caenorhabditis elegans: 
coelomocyte uptake defective mutants." Genetics 159(1): 133-145. 
 
Fearon, E. R. and B. Vogelstein (1990). "A genetic model for colorectal tumorigenesis." Cell 61(5): 759-
767. 
 
Feng, Y., B. Press, W. Chen, J. Zimmerman and A. Wandinger-Ness (2001). "Expression and properties 
of Rab7 in endosome function." Methods Enzymol 329: 175-187. 
 
Fili, N., V. Calleja, R. Woscholski, P. J. Parker and B. Larijani (2006). "Compartmental signal modulation: 
Endosomal phosphatidylinositol 3-phosphate controls endosome morphology and selective cargo sorting." 
Proc Natl Acad Sci U S A 103(42): 15473-15478. 
 
Firestein, R., P. L. Nagy, M. Daly, P. Huie, M. Conti and M. L. Cleary (2002). "Male infertility, impaired 
spermatogenesis, and azoospermia in mice deficient for the pseudophosphatase Sbf1." J Clin Invest 
109(9): 1165-1172. 
 
Forbes, S. A., N. Bindal, S. Bamford, C. Cole, C. Y. Kok, D. Beare, M. Jia, R. Shepherd, K. Leung, A. 
Menzies, J. W. Teague, P. J. Campbell, M. R. Stratton and P. A. Futreal (2011). "COSMIC: mining complete 
cancer genomes in the Catalogue of Somatic Mutations in Cancer." Nucleic Acids Res 39(Database issue): 
D945-950. 
 
Fosgerau, K. and T. Hoffmann (2015). "Peptide therapeutics: current status and future directions." Drug 
Discov Today 20(1): 122-128. 
 
Friedrich, T. (2013). Ras-driven mouse models of colorectal cancer: Interaction of MAPKs with the nuclear 
receptor PPAR, Technische Universität München. naturwissenschaftliche Dissertation. . 
 
  References 
 
85 
Friedrich, T., B. Richter, T. Gaiser, C. Weiss, K. P. Janssen, H. Einwachter, R. M. Schmid, M. P. A. Ebert 
and E. Burgermeister (2013). "Deficiency of caveolin-1 in Apcmin/+ mice promotes colorectal 
tumorigenesis." Carcinogenesis 34(9): 2109-2118. 
 
Futter, C. E., L. M. Collinson, J. M. Backer and C. R. Hopkins (2001). "Human VPS34 is required for internal 
vesicle formation within multivesicular endosomes." J Cell Biol 155(7): 1251-1264. 
 
Garland, C. F., F. C. Garland and E. D. Gorham (1999). "Calcium and vitamin D. Their potential roles in 
colon and breast cancer prevention." Ann N Y Acad Sci 889: 107-119. 
 
Geigl, J. B., A. C. Obenauf, T. Schwarzbraun and M. R. Speicher (2008). "Defining 'chromosomal 
instability'." Trends Genet 24(2): 64-69. 
 
Gelabert-Baldrich, M., D. Soriano-Castell, M. Calvo, A. Lu, A. Vina-Vilaseca, C. Rentero, A. Pol, S. 
Grinstein, C. Enrich and F. Tebar (2014). "Dynamics of KRas on endosomes: involvement of acidic 
phospholipids in its association." FASEB J 28(7): 3023-3037. 
 
Gianetto, R. and C. De Duve (1955). "Tissue fractionation studies. 4. Comparative study of the binding of 
acid phosphatase, beta-glucuronidase and cathepsin by rat-liver particles." Biochem J 59(3): 433-438. 
 
Gill, S., C. L. Loprinzi, D. J. Sargent, S. D. Thome, S. R. Alberts, D. G. Haller, J. Benedetti, G. Francini, L. 
E. Shepherd, J. Francois Seitz, R. Labianca, W. Chen, S. S. Cha, M. P. Heldebrant and R. M. Goldberg 
(2004). "Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who 
benefits and by how much?" J Clin Oncol 22(10): 1797-1806. 
 
Gillooly, D. J., I. C. Morrow, M. Lindsay, R. Gould, N. J. Bryant, J. M. Gaullier, R. G. Parton and H. Stenmark 
(2000). "Localization of phosphatidylinositol 3-phosphate in yeast and mammalian cells." EMBO J 19(17): 
4577-4588. 
 
Gillooly, D. J., C. Raiborg and H. Stenmark (2003). "Phosphatidylinositol 3-phosphate is found in 
microdomains of early endosomes." Histochem Cell Biol 120(6): 445-453. 
 
Gnjatic, S., C. Wheeler, M. Ebner, E. Ritter, A. Murray, N. K. Altorki, C. A. Ferrara, H. Hepburne-Scott, S. 
Joyce, J. Koopman, M. B. McAndrew, N. Workman, G. Ritter, R. Fallon and L. J. Old (2009). "Seromic 
analysis of antibody responses in non-small cell lung cancer patients and healthy donors using 
conformational protein arrays." J Immunol Methods 341(1-2): 50-58. 
 
Grady, W. M. and J. M. Carethers (2008). "Genomic and epigenetic instability in colorectal cancer 
pathogenesis." Gastroenterology 135(4): 1079-1099. 
 
Graham, J., M. Mushin and P. Kirkpatrick (2004). "Oxaliplatin." Nat Rev Drug Discov 3(1): 11-12. 
 
Green, S. E., D. M. Bradburn, J. S. Varma and J. Burn (1998). "Hereditary non-polyposis colorectal cancer." 
Int J Colorectal Dis 13(1): 3-12. 
 
Grommes, C., G. E. Landreth and M. T. Heneka (2004). "Antineoplastic effects of peroxisome proliferator-
activated receptor gamma agonists." Lancet Oncol 5(7): 419-429. 
 
Guinney, J., R. Dienstmann, X. Wang, A. de Reynies, A. Schlicker, C. Soneson, L. Marisa, P. Roepman, 
G. Nyamundanda, P. Angelino, B. M. Bot, J. S. Morris, I. M. Simon, S. Gerster, E. Fessler, E. M. F. De 
Sousa, E. Missiaglia, H. Ramay, D. Barras, K. Homicsko, D. Maru, G. C. Manyam, B. Broom, V. Boige, B. 
Perez-Villamil, T. Laderas, R. Salazar, J. W. Gray, D. Hanahan, J. Tabernero, R. Bernards, S. H. Friend, 
P. Laurent-Puig, J. P. Medema, A. Sadanandam, L. Wessels, M. Delorenzi, S. Kopetz, L. Vermeulen and 
S. Tejpar (2015). "The consensus molecular subtypes of colorectal cancer." Nat Med 21(11): 1350-1356. 
 
Hagan, S., M. C. Orr and B. Doyle (2013). "Targeted therapies in colorectal cancer-an integrative view by 
PPPM." EPMA J 4(1): 3. 
 
Haggar, F. A. and R. P. Boushey (2009). "Colorectal cancer epidemiology: incidence, mortality, survival, 
and risk factors." Clin Colon Rectal Surg 22(4): 191-197. 
 
References 
 
86 
Hnia, K., I. Vaccari, A. Bolino and J. Laporte (2012). "Myotubularin phosphoinositide phosphatases: cellular 
functions and disease pathophysiology." Trends Mol Med 18(6): 317-327. 
 
Hoshino, M., H. Fukui, Y. Ono, A. Sekikawa, K. Ichikawa, S. Tomita, Y. Imai, J. Imura, H. Hiraishi and T. 
Fujimori (2007). "Nuclear expression of phosphorylated EGFR is associated with poor prognosis of patients 
with esophageal squamous cell carcinoma." Pathobiology 74(1): 15-21. 
 
IARC Press (2014). World Cancer Report. B. Stewart and P. Kleihues. 
 
Jaffe, B. M. (1974). "Prostaglandins and cancer: an update." Prostaglandins 6(6): 453-461. 
 
Janout, V. and H. Kollarova (2001). "Epidemiology of colorectal cancer." Biomed Pap Med Fac Univ Palacky 
Olomouc Czech Repub 145(1): 5-10. 
 
Jemal, A., L. X. Clegg, E. Ward, L. A. Ries, X. Wu, P. M. Jamison, P. A. Wingo, H. L. Howe, R. N. Anderson 
and B. K. Edwards (2004). "Annual report to the nation on the status of cancer, 1975-2001, with a special 
feature regarding survival." Cancer 101(1): 3-27. 
 
Jemal, A., M. J. Thun, L. A. Ries, H. L. Howe, H. K. Weir, M. M. Center, E. Ward, X. C. Wu, C. Eheman, R. 
Anderson, U. A. Ajani, B. Kohler and B. K. Edwards (2008). "Annual report to the nation on the status of 
cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control." J Natl Cancer Inst 
100(23): 1672-1694. 
 
Jeong, W. J., J. Yoon, J. C. Park, S. H. Lee, S. H. Lee, S. Kaduwal, H. Kim, J. B. Yoon and K. Y. Choi 
(2012). "Ras stabilization through aberrant activation of Wnt/beta-catenin signaling promotes intestinal 
tumorigenesis." Sci Signal 5(219): ra30. 
 
Johns, L. E. and R. S. Houlston (2001). "A systematic review and meta-analysis of familial colorectal cancer 
risk." Am J Gastroenterol 96(10): 2992-3003. 
 
Johnson, L., A. Luke, A. Adeyemo, H. W. Deng, B. D. Mitchell, A. G. Comuzzie, S. A. Cole, J. Blangero, M. 
Perola and M. D. Teare (2005). "Meta-analysis of five genome-wide linkage studies for body mass index 
reveals significant evidence for linkage to chromosome 8p." Int J Obes (Lond) 29(4): 413-419. 
 
Karapetis, C. S., S. Khambata-Ford, D. J. Jonker, C. J. O'Callaghan, D. Tu, N. C. Tebbutt, R. J. Simes, H. 
Chalchal, J. D. Shapiro, S. Robitaille, T. J. Price, L. Shepherd, H. J. Au, C. Langer, M. J. Moore and J. R. 
Zalcberg (2008). "K-ras mutations and benefit from cetuximab in advanced colorectal cancer." N Engl J 
Med 359(17): 1757-1765. 
 
Kaspar, A. A. and J. M. Reichert (2013). "Future directions for peptide therapeutics development." Drug 
Discov Today 18(17-18): 807-817. 
 
Keohavong, P., M. A. DeMichele, A. C. Melacrinos, R. J. Landreneau, R. J. Weyant and J. M. Siegfried 
(1996). "Detection of K-ras mutations in lung carcinomas: relationship to prognosis." Clin Cancer Res 2(2): 
411-418. 
 
Kerbel, R. S., J. Yu, J. Tran, S. Man, A. Viloria-Petit, G. Klement, B. L. Coomber and J. Rak (2001). 
"Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of 
combination therapy approaches." Cancer Metastasis Rev 20(1-2): 79-86. 
 
Kim, S. A., P. O. Vacratsis, R. Firestein, M. L. Cleary and J. E. Dixon (2003). "Regulation of myotubularin-
related (MTMR)2 phosphatidylinositol phosphatase by MTMR5, a catalytically inactive phosphatase." Proc 
Natl Acad Sci U S A 100(8): 4492-4497. 
 
Kohli, L., N. Kaza, T. Coric, S. J. Byer, N. M. Brossier, B. J. Klocke, M. A. Bjornsti, S. L. Carroll and K. A. 
Roth (2013). "4-Hydroxytamoxifen induces autophagic death through K-Ras degradation." Cancer Res 
73(14): 4395-4405. 
 
Lang, L. (2008). "FDA approves sorafenib for patients with inoperable liver cancer." Gastroenterology 
134(2): 379. 
 
  References 
 
87 
Laporte, J., F. Bedez, A. Bolino and J. L. Mandel (2003). "Myotubularins, a large disease-associated family 
of cooperating catalytically active and inactive phosphoinositides phosphatases." Hum Mol Genet 12 Spec 
No 2: R285-292. 
 
Laporte, J., F. Blondeau, A. Buj-Bello, D. Tentler, C. Kretz, N. Dahl and J. L. Mandel (1998). 
"Characterization of the myotubularin dual specificity phosphatase gene family from yeast to human." Hum 
Mol Genet 7(11): 1703-1712. 
 
Laporte, J., F. Blondeau, A. Gansmuller, Y. Lutz, J. L. Vonesch and J. L. Mandel (2002). "The PtdIns3P 
phosphatase myotubularin is a cytoplasmic protein that also localizes to Rac1-inducible plasma membrane 
ruffles." J Cell Sci 115(Pt 15): 3105-3117. 
 
Laporte, J., L. J. Hu, C. Kretz, J. L. Mandel, P. Kioschis, J. F. Coy, S. M. Klauck, A. Poustka and N. Dahl 
(1996). "A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase 
family conserved in yeast." Nat Genet 13(2): 175-182. 
 
Lau, J. L. and M. K. Dunn (2017). "Therapeutic peptides: Historical perspectives, current development 
trends, and future directions." Bioorg Med Chem. 
 
Le, D. T., J. N. Uram, H. Wang, B. R. Bartlett, H. Kemberling, A. D. Eyring, A. D. Skora, B. S. Luber, N. S. 
Azad, D. Laheru, B. Biedrzycki, R. C. Donehower, A. Zaheer, G. A. Fisher, T. S. Crocenzi, J. J. Lee, S. M. 
Duffy, R. M. Goldberg, A. de la Chapelle, M. Koshiji, F. Bhaijee, T. Huebner, R. H. Hruban, L. D. Wood, N. 
Cuka, D. M. Pardoll, N. Papadopoulos, K. W. Kinzler, S. Zhou, T. C. Cornish, J. M. Taube, R. A. Anders, J. 
R. Eshleman, B. Vogelstein and L. A. Diaz, Jr. (2015). "PD-1 Blockade in Tumors with Mismatch-Repair 
Deficiency." N Engl J Med 372(26): 2509-2520. 
 
Lee, M. S. and S. Kopetz (2015). "Current and Future Approaches to Target the Epidermal Growth Factor 
Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer." Clin Colorectal Cancer 14(4): 
203-218. 
 
Lefebvre, A. M., I. Chen, P. Desreumaux, J. Najib, J. C. Fruchart, K. Geboes, M. Briggs, R. Heyman and J. 
Auwerx (1998). "Activation of the peroxisome proliferator-activated receptor gamma promotes the 
development of colon tumors in C57BL/6J-APCMin/+ mice." Nat Med 4(9): 1053-1057. 
 
Leslie, N. R., N. Kriplani, M. A. Hermida, V. Alvarez-Garcia and H. M. Wise (2016). "The PTEN protein: 
cellular localization and post-translational regulation." Biochem Soc Trans 44(1): 273-278. 
 
Levin, B., D. A. Lieberman, B. McFarland, R. A. Smith, D. Brooks, K. S. Andrews, C. Dash, F. M. Giardiello, 
S. Glick, T. R. Levin, P. Pickhardt, D. K. Rex, A. Thorson, S. J. Winawer, G. American Cancer Society 
Colorectal Cancer Advisory, U. S. M.-S. T. Force and C. American College of Radiology Colon Cancer 
(2008). "Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 
2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal 
Cancer, and the American College of Radiology." CA Cancer J Clin 58(3): 130-160. 
 
Liechti-Gallati, S., B. Muller, T. Grimm, W. Kress, C. Muller, E. Boltshauser, H. Moser and S. Braga (1991). 
"X-linked centronuclear myopathy: mapping the gene to Xq28." Neuromuscul Disord 1(4): 239-245. 
 
Lievre, A., J. B. Bachet, D. Le Corre, V. Boige, B. Landi, J. F. Emile, J. F. Cote, G. Tomasic, C. Penna, M. 
Ducreux, P. Rougier, F. Penault-Llorca and P. Laurent-Puig (2006). "KRAS mutation status is predictive of 
response to cetuximab therapy in colorectal cancer." Cancer Res 66(8): 3992-3995. 
 
Liu, I. H. and P. L. Kunz (2017). "Biologics in gastrointestinal and pancreatic neuroendocrine tumors." J 
Gastrointest Oncol 8(3): 457-465. 
 
Liu, Z. Q., T. Mahmood and P. C. Yang (2014). "Western blot: technique, theory and trouble shooting." N 
Am J Med Sci 6(3): 160. 
 
Lloyd, S., S. Mead and J. Collinge (2011). "Genetics of prion disease." Top Curr Chem 305: 1-22. 
 
Lo, H. W., W. Xia, Y. Wei, M. Ali-Seyed, S. F. Huang and M. C. Hung (2005). "Novel prognostic value of 
nuclear epidermal growth factor receptor in breast cancer." Cancer Res 65(1): 338-348. 
 
References 
 
88 
Lombardi, D., T. Soldati, M. A. Riederer, Y. Goda, M. Zerial and S. R. Pfeffer (1993). "Rab9 functions in 
transport between late endosomes and the trans Golgi network." EMBO J 12(2): 677-682. 
 
Lorenzo, O., S. Urbe and M. J. Clague (2006). "Systematic analysis of myotubularins: heteromeric 
interactions, subcellular localisation and endosome related functions." J Cell Sci 119(Pt 14): 2953-2959. 
 
Lu, Q., L. W. Hope, M. Brasch, C. Reinhard and S. N. Cohen (2003). "TSG101 interaction with HRS 
mediates endosomal trafficking and receptor down-regulation." Proc Natl Acad Sci U S A 100(13): 7626-
7631. 
 
Lynch, H. T. and A. de la Chapelle (2003). "Hereditary colorectal cancer." N Engl J Med 348(10): 919-932. 
 
Malumbres, M. and M. Barbacid (2003). "RAS oncogenes: the first 30 years." Nat Rev Cancer 3(6): 459-
465. 
 
Marin, J. J., M. R. Romero, P. Martinez-Becerra, E. Herraez and O. Briz (2009). "Overview of the molecular 
bases of resistance to chemotherapy in liver and gastrointestinal tumours." Curr Mol Med 9(9): 1108-1129. 
 
Marin, J. J. G., F. Sanchez de Medina, B. Castaño, L. Bujanda, M. R. Romero, O. Martinez-Augustin, R. D. 
Moral-Avila and O. Briz (2012). "Chemoprevention, chemotherapy, and chemoresistance in colorectal 
cancer." Drug Metabolism Reviews 44(2): 148-172. 
 
Marmol, I., C. Sanchez-de-Diego, A. Pradilla Dieste, E. Cerrada and M. J. Rodriguez Yoldi (2017). 
"Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer." Int J Mol Sci 
18(1). 
 
Marshall, J., D. E. Shuster, T. R. Goldberg, C. Copigneaux, S. Chen, H. Zahir, D. Dutta, M. N. Saleh, M. J. 
Pishvaian, M. S. Varela, F. Palazzo, N. Lazaretti, C. Costa, E. Loredo, J. Leon and R. W. V. Roemeling 
(2014). "A randomized, open-label phase II study of efatutazone in combination with FOLFIRI as second-
line therapy for metastatic colorectal cancer (mCRC)." Journal of Clinical Oncology 32(3_suppl): 535-535. 
 
Martinez-Useros, J. and J. Garcia-Foncillas (2016). "Obesity and colorectal cancer: molecular features of 
adipose tissue." J Transl Med 14: 21. 
 
McCullough, M. L., A. S. Robertson, C. Rodriguez, E. J. Jacobs, A. Chao, J. Carolyn, E. E. Calle, W. C. 
Willett and M. J. Thun (2003). "Calcium, vitamin D, dairy products, and risk of colorectal cancer in the 
Cancer Prevention Study II Nutrition Cohort (United States)." Cancer Causes Control 14(1): 1-12. 
 
Mochizuki, Y. and P. W. Majerus (2003). "Characterization of myotubularin-related protein 7 and its binding 
partner, myotubularin-related protein 9." Proceedings of the National Academy of Sciences 100(17): 9768-
9773. 
 
Mochizuki, Y. and P. W. Majerus (2003). "Characterization of myotubularin-related protein 7 and its binding 
partner, myotubularin-related protein 9." Proc Natl Acad Sci U S A 100(17): 9768-9773. 
 
Mruk, D. D. and C. Y. Cheng (2011). "The myotubularin family of lipid phosphatases in disease and in 
spermatogenesis." Biochem J 433(2): 253-262. 
 
Murray, J. T., C. Panaretou, H. Stenmark, M. Miaczynska and J. M. Backer (2002). "Role of Rab5 in the 
recruitment of hVps34/p150 to the early endosome." Traffic 3(6): 416-427. 
 
Nandurkar, H. H., K. K. Caldwell, J. C. Whisstock, M. J. Layton, E. A. Gaudet, F. A. Norris, P. W. Majerus 
and C. A. Mitchell (2001). "Characterization of an adapter subunit to a phosphatidylinositol (3)P 3-
phosphatase: identification of a myotubularin-related protein lacking catalytic activity." Proc Natl Acad Sci 
U S A 98(17): 9499-9504. 
 
Nandurkar, H. H., M. Layton, J. Laporte, C. Selan, L. Corcoran, K. K. Caldwell, Y. Mochizuki, P. W. Majerus 
and C. A. Mitchell (2003). "Identification of myotubularin as the lipid phosphatase catalytic subunit 
associated with the 3-phosphatase adapter protein, 3-PAP." Proc Natl Acad Sci U S A 100(15): 8660-8665. 
 
  References 
 
89 
Naughtin, M. J., D. A. Sheffield, P. Rahman, W. E. Hughes, R. Gurung, J. L. Stow, H. H. Nandurkar, J. M. 
Dyson and C. A. Mitchell (2010). "The myotubularin phosphatase MTMR4 regulates sorting from early 
endosomes." J Cell Sci 123(Pt 18): 3071-3083. 
 
Neumann, A., A. Weill, P. Ricordeau, J. P. Fagot, F. Alla and H. Allemand (2012). "Pioglitazone and risk of 
bladder cancer among diabetic patients in France: a population-based cohort study." Diabetologia 55(7): 
1953-1962. 
 
Nicot, A. S., H. Fares, B. Payrastre, A. D. Chisholm, M. Labouesse and J. Laporte (2006). "The 
phosphoinositide kinase PIKfyve/Fab1p regulates terminal lysosome maturation in Caenorhabditis 
elegans." Mol Biol Cell 17(7): 3062-3074. 
 
Nicot, A. S. and J. Laporte (2008). "Endosomal phosphoinositides and human diseases." Traffic 9(8): 1240-
1249. 
 
Normanno, N., S. Tejpar, F. Morgillo, A. De Luca, E. Van Cutsem and F. Ciardiello (2009). "Implications for 
KRAS status and EGFR-targeted therapies in metastatic CRC." Nature Reviews Clinical Oncology 6(9): 
519-527. 
 
Ogino, S., K. Shima, Y. Baba, K. Nosho, N. Irahara, S. Kure, L. Chen, S. Toyoda, G. J. Kirkner, Y. L. Wang, 
E. L. Giovannucci and C. S. Fuchs (2009). "Colorectal Cancer Expression of Peroxisome Proliferator-
Activated Receptor γ (PPARG, PPARgamma) Is Associated With Good Prognosis." Gastroenterology 
136(4): 1242-1250. 
 
Pan, T., Y. Zhang, N. Zhou, X. He, C. Chen, L. Liang, X. Duan, Y. Lin, K. Wu and H. Zhang (2016). "A 
recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits 
pancreatic tumor growth." Oncotarget 7(28): 44299-44309. 
 
Pancione, M., N. Forte, L. Sabatino, E. Tomaselli, D. Parente, A. Febbraro and V. Colantuoni (2009). 
"Reduced beta-catenin and peroxisome proliferator-activated receptor-gamma expression levels are 
associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, 
cyclooxygenase 2, and patient outcome." Hum Pathol 40(5): 714-725. 
 
Park, Y., D. J. Hunter, D. Spiegelman, L. Bergkvist, F. Berrino, P. A. van den Brandt, J. E. Buring, G. A. 
Colditz, J. L. Freudenheim, C. S. Fuchs, E. Giovannucci, R. A. Goldbohm, S. Graham, L. Harnack, A. M. 
Hartman, D. R. Jacobs, Jr., I. Kato, V. Krogh, M. F. Leitzmann, M. L. McCullough, A. B. Miller, P. Pietinen, 
T. E. Rohan, A. Schatzkin, W. C. Willett, A. Wolk, A. Zeleniuch-Jacquotte, S. M. Zhang and S. A. Smith-
Warner (2005). "Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort 
studies." JAMA 294(22): 2849-2857. 
 
Peters, J. M., Y. M. Shah and F. J. Gonzalez (2012). "The role of peroxisome proliferator-activated 
receptors in carcinogenesis and chemoprevention." Nat Rev Cancer 12(3): 181-195. 
 
Petiot, A., J. Faure, H. Stenmark and J. Gruenberg (2003). "PI3P signaling regulates receptor sorting but 
not transport in the endosomal pathway." J Cell Biol 162(6): 971-979. 
 
Peymani, M., A. Ghoochani, K. Ghaedi, F. Karamali, K. Karbalaie, A. Kiani-Esfahani, F. Rabiee, M. H. Nasr-
Esfahani and H. Baharvand (2013). "Dual effects of peroxisome proliferator-activated receptor gamma on 
embryonic stem cell self-renewal in presence and absence of leukemia inhibitory factor." Eur J Cell Biol 
92(4-5): 160-168. 
 
Pino, M. S. and D. C. Chung (2010). "The chromosomal instability pathway in colon cancer." 
Gastroenterology 138(6): 2059-2072. 
 
Polvani, S., M. Tarocchi, S. Tempesti, L. Bencini and A. Galli (2016). "Peroxisome proliferator activated 
receptors at the crossroad of obesity, diabetes, and pancreatic cancer." World J Gastroenterol 22(8): 2441-
2459. 
 
Poschl, G. and H. K. Seitz (2004). "Alcohol and cancer." Alcohol Alcohol 39(3): 155-165. 
 
Pox, C., S. Aretz, S. C. Bischoff, U. Graeven, M. Hass, P. Heussner, W. Hohenberger, A. Holstege, J. 
Hubner, F. Kolligs, M. Kreis, P. Lux, J. Ockenga, R. Porschen, S. Post, N. Rahner, A. Reinacher-Schick, J. 
References 
 
90 
F. Riemann, R. Sauer, A. Sieg, W. Scheppach, W. Schmitt, H. J. Schmoll, K. Schulmann, A. Tannapfel, W. 
Schmiegel, A. Leitlinienprogramm Onkologie der, V. Deutschen Krebsgesellschaft e and V. Deutschen 
Krebshilfe e (2013). "[S3-guideline colorectal cancer version 1.0]." Z Gastroenterol 51(8): 753-854. 
 
Prenen, H., S. Tejpar and E. Van Cutsem (2010). "New strategies for treatment of KRAS mutant metastatic 
colorectal cancer." Clin Cancer Res 16(11): 2921-2926. 
 
Prince, S. K. C. L. (2011). Molecular Chaperones. 
 
Prost, S., F. Relouzat, M. Spentchian, Y. Ouzegdouh, J. Saliba, G. Massonnet, J. P. Beressi, E. Verhoeyen, 
V. Raggueneau, B. Maneglier, S. Castaigne, C. Chomienne, S. Chretien, P. Rousselot and P. Leboulch 
(2015). "Erosion of the chronic myeloid leukaemia stem cell pool by PPARgamma agonists." Nature 
525(7569): 380-383. 
 
Psyrri, A., Z. Yu, P. M. Weinberger, C. Sasaki, B. Haffty, R. Camp, D. Rimm and B. A. Burtness (2005). 
"Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in 
oropharyngeal squamous cell cancer by using automated quantitative analysis." Clin Cancer Res 11(16): 
5856-5862. 
 
Robertson, D. (2012). "ABC of colorectal cancer." Gastroenterology. 
 
Robinson, F. L. and J. E. Dixon (2006). "Myotubularin phosphatases: policing 3-phosphoinositides." Trends 
Cell Biol 16(8): 403-412. 
 
Robinson, F. L. and J. E. Dixon (2006). "Myotubularin phosphatases: policing 3-phosphoinositides." Trends 
in Cell Biology 16(8): 403-412. 
 
Rothenberg, M. L., J. R. Eckardt, J. G. Kuhn, H. A. Burris, 3rd, J. Nelson, S. G. Hilsenbeck, G. I. Rodriguez, 
A. M. Thurman, L. S. Smith, S. G. Eckhardt, G. R. Weiss, G. L. Elfring, D. A. Rinaldi, L. J. Schaaf and D. 
D. Von Hoff (1996). "Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal 
cancer." J Clin Oncol 14(4): 1128-1135. 
 
Rousselot, P., S. Prost, J. Guilhot, L. Roy, G. Etienne, L. Legros, A. Charbonnier, V. Coiteux, P. Cony-
Makhoul, F. Huguet, E. Cayssials, J. M. Cayuela, F. Relouzat, M. Delord, H. Bruzzoni-Giovanelli, L. 
Morisset, F. X. Mahon, F. Guilhot, P. Leboulch and C. M. L. G. French (2017). "Pioglitazone together with 
imatinib in chronic myeloid leukemia: A proof of concept study." Cancer 123(10): 1791-1799. 
 
Rubin, G. L., Y. Zhao, A. M. Kalus and E. R. Simpson (2000). "Peroxisome proliferator-activated receptor 
gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for 
breast cancer therapy." Cancer Res 60(6): 1604-1608. 
 
Rudge, S. A., D. M. Anderson and S. D. Emr (2004). "Vacuole size control: regulation of PtdIns(3,5)P2 
levels by the vacuole-associated Vac14-Fig4 complex, a PtdIns(3,5)P2-specific phosphatase." Mol Biol Cell 
15(1): 24-36. 
 
Saltz, L. B., J. V. Cox, C. Blanke, L. S. Rosen, L. Fehrenbacher, M. J. Moore, J. A. Maroun, S. P. Ackland, 
P. K. Locker, N. Pirotta, G. L. Elfring and L. L. Miller (2000). "Irinotecan plus fluorouracil and leucovorin for 
metastatic colorectal cancer. Irinotecan Study Group." N Engl J Med 343(13): 905-914. 
 
Samuels, Y. and V. E. Velculescu (2004). "Oncogenic mutations of PIK3CA in human cancers." Cell Cycle 
3(10): 1221-1224. 
 
Sanchez-Juan, P., M. T. Bishop, Y. S. Aulchenko, J. P. Brandel, F. Rivadeneira, M. Struchalin, J. C. 
Lambert, P. Amouyel, O. Combarros, J. Sainz, A. Carracedo, A. G. Uitterlinden, A. Hofman, I. Zerr, H. A. 
Kretzschmar, J. L. Laplanche, R. S. Knight, R. G. Will and C. M. van Duijn (2012). "Genome-wide study 
links MTMR7 gene to variant Creutzfeldt-Jakob risk." Neurobiol Aging 33(7): 1487 e1421-1488. 
 
Sawayama, H., T. Ishimoto, M. Watanabe, N. Yoshida, H. Sugihara, J. Kurashige, K. Hirashima, M. 
Iwatsuki, Y. Baba, E. Oki, M. Morita, Y. Shiose and H. Baba (2014). "Small molecule agonists of PPAR-
gamma exert therapeutic effects in esophageal cancer." Cancer Res 74(2): 575-585. 
 
  References 
 
91 
Scheffzek, K., M. R. Ahmadian, W. Kabsch, L. Wiesmuller, A. Lautwein, F. Schmitz and A. Wittinghofer 
(1997). "The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras 
mutants." Science 277(5324): 333-338. 
 
Scheidig, A. J., C. Burmester and R. S. Goody (1999). "The pre-hydrolysis state of p21(ras) in complex 
with GTP: new insights into the role of water molecules in the GTP hydrolysis reaction of ras-like proteins." 
Structure 7(11): 1311-1324. 
 
Schmick, M., A. Kraemer and P. I. Bastiaens (2015). "Ras moves to stay in place." Trends Cell Biol 25(4): 
190-197. 
 
Schmick, M., N. Vartak, B. Papke, M. Kovacevic, D. C. Truxius, L. Rossmannek and P. I. H. Bastiaens 
(2014). "KRas localizes to the plasma membrane by spatial cycles of solubilization, trapping and vesicular 
transport." Cell 157(2): 459-471. 
 
Seger, R. and E. G. Krebs (1995). "The MAPK signaling cascade." FASEB J 9(9): 726-735. 
 
Senderek, J., C. Bergmann, S. Weber, U. P. Ketelsen, H. Schorle, S. Rudnik-Schoneborn, R. Buttner, E. 
Buchheim and K. Zerres (2003). "Mutation of the SBF2 gene, encoding a novel member of the myotubularin 
family, in Charcot-Marie-Tooth neuropathy type 4B2/11p15." Hum Mol Genet 12(3): 349-356. 
 
Shiaw-Yih Lin, K. M., Weiya Xia (2001). "Nuclear localization of EGF receptor." 
 
Shimazaki, N., N. Togashi, M. Hanai, T. Isoyama, K. Wada, T. Fujita, K. Fujiwara and S. Kurakata (2008). 
"Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of 
thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model." Eur J Cancer 
44(12): 1734-1743. 
 
Shisheva, A. (2008). "PIKfyve: Partners, significance, debates and paradoxes." Cell Biol Int 32(6): 591-604. 
 
Shukla, S., U. S. Allam, A. Ahsan, G. Chen, P. M. Krishnamurthy, K. Marsh, M. Rumschlag, S. Shankar, C. 
Whitehead, M. Schipper, V. Basrur, D. R. Southworth, A. M. Chinnaiyan, A. Rehemtulla, D. G. Beer, T. S. 
Lawrence, M. K. Nyati and D. Ray (2014). "KRAS protein stability is regulated through SMURF2: UBCH5 
complex-mediated beta-TrCP1 degradation." Neoplasia 16(2): 115-128. 
 
Simonsen, A., A. E. Wurmser, S. D. Emr and H. Stenmark (2001). "The role of phosphoinositides in 
membrane transport." Curr Opin Cell Biol 13(4): 485-492. 
 
Song, S. Y., M. R. Kang, N. J. Yoo and S. H. Lee (2010). "Mutational analysis of mononucleotide repeats 
in dual specificity tyrosine phosphatase genes in gastric and colon carcinomas with microsatellite 
instability." APMIS 118(5): 389-393. 
 
Srivastava, N., R. K. Kollipara, D. K. Singh, J. Sudderth, Z. Hu, H. Nguyen, S. Wang, C. G. Humphries, R. 
Carstens, K. E. Huffman, R. J. DeBerardinis and R. Kittler (2014). "Inhibition of cancer cell proliferation by 
PPARgamma is mediated by a metabolic switch that increases reactive oxygen species levels." Cell Metab 
20(4): 650-661. 
 
Srivastava, S., Z. Li, L. Lin, G. Liu, K. Ko, W. A. Coetzee and E. Y. Skolnik (2005). "The phosphatidylinositol 
3-phosphate phosphatase myotubularin- related protein 6 (MTMR6) is a negative regulator of the Ca2+-
activated K+ channel KCa3.1." Mol Cell Biol 25(9): 3630-3638. 
 
Stein, M. P., C. Cao, M. Tessema, Y. Feng, E. Romero, A. Welford and A. Wandinger-Ness (2005). 
"Interaction and functional analyses of human VPS34/p150 phosphatidylinositol 3-kinase complex with 
Rab7." Methods Enzymol 403: 628-649. 
 
Stein, M. P., Y. Feng, K. L. Cooper, A. M. Welford and A. Wandinger-Ness (2003). "Human VPS34 and 
p150 are Rab7 interacting partners." Traffic 4(11): 754-771. 
 
Taguchi-Atarashi, N., M. Hamasaki, K. Matsunaga, H. Omori, N. T. Ktistakis, T. Yoshimori and T. Noda 
(2010). "Modulation of local PtdIns3P levels by the PI phosphatase MTMR3 regulates constitutive 
autophagy." Traffic 11(4): 468-478. 
 
References 
 
92 
Taheri, M., A. Salamian, K. Ghaedi, M. Peymani, T. Izadi, A. S. Nejati, A. Atefi, M. Nematollahi, F. Ahmadi 
Ghahrizjani, M. Esmaeili, A. Kiani Esfahani, S. Irani, H. Baharvand and M. H. Nasr-Esfahani (2015). "A 
ground state of PPARgamma activity and expression is required for appropriate neural differentiation of 
hESCs." Pharmacol Rep 67(6): 1103-1114. 
 
Taylor, G. S., T. Maehama and J. E. Dixon (2000). "Myotubularin, a protein tyrosine phosphatase mutated 
in myotubular myopathy, dephosphorylates the lipid second messenger, phosphatidylinositol 3-phosphate." 
Proc Natl Acad Sci U S A 97(16): 8910-8915. 
 
Thomas, N. S., H. Williams, G. Cole, K. Roberts, A. Clarke, S. Liechti-Gallati, S. Braga, A. Gerber, C. Meier, 
H. Moser and et al. (1990). "X linked neonatal centronuclear/myotubular myopathy: evidence for linkage to 
Xq28 DNA marker loci." J Med Genet 27(5): 284-287. 
 
Tooze, S. A. and T. Yoshimori (2010). "The origin of the autophagosomal membrane." Nat Cell Biol 12(9): 
831-835. 
 
Traynor, A. M., T. L. Weigel, K. R. Oettel, D. T. Yang, C. Zhang, K. Kim, R. Salgia, M. Iida, T. M. Brand, T. 
Hoang, T. C. Campbell, H. R. Hernan and D. L. Wheeler (2013). "Nuclear EGFR protein expression predicts 
poor survival in early stage non-small cell lung cancer." Lung Cancer 81(1): 138-141. 
 
Tsujita, K., T. Itoh, T. Ijuin, A. Yamamoto, A. Shisheva, J. Laporte and T. Takenawa (2004). "Myotubularin 
regulates the function of the late endosome through the gram domain-phosphatidylinositol 3,5-
bisphosphate interaction." J Biol Chem 279(14): 13817-13824. 
 
Tyagi, S., P. Gupta, A. S. Saini, C. Kaushal and S. Sharma (2011). "The peroxisome proliferator-activated 
receptor: A family of nuclear receptors role in various diseases." J Adv Pharm Technol Res 2(4): 236-240. 
 
van Beekum, O., V. Fleskens and E. Kalkhoven (2009). "Posttranslational modifications of PPAR-gamma: 
fine-tuning the metabolic master regulator." Obesity (Silver Spring) 17(2): 213-219. 
 
Velichkova, M., J. Juan, P. Kadandale, S. Jean, I. Ribeiro, V. Raman, C. Stefan and A. A. Kiger (2010). 
"Drosophila Mtm and class II PI3K coregulate a PI(3)P pool with cortical and endolysosomal functions." J 
Cell Biol 190(3): 407-425. 
 
Vergne, I., E. Roberts, R. A. Elmaoued, V. Tosch, M. A. Delgado, T. Proikas-Cezanne, J. Laporte and V. 
Deretic (2009). "Control of autophagy initiation by phosphoinositide 3-phosphatase Jumpy." EMBO J 
28(15): 2244-2258. 
 
Wactawski-Wende, J., J. M. Kotchen, G. L. Anderson, A. R. Assaf, R. L. Brunner, M. J. O'Sullivan, K. L. 
Margolis, J. K. Ockene, L. Phillips, L. Pottern, R. L. Prentice, J. Robbins, T. E. Rohan, G. E. Sarto, S. 
Sharma, M. L. Stefanick, L. Van Horn, R. B. Wallace, E. Whitlock, T. Bassford, S. A. Beresford, H. R. Black, 
D. E. Bonds, R. G. Brzyski, B. Caan, R. T. Chlebowski, B. Cochrane, C. Garland, M. Gass, J. Hays, G. 
Heiss, S. L. Hendrix, B. V. Howard, J. Hsia, F. A. Hubbell, R. D. Jackson, K. C. Johnson, H. Judd, C. L. 
Kooperberg, L. H. Kuller, A. Z. LaCroix, D. S. Lane, R. D. Langer, N. L. Lasser, C. E. Lewis, M. C. Limacher, 
J. E. Manson and I. Women's Health Initiative (2006). "Calcium plus vitamin D supplementation and the 
risk of colorectal cancer." N Engl J Med 354(7): 684-696. 
 
Weidner, P. (2016). "Die Interaktion des Kernrezeptors PPARγ mit der Lipidphosphatase MTMR7 im 
kolorektalen Karzinom." Inauguraldissertation. 
 
Weidner, P., M. Söhn, T. Gutting, T. Friedrich, T. Gaiser, J. Magdeburg, P. Kienle, H. Ruh, C. Hopf, H. M. 
Behrens, C. Rocken, T. Hanoch, R. Seger, M. P. Ebert and E. Burgermeister (2016). "Myotubularin-related 
protein 7 inhibits insulin signaling in colorectal cancer." Oncotarget 7(31): 50490-50506. 
 
Weisenberger, D. J., K. D. Siegmund, M. Campan, J. Young, T. I. Long, M. A. Faasse, G. H. Kang, M. 
Widschwendter, D. Weener, D. Buchanan, H. Koh, L. Simms, M. Barker, B. Leggett, J. Levine, M. Kim, A. 
J. French, S. N. Thibodeau, J. Jass, R. Haile and P. W. Laird (2006). "CpG island methylator phenotype 
underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal 
cancer." Nat Genet 38(7): 787-793. 
 
Willett, W. C. (2005). "Diet and cancer: an evolving picture." JAMA 293(2): 233-234. 
 
  References 
 
93 
Willumsen, B. M., A. Christensen, N. L. Hubbert, A. G. Papageorge and D. R. Lowy (1984). "The p21 ras 
C-terminus is required for transformation and membrane association." Nature 310(5978): 583-586. 
 
Wu, K., Y. Yang, D. Liu, Y. Qi, C. Zhang, J. Zhao and S. Zhao (2016). "Activation of PPARgamma 
suppresses proliferation and induces apoptosis of esophageal cancer cells by inhibiting TLR4-dependent 
MAPK pathway." Oncotarget 7(28): 44572-44582. 
 
Xue, Y., H. Fares, B. Grant, Z. Li, A. M. Rose, S. G. Clark and E. Y. Skolnik (2003). "Genetic analysis of 
the myotubularin family of phosphatases in Caenorhabditis elegans." J Biol Chem 278(36): 34380-34386. 
 
Yanagiya, T., A. Tanabe, A. Iida, S. Saito, A. Sekine, A. Takahashi, T. Tsunoda, S. Kamohara, Y. Nakata, 
K. Kotani, R. Komatsu, N. Itoh, I. Mineo, J. Wada, H. Masuzaki, M. Yoneda, A. Nakajima, S. Miyazaki, K. 
Tokunaga, M. Kawamoto, T. Funahashi, K. Hamaguchi, K. Tanaka, K. Yamada, T. Hanafusa, S. Oikawa, 
H. Yoshimatsu, K. Nakao, T. Sakata, Y. Matsuzawa, N. Kamatani, Y. Nakamura and K. Hotta (2007). 
"Association of single-nucleotide polymorphisms in MTMR9 gene with obesity." Hum Mol Genet 16(24): 
3017-3026. 
 
Yousefnia, S., S. Momenzadeh, F. Seyed Forootan, K. Ghaedi and M. H. Nasr Esfahani (2018). "The 
influence of peroxisome proliferator-activated receptor gamma (PPARgamma) ligands on cancer cell 
tumorigenicity." Gene 649: 14-22. 
 
Yuvaniyama, J., J. M. Denu, J. E. Dixon and M. A. Saper (1996). "Crystal structure of the dual specificity 
protein phosphatase VHR." Science 272(5266): 1328-1331. 
 
Zeng, T., Q. Wang, J. Fu, Q. Lin, J. Bi, W. Ding, Y. Qiao, S. Zhang, W. Zhao, H. Lin, M. Wang, B. Lu, X. 
Deng, D. Zhou, Z. Yin and H. R. Wang (2014). "Impeded Nedd4-1-mediated Ras degradation underlies 
Ras-driven tumorigenesis." Cell Rep 7(3): 871-882. 
 
Zhang, B., J. Berger, G. Zhou, A. Elbrecht, S. Biswas, S. White-Carrington, D. Szalkowski and D. E. Moller 
(1996). "Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of 
peroxisome proliferator-activated receptor gamma." J Biol Chem 271(50): 31771-31774. 
 
Zhao, R., Y. Qi, J. Chen and Z. J. Zhao (2001). "FYVE-DSP2, a FYVE domain-containing dual specificity 
protein phosphatase that dephosphorylates phosphotidylinositol 3-phosphate." Exp Cell Res 265(2): 329-
338. 
 
Zhou, Y. and J. F. Hancock (2015). "Ras nanoclusters: Versatile lipid-based signaling platforms." Biochim 
Biophys Acta 1853(4): 841-849. 
 
Zhou, Y., P. Prakash, H. Liang, K. J. Cho, A. A. Gorfe and J. F. Hancock (2017). "Lipid-Sorting Specificity 
Encoded in K-Ras Membrane Anchor Regulates Signal Output." Cell 168(1-2): 239-251 e216. 
 
Zhou, Y., C. O. Wong, K. J. Cho, D. van der Hoeven, H. Liang, D. P. Thakur, J. Luo, M. Babic, K. E. 
Zinsmaier, M. X. Zhu, H. Hu, K. Venkatachalam and J. F. Hancock (2015). "SIGNAL TRANSDUCTION. 
Membrane potential modulates plasma membrane phospholipid dynamics and K-Ras signaling." Science 
349(6250): 873-876. 
 
Zurlo, D., P. Ziccardi, C. Votino, T. Colangelo, C. Cerchia, F. Dal Piaz, S. Dallavalle, S. Moricca, E. 
Novellino, A. Lavecchia, V. Colantuoni and A. Lupo (2016). "The antiproliferative and proapoptotic effects 
of cladosporols A and B are related to their different binding mode as PPARgamma ligands." Biochem 
Pharmacol 108: 22-35. 
 
 
  
7. Appendix 
7.1. Interaction between MTMR7-PPARγ and HSP90 (CoIP) 
 
Figure 43: MTMR7 forms a complex with HSP90 and PPARγ. CoIP of MTMR7 and PPARγ from total cell lysates. HEK293T cells 
were transiently transfected with Flag-MTMR7 + GFP-PPARγ. Immunoprecipitation (“IP”) was performed using an anti-GFP Ab or 
no Ab (bead control). Coprecipitated proteins were detected by Western blot (“IB”) using an antibody against anti-Flag or HSP90. 
 
7.2. Melting curves of realtime PCRs 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
7.3. RAS down-regulation does not take place on the mRNA level 
 
Figure 44: MTMR7-mediated RAS down-regulation is no transcriptional event. Detection of KRAS, NRAS and HRAS cDNA in 
total RNA extracted from SW480 cells. Representative agarose gels of RT-PCR (35 x cycles) are shown. Expected sizes of 
amplification products: KRAS = 165 bp, NRAS = 103 bp, HRAS = 130 bp and B2M = 85 bp. 
 
7.4. Colocalization between MTMR7 and PH-domains of AKT and PLCδ 
 
Figure 45: Costaining of MTMR7 and PH-domains of AKT and PLCδ. HEK293T cells were transiently transfected with MTMR7 
together with PH-AKT-GFP plasmid or PH-PLCδ-GFP for 24 h. Immunofluorescence staining was done with anti-MTMR7 antibody. 
Colors: green = PH-AKT-GFP/ PH-PLCδ-GFP, red = MTMR7, blue = nuclei; magnification 400x. 
 
